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Azetidines have played a significant role in the medicinal arena for many years, and azetidine 
core is an important building block for the synthesis of β-lactam antibiotics. In this project, a 
review of the chemistry and literature synthetic routes for azetidine synthesis and its application 
in organometallic chemistry and medicine was presented. Additionally, the chemistry of γ-
lactams, fused tricyclic systems and pyrazolines was discussed. The scope of the iodocyclisation 
protocol was expanded by introducing heterocyclic and bulky substituents, and through 
generating azetidine derivatives in good yields. The studies of the iodocyclisation procedure on 
various homoallylamine derivatives for the synthesis of new heterocyclic compounds for medical 
applications were presented.  
The formation of γ-lactam derivatives in 34-99% yields, as a mixture of diastereomers from 
iodocyclisation of 3-methyl substituted homoallylamines was described. In addition, the structure 
and relative stereochemistry of nine single diastereomers were confirmed by single crystal X-ray 
diffraction. When 3-phenyl substituted homoallylamines were cyclised, intriguing furan 
bispyrrolidines were obtained stereoselectively in 20-48% yields. Their identity confirmed by X-
ray diffraction analysis. 
The iodocyclisation of homoallylhydrazine was investigated and a new synthetic method was 
estabilished to prepare a library of novel pyrazoline derivatives in 61-86% yields. 
Intriguing biological responses such as brain haemorrhage and ten other biological features for 
nine of the synthesised mixture of diastereomers of pyrrolidin-2-ones in zebrafish embryos 




Aim of the project 
The main goal of this project is to synthesise multi-substituted azetidines from the iodocyclisation 
of various substituted homoallylamines using the recently established iodocyclisation 
methodology in Fossey research group, and to study the effect of substitution on regioselectivity 
of cyclisation of homoallylamines. In addition, the study aims to investigate the synthesis of 
azetidines or pyrazolidines that could be accessed from the iodocyclisation of 
homoallylhydrazines, and provide a new synthetic route for their synthesis. 
Furthermore, the biological activity of the synthesised compounds is to be investigated in 
zebrafish developmental assay to provide an early indication of the activity of these compounds 
in medical arenas. 
The substrate scope of the previous work for the synthesis of racemic and enantiopure azetidines 




















Azetidine 1 is a four membered saturated heterocyclic nitrogen-containing compound. Azetidine 
derivatives are an important class of organic compounds in synthetic organic chemistry for drug 




is an analogue 
of proline, it can be found in the leaves of Convallarinmajalis. Sphingosine-derived azetidine 
alkaloid penaresidin A (3) and B (4) were extracted from an Okinawan marine sponge
3
, and they 
have been found to be potent actomyocin ATPase activators. 
 
Figure 1: Azetidine and azetidine-containing natural products and alkaloids 
Azetidine derivatives are important intermediates for the synthesis of numerous polyamine 
ligands.
4 




such as chiral ligand 5, used in asymmetric diethyl zinc additions to aldehydes.
5
 It has been found 
that azetidines could be good ligands for metal complexes such as palladium 7,
6




The synthesis of azetidines derivatives was challenging due to the unfavourable high energy 
strained nature of transition states that leads to four-membered rings,
 7,8 
this makes them difficult 
and problematic to form. It has also been found that due to the facile ring opening, it is difficult to 
obtain a high yield of the desired azetidine products.
8 
Therefore, the synthesis of azetidine 
derivatives still needs tobe further developed in order to improve yields and applications. 
 
Figure 2: Azetidine metal complexes 
1.1.1 Synthesis of azetidine derivatives 
Several reports have been published concerning the synthesis of azetidine derivatives.
9
 Herein, 
some of the methods for synthesis and applications in other areas of science, such as medicine, 
agrochemistry
10
 and organometallic chemistry are discussed, along with limitations, such as a 







1.1.1.1 Azetidine synthesis via selenium-induced cyclisation of homoallylamine derivatives. 
Azetidines can be generated from electrophilic cyclisation of homoallylamines via 4-exo-tet ring 
cloure.
11
 Berthe et al.
12
 reported an efficient synthetic route to produce 1,2,4-trisubstituted 
azetidines 10 through a 4-exo-tet cyclisation process (Scheme 1). The authors demonstrated that 
selenium-induced cyclisation of homoallylbenzylamines 9 in acetonitrile at room temperature can 
deliver a mixture of azetidine 10 and pyrrolidine 11 in 70-100% conversions. When 
homoallylbenzylamines derived from ketimines were used, the azetidines 10 were isolated as the 
major products, especially in the case of sterically hindered R groups on the α-carbon. When 
three equivalents of selenide were used, pyrrolidine compounds 13 were obtained as the major 
products. The limitations of this methodology include the formation of mixtures of products, 
which leads to poor yields of azetidines. In the absence of a sufficient amount of selenium 
reagent, incomplete cyclisation leads to compound 12, which is hydrolysed during the work up to 
the corresponding amine 9. This selenium reagent method benefits from the ready availability of 





Scheme 1: Selenium-induced cyclisation of homoallylamines at room temperature and acetonitrile11 
The nature of the counter ion (X=Cl or Br, Scheme 1), was found to have a major effect on the 
ratio of azetidine to pyrrolidine. Only azetidine 10 was produced, when X=Br, but the isolated 





=Ph) only azetidine 10 was observed as the major product.  
 
Scheme 2: Reaction mechanism of selenium-induced cyclisation of homoallylamines 
The suggested reaction mechanism for both possible products, azetidine and pyrrolidine, include 




overall 4-exo-tet (a) or an overall 5-endo-tet (b) cyclisation pathway) which are shown in Scheme 
2. The stereochemistry at C2 and C4 of the synthesised azetidine 10 and pyrrolidine 11 were not 
assigned, and the synthesis of pyrrolidine 11 was direct from cyclisation of homoallylamine 9, 
and not via ring expansion of azetidine 10.  
The synthesis of a mixture of (cis/trans)-2,4-azetidines has been reported by Franck et al.
8 
from 
the cyclisation of β-methyl substituted homoallylamines 14 using electrophilic selenium bromide. 
Selenium induced cyclisation of compound 14 can deliver a mixture of (cis/trans)-azetidines (15a 
and 15b) in a>80:20 ratio (Scheme 3). 
 
Scheme 3: Selenium mediated cyclisation of methyl substituted homoallylamine 
The synthesised azetidines 15a and 15b apparently underwent partial acid catalysed isomerisation 
during silica column purification to deliver pyrrolidine 16. An addition of 1% TEA and the use of 
alumina for purification were found to be effective for avoiding such isomerisation (Scheme 4). 
 




The yield of 15a and 15b were found to be increased with increasing the size of R groups, when 
R
1
=Me to t-Bu and R
2




=H the yield 





1.1.1.2 Azetidine synthesis via reductive cyclisation of imines. 
Different research groups have studied the synthesis of azetidines from reductive cyclisation of 
halogenated imines. Salgado and co-workers
13
 proposed that 1,2,3-substituted azetidines (22a-d) 
could be obtained in moderate to high yields from the reductive cyclisation of imines (21a-d) 
using sodium borohydride in refluxing methanol. The reaction starting from selective acylation of 
readily available diketone 17 to obtain compound 18, followed by pyrolysis of compound 18 at 
130-150 
°
C resulted in the formation of enol ether 19 in only 48% yield and recovery of 26% of 
unreacted 18. The mixture was treated with 1.5 equivalents of NBS to form 4-bromo-3,3-
dimethoxy-2-butanone 20 in an 80% isolated yield. Compounds 21a-d were synthesised though 
the reaction of compound 20 with various amines (aliphatic and aromatic). The conditions for 
some aromatic amines and sterically bulky amines were changed to obtain higher yields. The 
reductive cyclisation of 21a-d with two equivalents of sodium borohydride in methanol afforded 





Scheme 5: Synthesis of azetidines from reductive cyclisation of imines 
In the cyclisation step, the reaction conditions were changed in order to drive the reaction to 
completion. For sterically bulky substituents, such as i-Bu in 21b, two equivalents of sodium 
borohydride were used. In this method, multiple complicated steps were needed to produce 
azetidines. N-Substituted azetidines 24a-d can be synthesised via reductive cyclisation of γ-





where the synthesis of N-substituted azetidines 24a-d was achieved by treatment 
of γ-haloalkyl-imines 23a-d, with an equimolar amount of sodium borohydride in refluxing 
methanol to form amine, which then intramolecularly cyclised to generate compounds 24a-d in 





Scheme 6: Synthesis of azetidines via reductive cyclisation of imines 
The authors presented that the addition of alkyl and aryl lithium reagents to imines and then 
subsequent cyclisation in THF at -78 
°
C could deliver alkyl or aryl substituted azetidines on the 
benzylic position. 
In 2011, De Kimpe and co-workers
15
 reported that 3-methoxyazetidines 26 could be synthesised 
via an aziridine to azetidine ring rearrangement upon treatment of N-alkylidene-(2,3-dibromo-2-
methylpropyl) amines 25 with sodium borohydride through the reductive cyclisation of imines in 
methanol under reflux conditions (Scheme 7). The authors unexpectedly found that the highly 
substituted azetidine compounds 24a-d could be synthesised by variation of the R group. 
However, the isolated yields were poor due to the unexpected isomerisation that resulted in the 
formation of three membered rings. This side reaction proceeds through the kinetic aziridines 





Scheme 7: Synthesis of 3-methoxyazetidine via an aziridine to azetidine rearrangement 
The reaction of imine 25 proceeds through reduction was followed by subsequent cyclisation via 
an SN2 mechanism to give aziridine 26, and finally thermal ring expansion afforded azetidine 27. 
This study was not investigated the aromatic substituents on the nitrogen atom to furnish the 
desired azetidine product, also the undesired ring rearrangement was found to reduce the isolated 
yield. 
1.1.1.3 Azetidine synthesis via [2+2]-cycloaddition of 2-aminomalonate. 
Ye et al.
16
 have developed an efficient two-step procedure for the synthesis of highly 
functionalised chiral azetidines 30 from a [2+2]-cycloaddition of amide protected 2-
aminomalonates 28 with two equivalents of chalcones 29. The reaction proceeds via a grind-
generation of a Micheal adduct and a subsequent oxidative cyclisation at room temperature to 
furnish azetidine 30 (Scheme 8). Highly functionalised azetidines containing two stereogenic 
centres 30, were synthesised in moderate to good yields (46-75%) and high diastereoselectivitiy 




chalcones played an important role on the reaction outcome. For example, p-tolyl and p-chloro 
substituted chalcones produced 69% and 66% yields, respectively, while strongly electron-
withdrawing substituent (p-nitro) only produced 58% azetidine. The addition of an ammonium 
salt PhNEt3Cl as a catalyst was found to increase the yield of Michael adduct up to 90%. In 
contrast, changing the catalyst to a bulkier one such as BuNEt3X (X= Br, I) decreased the yield of 
the Michael adduct 64-18%, respectively. In the case of BuNEt3Cl, the expected azetidine was 
not obtained. 
 
Scheme 8: [2+2]-Cycloaddition to synthesis of highly functionalised azetidines. 
1.1.1.4 Azetidine synthesis via cyclisation of 1, 3-diol. 
Marinetti et al.
17
 reported a stereoselective synthesis of symmetrically 2,4-disubstituted 
azetidines (33a-d) from optically pure 1,3-diols 32 which are prepared from 1,3-diketones 31 by 
selective hydrogenation at room temperature in the presence of (R) or (S)-BINAP as a catalyst. 
The hydroxyl groups were converted to good leaving group by mesylation in TEA and then the 
crude material was treated with benzylamine nucleophile, were a subsequent cyclisation leds to 




excess >95% ee (Scheme 9). The synthesised azetidine compounds (33a-d) could be employed in 
the preparation of cyclopalladated complexes (Scheme 26). 
 
Scheme 9: Synthesis of chiral 2,4-disubstituted azetidines. 
Variation of the R group on 31 caused small changes in the product yields (Table 8). The 
selectivity was not changed by changing the R group from R=Me, Et and n-Pr (Table 1, entries 1, 
2 and 3), but when R is an aromatic substituent (Table 1, entry 4), the selectivity was inverted. 
Variations of N-substituents instead of benzyl group were not studied to explore their roles. 
Table 1: Synthesised chiral 2,4-disubstituted azetidines 
Entry  Compound R
 
% ee %yield 
1 31a Me >95(R,R) 60 
2 31b Et >95(R,R) 70 
3 31c n-Pr >95(R,R) 85 




 reported a one-pot preparation of 1,3-disubstituted azetidines 35 by treatment of 
1,3-propane diols 34 with trifluromethanesulfonic anhydride, converting the hydroxyl groups to 




nucleophile via intramolecular cyclisation of secondary amine to the triflate leaving group 
modified carbon to form 1,3-disubstituted azetidines 35 (Scheme 10). 
 
Scheme 10: Azetidine formation via bis-triflate activation 
Various substituents at R
1 
were studied, and they were found to be intramolecularly cyclised to 
furnish 1,3-disubstituted azetidines 35 in good to excellent yields (64-92%). When sterically 
bulky tert-butyl at R
1 
used (Table 2, entry 5) isolated yield was slightly reduced to (86%). The 
variation of R
2 
using various amine nucleophiles was not studied in detail. 
Table 2: Synthesised 3-substituted azetidines 





1 34a H (Ph)2CH 64 
2 34b Me Ph 64 
3 34c Ph Bn 92 
4 34d OBn Bn 92 






1.1.1.5 Azetidine synthesis via reduction of azetidine-2-one. 
Chiral haloalkyl azetidines 37 can be synthesised from the reduction of azetidin-2-one 36. In 
2006, Van Brabandt and co-workers
19
 reported the reduction of 4-haloalkyl-azetidines by using 
six equivalents of chloroalane (AlH2Cl) prepared in situ from AlCl3 and LiAlH4 affording new 2-
(haloalkyl)azetidines 37 in moderate to high yields 57-98% (Scheme 11). Ring rearrangement 
was observed at elevated temperature, which reduced the isolated yield of 73. The authors 
suggested reactions at room temperature would avoid ring expansion, since rearrangement only 
occurs at a higher temperature (Scheme 12). 
 
Scheme 11: Synthesis of 2-(haloalkyl) azetidines via reduction of 4-(haloalkyl)azetidin-2-ones18 
The azetidine derivatives synthesised from this route could be useful starting materials for the 
synthesis of five-membered aza-heterocycles 38 via the bicyclic azetidinium ion intermediate 
formed through rearrangements of the azetidine derivatives 37 without changing the relative 





Scheme 12: Azetidine ring rearrangement 
The limitations of this method lie in the formation of the starting material azetidin-2-one 36, 
which involves three steps, starting from the synthesis of imines, α-chlorination of imines and 
then cyclo condensation of the α-chloroimines 39 with methoxy- or benzyloxyacetyl chloride in 




Scheme 13: Reaction of α-chloroimines with acetyl chloride derivatives 
 
1.1.1.6 Miscellaneous methods for synthesis of azetidines: 
The densely functionalised epimeric mixture of 2-cyanoazetidine (42a and 42b) is produced 
starting from β-amino alcohol 40. Lowe et al.
21
 presented a four steps synthetic route for the 
synthesis of chiral azetidines (42a and 42b). This included N-alkylation of the secondary amine 




high yield (92%). Then the primary alcohol was protected with retention of configuration by 
treatment with triphenylmethyl chloride in the presence of TEA. Then deprotonation of the α-
carbon and subsequent intramolecular cyclisation of 41 by treatment with LiHMDS gave 42a and 
42b (Scheme 14). 
 
Scheme 14: Azetidine synthesis through β–amino alcohols 
The synthesised azetidine compounds could functionalise to provide access to the synthesis of a 
variety of higher ring systems, such as fused rings, or spirocyclic azetidine compounds. In silico 
analysis means computational simulation of the molecule, which includes calculation of 
physicochemical properties, such as molecular weight, cLogP, pKa, and HB acceptors and 
donors. These values for all the synthesised compounds fell in the range of the corresponding 
CNS drugs. The drawback of this synthetic route is the availability of the starting materials that 
are not commercially available, and hence needed to be synthesised, which in turn increased the 
number of steps in an already long synthetic route. 




 suggested three rules for ring closing process and forming ring system. This 
process is more likely described in three rules: In the tetrahedral systems, only 3- to 7-exo-tet are 




systems, all 3- to 7-exo-trig are favoured and 3- to 5-endo-trig are disfavoured but 6- to 7-endo-
trig are favoured. In diagonal systems 3- to 4-exo-dig are all disfavoured, but 5- to 7-exo-dig and 
3- to 7-endo-dig are favoured. 
 
Figure 3: Four and five-member ring forming system according Baldwin rule 
 
Recently our research group has been focusing on the synthesis of azetidines and pyrrolidines for 
application in both medicinal chemistry and catalysis. A recent report from Feula et al.
22
 
presented a new protocol for the synthesis of 1,2,4-trisubstituted azetidines 43a bearing a good 
leaving group, which could be displaced with another nucleophile. This new procedure consists 
of iodine-mediated cyclisation of homoallylamines through 4-exo-tet ring closure system,
11
 which 
requires three equivalents of iodine and five equivalents of NaHCO3 in acetonitrile as a solvent at 
20 
°
C. A racemic mixture of cis-iodoazetidines 43a was obtained as the major product plus trace 
iodopyrrolidine 43b as the minor product when the temperature was controlled at less than 20 
°
C. 
Iodoazetidines 43a were not stable above 20 
°
C. Ring expansion to five membered rings proceeds 
with ease above 20 
°
C (Scheme 22). Iodoazetidines can undergo further transformation with 
different nucleophile to displace iodine and form more stable cis-aminoazetidines 44a-o in a high 






Scheme 15: Iodine mediated cyclisation of homoallylamine derivatives 
It was found that the undesired isomerisation of iodoazetidines occurs during cyclisation of the 
homoallylamines to form iodopyrrolidine instead of iodoazetidine. Such isomerisation could be 
avoided by controlling the temperature. Another limitation is the synthesis of 3-substituted 
azetidines and multi-substituted azetidines, which was not addressed. However, the scope was 
expanded by changing the R groups by varying the aldehyde and amine sources. The ratio of 




 substituents dependent. For example, using 
electron releasing substituents and electron withdrawing substituents at R
2
 produced azetidines as 














1 43a Ph Bn >99:1 86 
2 43b Ph 4-Methoxybenzyl
 
>99:1 85 
3 43c Ph 4-Methylbenzyl
 
>99:1 93 
4 43d 3-Pyr Bn 5:1 91 
5 43e 4-Pyr Bn 5:1 95 
6 43f 4-Nitrophenyl Bn 3:1 90 
7 43g 2-Bromophenyl Bn 3:1 83 
8 43h t-Bu Bn >99:1 87 
(a) Conversion based on 1H NMR spectroscopy,(b) yield after purification 
 
It was found that the ratio of azetidine to pyrrolidine is R group dependant (Table 3), which 
means that the ratio could be varied by replacing phenyl substituent at R
1
 and introducing 
electron withdrawing substituent. For example when R
1
=phenyl and 4-nitrophenyl (Table 3, 
entries 1, 2, 3 and 6) respectively, azetidine cis-43a was obtained as the major product (>99:1) 
and the ratio of azetidine was reduced to (3:1) when R=4-nitrophenyl was used. When 
heterocyclic substituents at R
1
 were used (Table 3, entries 4 and 5), the ratio was slightly higher 




were phenyl and 
benzyl groups respectively (Table 3, entry 1) which also gave a higher conversion with minimum 
isomerisation (>99:1). The author showed that only cis-isomer was formed, as confirmed by nOe 




The proposed reaction mechanism and butterfly-like transition states (Scheme 16) are explain the 
formation of the four membered azetidine rings. At least two possible transition states were 
suggested to generate azetidine, the transition state TS1 is most favoured because the protons are 
in the pseudo 1,3-diaxial position, while the transition state TS2 is disfavoured due to an increase 
in pseudo 1,3-diaxial interaction. 
 
Scheme 16: Reaction mechanism and transition states for azetidine synthesis 
This procedure was found to be highly applicable to the synthesis of various new aminoazetidines 
compounds by simple SN2 substitution of iodide with different amine nucleophile and it is 
applicable to alkyl, aryl, heterocycle, and bulky groups (Table 4). Formations of aminoazetidines 
cis-44a-o were found slightly affected by changing the amines in the last step. This difference 
can be explained by employing primary and secondary amines and using the correct method of 


















1 44a Ph Bn
 
Bn H 86 
2 44b Ph Bn n-Pr H 87 
3 44c Ph Bn i-Pr H 69 
4 44d Ph Bn Pipyridine 83 
5 44e Ph Bn Morpholine 71 
6 44f Ph Bn Pipyrazine 81 
7 44g Ph Bn 4-Methoxybenzyl H 78 
8 44h Ph 4-Methoxybenzyl n-Pr H 74 
9 44i Ph 4-Methylbenzyl Bn H 75 
10 44j 3-Pyr Bn Bn H 72 
11 44k 3-Pyr Bn 2-hydroxyethyl H 82 
12 44l 3-Pyr Bn Pyrrolidine 76 
13 44m 4-Pyr Bn Bn H 71 
14 44n 4-Bromophenyl Bn Bn H 65 
15 44o t-Bu Bn Bn H 86 
(a)Isolated yield after purification 





In 2013, Fossey and co-workers showed that it was possible to synthesise enantiopure 2,4-
azetidines in high yield (99%) and high enantiomeric excess (>99% ee) using an Ellman auxiliary 




Figure 4: Chiral amine auxiliary and enantiopure homoallylamine 
Based on the previous work from our research group, the synthesis of enantiopure azetidines will 
be continued and the scope of the previous method will be expanded. The study of the 
iodocyclisation protocol using various homoallylamines, such as 3-methyl substituted 
homoallylamines 47, 2-gem-dimethyl substituted homoallylamine 48, 2-methylhomoallylamine 
49 and enantiopure homoallylamines 46, remains to be investigated (within this project). 
 
Figure 5: Various homoallylamines 
1.1.3 Reactions of azetidines 
The ring strain in azetidines makes them excellent candidates for nucleophilic ring opening or 
ring expansion reactions yielding larger ring systems or obtaining highly substituted acyclic 






(Scheme 18) and acid-catalysed
7,25 
(Scheme 17) ring opening or ring rearrangement to 
larger ring systems. 
 
Scheme 17: Acid catalysed ring opening of azetidines 
 
Scheme 18: Thermal catalysed ring opening of azetidines 
 
Scheme 19: Plausible mechanism of thermal ring opening of azetidines 
Azetidines can undergo ring expansion to form larger ring systems because of ring strain. Vargas-
Sanchez et al.
26
 showed that the N-benzylpyrrolidine 54 with four stereogenic centres can be 
prepared in a quantitative yield with (dr 50-95%) via Lewis acid catalysed ring rearrangement of 





Scheme 20: Rearrangement of substituted azetidine to pyrrolidine 
In 2008, Brandi and co-workers
9
 reported that ring enlargement occurred in the presence of 
Lewis acids. The result showed that azetidine carboxaldehyde acetals-2-one 55 under reduction 
conditions on treatment with chloroalane in DCM were converted to 2,3,4-substituted 
pyrrolidines 56 in moderate to good yield 30-86% (Scheme 21). 
 
Scheme 21: Azetidines ring enlargement under Lewis acid action. 
In 2003, Couty et al.
27
 reported thermal ring expansion of racemic 2-halomethylazetidines 57 into 
3-halopyrrolidine 58 with complete stereo control. Similarly, the same ring enlargement was 
reported and verified by Feula et al.
22
 in 2010. It was shown that cis-iodomethyl azetidines 57 




heated above room temperature (Scheme 22). The proposed mechanism explained the control of 
stereochemistry during the conversion. 
 
Scheme 22: Thermal ring enlargement of azetidines 
 
1.1.4 Application of azetidines 
Azetidines have been discussed in terms of their application in a wide range of areas, such as 
agrochemistry,
10
 metal-ligand complexes in catalysis
6
 and medical applications.
26 
1.1.4.1 Agrochemistry of azetidines 
Furutani et al.
10
 found that the azetidine moiety has the potential to enhance the insecticidal 
activity of alkaloid okaramines. The study was conducted on silkworm larval neurons, and it 
indicated the activity of okaramine with azetidine moiety 59 over the sixteen other derivatives 
with no azetidine core. The study also concluded that the azetidine ring has played a major role in 





Figure 6: Structure of okaramine B 
1.1.4.2 Industrial application 
Azetidines are widely described for their use as intermediates in the construction of potential 
energetic molecules.
28
 Katritzky showed that 1,3,3-trinitroazetidine (TNAZ) 60 could be a 
potential energetic material due to the positive heat of formation 26.1K J/mol, that can be 




Figure 7: Structure of TNAZ  
1.1.4.3 Catalytic applications of azetidines 
Azetidines could be used as a ligand for the formation of metal complexes,
6
 especially when they 
are functionalised with amine groups. Azetidines have been used as chiral ligand in asymmetric 
catalysis,
6 




chiral induction potential. Several researchers used chiral azetidines for asymmetric addition of 
diethyl zinc to aldehydes.
5,29
 For example; Liu et al.
29
 showed that chiral 3-hydroxyazetidine 
derivatives 63 and 64 have excellent catalytic activities and enantiomeric selectivity towards 




Scheme 23: Azetidine as chiral ligand 
Table 3 details the effects of using ligand 63 and 64 on the selectivity of the produced alcohol 62. 
In the presence of ligand (63a-d) the (S)-62 was obtained in a 98% isolated yield with 
enantiomeric excess up to 94% (entry 1). Conversely, (R)-62 produced a 93% yield with up to 
97% ee as a result of using ligand 64 (entry 5). Moreover, the yield and ee was found to be 
dependent on the substituents on the phenyl ring. For example, the presence of an electron-
withdrawing group at the para-position of phenyl group leads to lower enantioselectivity 





Table 5: Azetidine as chiral ligand 
Entry Compound Ar % Yield
a 
% ee 
1 63a Ph 98 94 (S) 
2 63b 4-Chlorophenyl 97 89 (S) 
3 63c 3-Chlorophenyl 96 96 (S) 
4 63d 2-Chlorophenyl 94 97 (S) 
5 64 Ph 93 97 (R) 
(a) Isolated yield 
Keller and co-workers
6
 showed the efficiency of their synthesised azetidine ligand in catalysis. It 
was shown that palladium-azetidine complex 67 was a good catalyst in Suzuki cross-coupling 
reactions for the formation of new carbon-carbon bonds, upon reaction of aryl halide 64 and 
boronic acid 66. When the catalyst loading was 0.1% mol, the isolated product 68 was even 
higher at 87% (Scheme 24).
6 
 
Scheme 24: Azetidine complex as catalyst for Suzuki cross-coupling reaction 
Marinetti and co-workers
17
 synthesised chiral 2,4-dimethylazetidine from an efficient coupling of 
azetidines 69 with aryl halides using palladium complexes as a catalyst to afford chiral N-aryl 




70 was higher than when R is ethyl group. When Ar was a phenyl substituent, compound 70 was 
obtained in a 75% isolated yield (Scheme 25).  
 
Scheme 25: Synthesis of N-aryl azetidines through palladium promoted coupling reaction 
When electron releasing substituents at Ar were used (Ar=2-methoxyphenyl and 2-
methylphenyl), compound 70 was obtained in a slightly high yield (83-85%). When Ar is 
electron withdrawing substituent at para-position (Ar= 4-CF3-phenyl), a better yield of product 
96% was obtained. When Ar is bulky naphthyl substituent, the product was obtained in an 80% 
isolated yield. The synthesised azetidine derivatives could be good candidates for the synthesis of 
palladium containing complexes (Scheme 26). 
Cyclopalladated azetidine complexes 71 can be synthesised from the reaction of (R,R)-1-benzyl-
2,4-dimethylazetidine 70 with Na2PdCl4 in methanol at room temperature. A single isomer of cis-
dimeric complex with two azetidine moieties was obtained in a 57% isolated yield (Scheme 26). 
The author showed that only cis-isomer was formed due to chiral discrimination produced from 





Scheme 26: Synthesis of a cyclopalladated N-benzylazetidine complex 
1.1.4.4 Biological applications of azetidines 
Azetidines have played significant roles in pharmaceutical chemistry because of their existence in 




A number of azetidines have already been used in medicines, such as azelnidipine 72, as an 
antihypertensive agent.
31 







 and anti-depressant agents.
25 
The azetidine analogue of nicotine 73 has been 




Figure 8: Azelnidipine and azetidine analogue of nicotine 
Holladay and co-workers
34
 prepared and studied azetidine derivative 74 and its enantiomer 75 




showed analgesic activity in mice. In addition, it had an affinity to nicotinic acetylcholine 
receptor binding sites in the brain of rats. The synthesised analogue 76 two methyl substituents at 
the 3-position of the azetidine ring was found to be less active. It was also found that variation of 
X (X= H, F, Me, Ph, Cl) has only a slight effect on the activity, for example, when X=Cl, the 
activity slightly increased.  
 
Figure 9: Azetidine analogues 
Azetidine amino acids are important examples of biologically active azetidines. Burtoloso and 
co-workers
36
 has investigated some analogues of azetidine-derived glutamate and aspartate. They 
have been shown to display pharmacological activities. It was reported that azetidine 77 could act 
as an activator of the metabotropic receptors, while compound 78 could be a potent agonist of the 
kainite receptor. 
 




In 2012, Han et al.
37 
published a new study on antidepressant activity of a group of novel 2-
substituted azetidines. In this study, several azetidine derivatives were screened against serotonin, 
dopamine and noripenephrine transporter, compared with reference drugs such as fluoxetine, 




=C6H5 presented higher activity than 
reference drugs in enhancing triple reuptake inhibitor. 
 
Figure 11: 2-Substituted azetidine 
 
In conclusion, the importance of azetidine derivatives was found in the synthesis of natural 
products, pharmaceuticals and medicine. Azetidines can be synthesised from various procedures, 
but isolated yields were found to be low, due to purification problems, isomerisation and limited 
diversifications. In addition, azetidines presented several biological activities, such as triple 
reuptake inhibitor activity, and binding to acetylcholine receptors activity. Scientists are trying to 
find a new methodology for their synthesis in order to improve yields and selectivity, and to 
obtain a higher activity involved with the novel compounds compared to the previously 
synthesised compounds. In this study, we have tried to synthesise novel multi-substituted 
azetidines from readily available starting material with improved isolated yields, and have 





1.2 Pyrrolidin-2-one (γ-lactam) 
Pyrrolidin-2-ones (γ-lactams) (80) are an important class of organic compounds, particularly in 
synthetic organic chemistry, several biologically active natural products contain γ-lactam cores. 
38 
They are well known for their therapeutic applications, such as cotinine alkaloid
39 
81 found in 
tobaccos, which is used as an antidepressant. Natural product (-)-pramancine 82 isolated from 
fungal genus Stagonospora was discovered as an antimicrobial agent.
40
 The γ-lactam with 
morpholine and biphenyl moiety Doxapram 83 has been reported as a respiratory stimulant.
41
 
Significantly, cis-1,3,5-γ-lactam derivatives have been found to display as potential α7 nicotinic 
acetylcholine receptors (nAChR) agonists.
42
 There are several research groups interested in 
synthesising γ-lactam derivatives. For example, 1,5-disubstituted γ-lactams have been 
synthesised in good to excellent yields via cyclisation of carbinolamide by treatment with 
trifluoroacetic acid.
43
 In 2013, Sun et al.
44
 synthesised tri-substituted chiral γ-lactams from the 
reaction of aromatic halide with γ-ketoester through a series of complicated steps. It was found 









Highly functionalised enantiomerically enriched pyrrolidin-2-one derivatives bearing 
hydroxylated stereogenic quaternary carbon centres can be prepared, starting from catalytic 
asymmetric intramolecular nucleophilic addition of tertiary enamides.
45
 Yang et al. presented the 
treatment of enamide diketone 84 with sodium carbonate in benzene at room temperature in the 
presence of catalyst 85 and this resulted in affording hydroxylated 2,3-dihydro-pyrrol-2-ones 86 
in very high yields and high selectivity up to 99% ee. 
 
Scheme 27: Catalytic enantioselective reaction of enamides to form pyrrolidin-2-ones 
The authors showed that the reaction scope could be explored for different substrates and found 
that all enamides were consumed to afford the product 86a-k in an excellent yields 88-99% and 





=Phenyl substituent (Table 6, entry 10), the product was obtained in 98%, but the ee was 
slightly decreased to 94%. The ee was decreased to 89% and an isolated yield of 99% when 




=Phenyl (Table 6, entry 11). When enamides bearing 




 and R (Table 6, entry 12), the isolated yield of product dropped to 




Table 6: Substrate scope of catalytic enantioselective reaction of enamides 











1 84a Bn Ph Ph 16 86a (98) 96 
2 84b Bn 4-Me-Ph Ph 4 86b (98) 98 
3 84c Bn 4-Cl-Ph Ph 114 86c (98) 96 
4 84c Bn 4-Cl-Ph Ph 17 86c (98) 97 
5 94d Bn 4-Br-Ph Ph 96 86d (98) 99 
6 84e Bn Ph 4-Me-Ph 68 86e (98) 97 
7 84f Bn Ph 4-F-Ph 72 86f (98) 97 
8 84g Bn Ph 4-Cl-Ph 16 86g (98) 97 
9 84h PMB Ph Ph 11 86h (98) 98 
10 84i Allyl Ph Ph 15 86i (98) 94 
11 84j Me Ph Ph 4 86j (99) 89 
12 84k Ph Ph Ph 4 86k (88) 87 
(a) Isolated yield, (b ) determined with HPLC, 
Enamides bearing bulky substituent at Ar
2
, such as tert-butyl was also probed. When sterically 
hindered enamide was used, the product was obtained in a 99% yield with (94% ee). 
Indeed, further improvement in this field is needed, so that readily available starting materials can 





1.3 Fused tricyclic ring system 
Fused tricyclic systems are a significant class of organic compounds found in alkaloids, such as 
Calycanthine (Figure 13).
46 
Only a few examples were reported regarding the oxidative 
dimerisation that leads to the formation of a ring-fused system.
46 
 
Figure 13: Calycanthine alkaloid 
Poulton and co-workers
47
 reported the oxidation of enamino-ketones 87a-f in aqueous solution by 




. However, the problematic purification of the product resulted 
in a poor 30-35% isolated yields of compound 88a-f (Scheme 28). 
 
Scheme 28: Oxidative dimerisation of enamino-ketones 
In 2002, K.-Q. Ling et al.
48
 reported the formation of a single diastereomer of 





Scheme 29: Oxidative dimerisation of 3-methylindole to form hexahydrofurodiindole 
The oxidative coupling of 3-methylindole 89 was found to give oxidative coupled dimer 90, 
followed by hydration, which led to the formation of 91. The stereochemistry of 91 was not 
assigned, it was believed the two-pyrrolidine ring must have been cis-, but the furan ring could be 






2-Pyrazoline 92 is a five membered unsaturated heterocyclic nitrogen-containing compound. 
Pyrazoline derivatives have been reported as a valuable biological active compounds.
49
 1,3,5-







 and Cannabinoid CB1 
receptor antagonist activity. Additionally, it has been found that pyrazolines are important 
materials due to their emission properties and ability to chelate with various metals when 
decorated with appropriate functionality.
53 





Figure 14: 2-pyrazoline and 2-pyrazoline derivatives 
Several procedures for the synthesis of pyrazoline derivatives have been reported,
55
 the most 
commonly employed procedure for the synthesis of pyrazoline derivatives is a base catalysed 
cyclisation of a chalcone with aryl hydrazine starting with Claisen-Schmidt condensation of 
acetophenone with aldehydes to form chalcones which are then reacted with aryl hydrazines to 
form pyrazolines. Recently, in 2012, Manzoor and co-workers
55
 synthesised 1,3,5-pyrazoline 
derivatives through condensation of acetophenone 94 with p-chlorobenzaldehyde 95 to form 
chalcone 96, followed by base catalysed cyclisation with thiosemicarbazide to form the desired 2-




out with copper and nickel to furnish 98 in 58% and 60% yields, respectively. The synthesised 
metal-ligand was shown to have efficient antifungal activity after coordination with copper and 
nickel metal 98 (Scheme 30).  
 
Scheme 30: Synthesis of 2-pyrazoline from Claisen-Schmidt condensation 
In 2012, Caggiano and co-workers
56
 described a method for the synthesis of a pyrazoline and a 
pyrazole from condensation of ketone 99 and benzaldehyde 60 to form aza-chalcone 100, which 
was further reacted with methyl hydrazine to form pyrazoline 101 in 72% isolated yield (Scheme 
31). 
 




The synthesised pyrazoline 101 was further oxidised to obtain the corresponding pyrazole 102 in 
the presence of a catalytic amount of palladium on carbon at a high temperature (Scheme 32). 





, and they were shown to be capable of distinguishing between these metal ions in 
acetonitrile. 
 
Scheme 32: Aromatisation of 2-pyrazoline 101 to from the corresponding pyrazole 102 
Only one example of pyrazoline was synthesised and employed for application, which could be 
expanded for further investigation on different substrates. 
In conclusion, the synthesis of pyrazoline derivatives featured with a number of limitations in 
yields and selectivity. The investigation of new methods is needed toward developing efficient 
procedures in terms of isolated yield and selectivity. These results encouraged our interest 
towards synthesising compounds with 2-pyrazoline as a core structure, starting from the 
cyclisation of readily available homoallylhydrazines. 
In terms of an overall conclusion of the literature review, several synthetic routes are available 
for the synthesis of azetidines, pyrrolidin-2-ones, γ-lactams and pyraolines, but not for fused 
furan bispyrrolidines. In general, they could be synthesised in better yields and selectivity by 




The synthesis of multi-substituted azetidines 105 started from iodocyclisation of different 
homoallylamines 103 using the recently established methodology in Fossey research group 
(iodine-mediated cyclisation of homoallylamines using iodine and sodium bicarbonate in 
acetonitrile). The effect of substitution on regioselectively of cyclisation is planned to be 
investigated. 
In addition, a plan has been made to investigate the synthesis of azetidines 108 or pyrazolidines 
110, which can be accessed from the cyclisation of homoallylhydrazines 106 using 
iodocyclisation protocols to provide a new synthetic route for their synthesis (Scheme 33).  
 
Scheme 33: Proposed routs for the desired target compounds. i) The synthesis of multi-substituted azetidine derivatives via 
iodocyclisation of multi-substituted homoallylamines. ii) The synthesis of azetidine derivatives and pyrazoline derivatives 




The biological activity of these compounds was probed by screening in a zebrafish embryo 
developmental assay. Moreover, screening all the newly synthesised compounds in medicinal and 
agrochemical arenas will be investigated through an ongoing screening partnership by sending 












Results and discussion 





2. Results and discussion 
Previous work of Fossey and co-workers showed that the 2,4-cis-azetidines can be synthesised 
via iodine-mediated cyclisation of various homoallylamines. Initially, this procedure was 
employed in this project to expand the scope of the previous studies toward applications in 
catalysis and biological screening. This led to new findings and chemical understanding, which 
are explored in this thesis (Scheme 34). 
 
Scheme 34: Summary scheme 
2.1 Racemic azetidine synthesis 





 groups were studied (Scheme 35). In order to do this study, the synthesis 
of intermediates, imines and homoallylamines were started. 
 




2.1.1 Synthesis of intermediates 
Homoallylamines are important intermediates in organic synthesis. They can be used as building 
blocks for the synthesis of many natural products, and biologically active compounds.
55,56 
It was 
believed that the majority of the target homoallylamines (Figure 15) could be prepared according 
to literature protocols.
57 
Metal (zinc and magnesium) mediated allylation of imines in dry THF at 
room temperature was proposed as the ideal methodology (Scheme 36). 
 
Scheme 36: Proposed route for preparation of homoallylamines 
 
Figure 15: Different substitution patterns of homoallylamines 
The syntheses of homoallylamines was planned in order to generate azetidines with different 







Scheme 37: Proposed retrosynthetic route for the synthesis of azetidine using iodocyclisation procedure 
The synthesis of azetidine with different substitution patterns was planned in order to study their 
biological activity and to compare their activities with the previously synthesised azetidines in 
our research group by using the same strategy. It has been hoped that structure activity 
relationships (SAR) could be understood. 
To prepare these compounds (46-49), commercially available allyl bromides (113, 114, 115 and 
116) were used to prepare allyl metal species, which were utilised in the allylation of the 
synthesised imines. Imines were first synthesised, as described in the next section.  
 
Figure 16: Ally bromide species 
2.1.1.1 Synthesis of imines  
Imines are an important class of organic compounds in synthetic organic chemistry because of 
the diverse reactivity of the carbon-nitrogen double bond. They were used as a primary substrate 
for a wide range of syntheses,
58
 such as the synthesis of enantiomerically enriched amino 
phosphoric acids as enzymatic inhibitors from hydrophosphonylation of imines.
59




imine 8 was prepared from condensation of benzaldehyde with benzylamine in refluxing ethanol 
for six hours. 
 
Scheme 38: Synthesis of imines 
The majority of imines used in this project have been prepared using the same protocol except in 
two cases: N-methylimines 120 were prepared by treating aldehydes with methylamine solution 
119 and the reaction was performed at room temperature. 
 
Scheme 39: Synthesis ofmethylimines 
After preparation of imines, the synthesis of homoallylamines was attempted. 
2.1.1.2 Synthesis of homoallylamines 
Homoallylamines 9a-k can be prepared by using the two standard literature protocols.
57,60 
the first 
method is through the addition of allyl Grignard reagents, which were prepared in situ, to 
appropriate solutions of the corresponding imines in dry THF at room temperature. The 
corresponding homoallylamines 9a-k were synthesised in moderate to good yields (except entries 




synthesised in order to apply the cyclisation procedures to synthesise azetidines with various 
substituents. 








1 9a Ph Bn 91 
2 9b t-Bu Bn 85 
3 9c 3-Pyr Bn 89 
4 9d Ph 3-Picolyl 83 
5 9e 9-Anthracenyl Bn <10b,c 
6 9f Ph 4-Methoxybenzyl 93 
7 9g 2-Thienyl Bn 89 
8 9h Ph n-Pr 94 
9 9i Ph Allyl -
d 
10 9j Ph 2-Methylbenzyl 37 
11 9k 2-Hydroxybenzyl Bn -
d 
(a) isolated yield, (b) not purified,(c) reaction time extended to 72 hours, (d) product not observed 
 
Table 7 shows that the different substituent (R) groups affect the formation of the 
homoallylamines, for example, steric effects are expected to inhibit the allylation process, which 




obtained despite extending reaction time to 72 hours and heating at reflux. The reaction was 
unsuccessful when R
1 
was an ortho-hydroxyl substituted benzyl group 9k (Table 7, entry 11). A 
possible explanation for this could be the Grignard being quenched by the phenol, though this is 
not yet proven. Compound 9i (Table 7, entry 9) was not obtained as a pure product, due to 
difficulties faced during purification, as several spots were found on the TLC plate. The allylation 
of (Table 7, entry 10) was carried out at room temperature, giving a 20% yield. However, by 
refluxing in dry THF, the yield was slightly improved to 37%.  
The expected reaction mechanism and the chair like transition state for the formation of a racemic 
mixture of homoallylamines are illustrated in Scheme 40. 
 
Scheme 40: Reaction mechanism and transition state of homoallylamine 
The above reaction mechanism shows that the magnesium metal coordinates to the nitrogen atom 
of the imine and increases the electrophilicity of the imine carbon, then the ally metal double 
bond, which acts as a nucleophile and attacks the electrophilic carbon atom of the imine leading 




Homoallylamines also could be prepared from the addition of allyltributyltin 121 to the imine 
solution in dichloromethane in the presence of borontriflouride diethyl etherate as a Lewis acid to 
activate the imine double bond.
60 
This method was used as an alternative route to the formation of 
homoallylamines 9 due to limitation being reached when Grignard reagents were employed. 
Homoallylamines 9a-b were prepared by dissolving imines 8a-b in dichloromethane and were 
treated with boron trifloride diethyl etherate and compound 121 at room temperature. The 
products 9a-b were obtained in 75-80% isolated yields (Table 8) and they were comparable with 
the former procedure, which gives a moderate to good yields. However, this procedure is 
expensive and involves toxic substances. 








1 9a Ph Bn 75 
2 9b Ph 3-Picolyl 80 
a Isolated yield 
The allylation process could be problematic when using magnesium metal, as a layer of oxide 
forms on the surface of the metal that is difficult to remove compared to zinc powder. However, 
the use of activated zinc powder
61 
was found to solve this problem and the best yields have been 












1 9a Ph Bn 91 
2 9k Ph 3-Picolyl 89 
(a) Isolated yield 
In general, the allylation of imines using zinc metal has been found to be more efficient than 
using magnesium turning, but not more efficient than using allyltributyltin 121. The factor that 
affects the allylation process in general is activation of the metal and the presence of water or air, 
resulting in the decomposition of the ally metal reagent. Therefore, the reaction has to be carried 
out in rigorously anhydrous conditions, minimising the presence of water and air, aiding the 
formation of the organometallic reagents. 
2.1.2 Cyclisation of racemic homoallylamines 
As discussed earlier, cis-2,4-disubsituted iodoazetidines 43 can be prepared by iodine mediated 
4-exo-trig cyclisation
11
 of homoallylamines 9. The procedure established for the preparation of 
cis-2,4-azetidines, by Fossey and co-workers,
22
 utilises three equivalents of iodine and five 
equivalents of sodium bicarbonate in acetonitrile at 20 
°
C (Table 10). The synthesised 
iodoazetidines were not purified due to the undesired isomerisation in to pyrrolidines on silica gel 
during column chromatography. Despite this, overall good conversion and these unstable 




At the starting point of this project, heterocyclic groups in R
2 
9b (Table 10, entry 2) and bulky 
groups in R
1 
9c (Table 10, entry 3) had not been explored. This project aims to develop this 





=3-picolyl with the iodocyclisation protocol, gave the 
desired azetidine generated as the major product in 80- >99% conversion respectively, based on 
analysis of the proton NMR spectrum. 








1 9a Ph Ph >99
b 
2 9b Ph 3-Picolyl >99 
3 9c 1-Naphthyl Bn 80 
4 9d Ph 2-Methylbenzyl -
c 
5 9e Ph 2-Bromobenzyl -
c 
6 9f Ph 4-Methoxybenzyl >99
b 




is aromatic and R
2 
is benzyl groups, the quantitative conversion to the desired 
iodoazetidine was achieved. When R
2
=3-picolyl (Table 10, entry 2) the corresponding 






(Table 10, entry 3) delivered only 80% conversion and recovery of 20% starting material. An 
ortho-substituted benzyl was probed. When R
2
 is 2-bromo benzyl and 2-methyl benzyl (Table 10, 
entries 4 and 5), starting materials were recovered without any evidence of cyclisation. This is 
also observed for a similar substrate discussed later in this thesis (Table 13, entry 7), which 
suggests that ortho-substituted aromatic groups inhibit cyclisation. The reason for the observation 
may be due to the electronic effect introduced by ortho-position substitution of the phenyl group. 
In contrast, the electronic effect on para-position did not affect the cyclisation, for example 




The crude product 43a was then treated with neat benzyl amine as a nucleophile, for 48 hours, 
delivering aminoazetidine 44a in a 65% isolated yield. The same strategy was applied for the rest 
of the synthesised iodoazetidines through treatment with a large excess of piperidine to afford 
aminoazetidines 44b in a 76% isolated yield, and through treatment with a large excess of n-

















1 44a Ph 3-Picolyl Bn H 65 
2 44b Ph 3-Picolyl Piperidine 76 
3 44c 1-Naphthyl Ph n-Pr
 
n-Pr 50 
4 44d Ph Ph n-Pr
 
n-Pr 65 
(a) Isolated yield  
The analysis of crude proton NMR revealed the recovery of some starting materials, but in all 
cases cis-2,4-aminoazetidine 44a-d was found to be a major product. Novel azetidine derivatives 
with a 3-picolyl group were generated in good yields 65-76% (Table 11, entries 1 and 2). When a 
bulky group was used, R
1
= 1-Naphthyl substituent, the desired azetidine 44c was obtained in only 
a 50% isolated yield and 30% starting material was recovered (Table 11, entry 3). Additionally 
homoallylamines with R
2
=2-bromobenzyl and 2-methylbenzyl (Table 10, entries 4 and 5) could 
not be cyclised to deliver azetidines utilising this protocol. Since the scope of the previous 
method was probed, and the cyclisation of some racemic homoallylamines were clarified, 




2.2 Enantiopure azetidine synthesis 
2.2.1 Synthesis of enantiopure homoallylamines 
Several reports have been published regarding the synthesis of enantiopure homoallylamine in a 
high yield with high ee (up to >99%) using an Ellman auxiliary 45.
62,63 
(R)-N-tert-
butylsulfinylimine 122 was synthesised from the condensation of benzaldehyde 60 with (R)-tert-
butylsulfinamide R-45 in the presence of PPTS and anhydrous MgSO4 using standard literature 
protocol (Scheme 41).
64 
Compound R-122 was obtained in a 91% isolated yield after column 
chromatography, then it was reacted with ally zinc reagent in the presence of a mild Lewis acid 
indium triflate, according to a literature procedure.
65 
Compound (1R, 1R)-123 was obtained in an 
86% isolated yield after column chromatography with [α]D
20
=+120.1 (C. 9.7, CHCl3) and 
compared with the literature value (+121.6)
23
 and high diastereoselectivitiy >99% d.r that was 
confirmed by the analysis of the crude proton NMR spectrum (Scheme 41). 
 





Figure 17: Transition state for the synthesis of enantiopure homoallyl Ellman amine 
The transition state involves the metal coordination by the nitrogen of the imine functional group 
and the oxygen of the sulfinyl oxygen. 
The enantiopure amine 124 (99% ee) was obtained from the removal of the chiral auxiliary from 
123 using 4M hydrochloric acid in 1, 4-dioxane. Compound 46a-c was generated from reductive 
amination of 124. The resulting chiral primary amine was condensed with various readily 
available aldehydes to obtain imines, which were reduced with sodium borohydride to furnish 










% Yield ee %
 
1 46a Ph 91 >99
a 
2 46b t-Bu 86 91
b 
3 46c 3-Picolyl 92 93
b 
(a)Calculated by comparison of literature value of optical rotation, (b) Calculated by HPLC (see experimental data) 
The reductive amination of 124b with sodium borohydride generated 46b in 86% yield with 93% 
ee [α]D
20
= +52 (c.5, DCM) calculated by chiral HPLC (AD column). However, the ee obtained 
for 46a is >99% calculated by comparison of literature value of [α]
20
D= +56.5 (c.5, CHCl3) (lit. 
+55.4)
23
 and >99% ee. The compound 46c was obtained in a 92% yield with >99% ee calculated 
by chiral HPLC (AD column). Since the synthesised enantiopure homoallylamines in hands, then 
the cyclisation was investigated. 
2.2.2 Cyclisation of enantiopure homoallylamines 
Cyclisation of enantiopure homoallylamine 46a was attempted in order to test the suitability of 
the cyclisation protocol for the synthesis of single enantiomer azetidines. Treatment of 
enantiopure homoallylamine 46a with molecular iodine utilising a previous cyclisation procedure 
delivered enantiopure iodoazetidines 125a (Table 13). Further reaction with an amine nucleophile 
afforded 126a in a 83% isolated yield and >99% ee [α]D
20
= +97.2 (c.5, CHCl3) (lit. +98.7).
23
 This 






Further synthesis of novel enantiopure azetidines was needed for biological activity screening 
and investigation in catalysis. The same strategy was applied when expanding the scope of the 
method, and several enantiopure azetidine compounds were prepared (Table 13). Cyclisation of 
homoallylamines 46a-f was attempted and aminoazetidines 126a-f were prepared in 46-82% 
yields after purification with an enantiomeric excess of 85-99% ee calculated by chiral HPLC 
(AD column was used (see experimental section). The cyclisation of homoallylamines when R
2
 is 
3-picolyl resulted in quantitative conversion to iodoazetidines. When R
2
 is t-butyl only 50%, 
conversion was achieved, as determined by the analysis of crude proton NMR spectrum. When 
R
2
=2-bromobenzyl no product was detected by analysis of the crude proton NMR. The crude 
products were subjected to the next step without further purification to generate 126a-f. In the 
cases of 126b, 126e and 126f, purification was problematic and at least two columns were run for 
the purification of each compound, which resulted in reducing the isolated yield of the product. 
When R
2
 is 3-picolyl, the conversion to iodoazetidine was quantitative, but after conversion to 
aminoazetidine 126c-e and purification using column chromatography, the isolated yield was 
reduced to 57-82%. When R
1
= phenyl and R
2
= benzyl, the conversion by analysis of crude 















 % Yield % ee 
1 126a Ph Bn Bn 83 >99
a 
2 126b Ph Bn i-Pr H 46 >96
a 
3 126c Ph 3-Picolyl piperidyl 82 89
b 
4 126d Ph 3-Picolyl Bn 76 85
b 
5 126e Ph 3-Picolyl Pyrrolidyl 57 91
b 
6 126f Ph t-Bu n-Pr 50 87
b 
7 126g Ph 2-Bromobenzyl - - - -
c 
(a) literature compound, (b) calculated by HPLC (see experimental data), (c) Azetidine not observed 
 
The decrease in ee can be explained by the thermal stability of the iodoazetidine 125a-f. When 
R
2
=3-picolyl, the treatment of iodoazetidine 125b with isopropylamine furnished aminozetidine 
126b (Table 13, entry 2) in a 46% isolated yield with enantiomeric excess >96% ee [α]D
20
= +89.4 
(C.5, CHCl3) (lit. +96).
23
When the crude iodoazetidine was treated with pipperidine, benzylamine 
and pyrrolidine produced aminoazetidine 126c-e in 82% (89% ee), 76% (85% ee) and 57% (91% 
ee) (Table 13, entries 3, 4 and 5 respectively). The ortho-bromobenzyl substituent (Table 13, 




material was recovered, this result confirms the previous suggestion for cyclisation of ortho-
substituted group in R
2
 restrict cyclisation to form azetidine. 
In summary, throughout this section, the scope of the previously developed procedure for the 
synthesis of azetidines was expanded, to some extent, to include heterocyclic substituents at R
1
 
and bulky naphthalene group at R
2
. The cyclisation was found to be successful and azetidines 
were obtained in moderate to high yields. In addition, enantiopure azetidines were prepared in 
46-83% yields with high enantiomeric excess up to >99% ee. 




 and synthesising enantio-
enriched azetidines, attention was then turned to work on the allyl part of the homoallylamine. 
The previous cyclisation protocol was applied to various homoallylamine substrates synthesised 
from allyl bromide species 113, 114, 115 and 116 (Figure 18). 
 










Results and Discussion 





2.3 γ-Lactams synthesis 
To study the possibility of the cyclisation, methyl substituted homoallylamine was cyclised 
(Scheme 42).   
 
Scheme 42: General scheme for the synthesis of γ-lactams 
2.3.1 Synthesis of 3-methyl substituted homoallylamines intermediates 
This project aims to probe the effects of substitution on the allyl part for the first time (R
3
, Figure 
19). First of all, synthesis of homoallylamines with methyl substitution in the 3-position was 
planned. 
 
Figure 19: Homoallylamine with methyl substitution in 3-position 
The generation of 3-methyl substituted homoallylamine 47 was tried through the treatment of 
imine 12 with in situ prepared methallylzinc reagent in accordance with the literature procedure,
 
57





Scheme 43: Synthesis of 3-methylsubstituted homoallylamine 
The proposed transition state in Figure 20 shows the possibility of the formation of a racemic 
mixture of the 3-methyl substituted homoallylamine, which results from the allyl rearrangement. 
 
Figure 20: Transition states for the synthesis of racemic 3-methyl substituted homoallylamine 
With satisfactory reaction conditions in hand for cyclisation, and to expand the scope of the 
developed procedure later on, several 3-methyl substituted homoallylamines (47a-r) were 
prepared in 34-98% isolated yields (Table 14). Various imines, including aromatic, benzylic, 
aliphatic and heterocyclic substituents were employed, in order to obtain comprehensive results 





Table 14: Synthesis of racemic 3-methyl homoallylamines 
 






1 47a Ph Bn 98 
2 47b Ph 3-Picolyl 74 
3 47c Ph n-Pr 41 
4 47d 3-Pyr Bn 87 
5 47e Ph 2-Methylbenzyl 91 
6 47f 3-Furyl Bn 84 




9 47i Ph 4-Methoxybenzyl
 
73 
10 47j 2-Thienyl Bn 93 
11 47k 1-Naphthyl Bn 19 
12 47l Ph Adamantly
 
81 
13 47m 2-Bromophenyl Bn 47 
14 47n Ph 4-Chlorobenzyl 34 
15 47o 4-Nitrophenyl Bn 57 
16 47p 3-Pyr 4-Methoxybenzyl
 
75 
17 47q Ph Me 82 
18 47r 3-Pyr Me 67 
19 47s 3-Indole Bn -
b 





When phenyl substituent at R
1
 and Benzyl substituent at R
2
 were employed (Table 14, entry 1) 
the allylated product was obtained in a very high yield 98%. When 3-picolyl substituent was 
employed at R
2
 (Table 14, entry 2), this led to reduction of the allylated product to 74%. Alkyl 
substituted amine (Table 14, entry 3) gave a low yield of 41%. When R
1
=3-pyr (Table 14, entry 





were employed (Table 14, entries 5, 8 and 9) the products were obtained in relatively good 
yields of 66-91%. Bulky tert-butyl substituent (Table 14, entry 7) also gave the allylated product 





 in the ortho- and para-position led to a reduction in the yield to 47%, 34% and 57% for 
bromo-, chloro- and nitro-substituents respectively (Table 14, entries 13, 14 and 15). The 
minimum isolated yield of 19% was obtained with a bulky naphthalene substituent 47k (Table 
14, entry 11). When heterocyclic substituents (R
1
= 3-Furyl, 2-Thienyl and 3-Pyr) were employed 
(Table 14, entries 6, 10 and 16), the isolated yield remained high at 75-93%. When R
2
= Me 
(Table 14, entries 17 and 18) the compounds 47q and 47r were generated in high isolated yields 
of 82% and 67%, respectively. The allylated product 47s (Table 14, entry 19) was not found for 
indole containing imine, due to the enamine tautomerisation, which results in reducing 





Scheme 44: Indole enamine tautomerisation 
The synthesised 3-methyl substituted homoallylamines 47a-r was used later when expanding the 
scope of γ-lactam synthesis (Table 16, Page 65). 
A mixture of epimers of homoallylamine derived from chiral amine (R-methyl-phenylamine) was 
synthesised from the treatment of enantiopure imine 127 with ally zinc reagent prepared in situ. 
The product was obtained as a mixture of epimers 128 (7:3 syn/anti), which could not be 
separated. The ratio was determined by analysis of 
1
H NMR spectrum of the isolated mixture of 
the synthesised compound. 
 




In Figure 21, the formation of the different ratio of the diastereoisomers, based on the suggested 
transition states is drawn. The methyl group could result in reducing the amount of one isomer in 
comparison to the other isomer. The reason could be steric clashes between 1-3 diaxial 
interaction of the phenyl and the methyl group, which resulted in the formation of two 
disfavoured transition states: TS II and TS IV. 
 
Figure 21: Possible transition states for the formation a mixture of two diastereoisomers 
2.3.2 Cyclisation of 3-methyl substituted homoallylamines 
The cyclisation of 3-methyl substituted homoallylamines is important because we believed that 
the cyclisation of 3-methyl substituted homoallylamine could give azetidine 129 (Scheme 46).In 
order to investigate the synthesis of azetidines bearing a quaternary stereocentre at the 4-position, 
the cyclisation of 3-methyl substituted homoallylamine had not been attempted by using 
molecular iodine. However, as mentioned previously the cyclisation by using electrophilic 
selenium reagent was reported to give a mixture of azetidine and pyrrolidine.
8




azetidine from the cyclisation of 3-methyl substituted homoallylamine was attempted according 
to the iodocyclisation protocol.
21
 Unlike the cyclisation of homoallylamine to generate azetidine, 
the desired azetidine was not obtained as envisaged. The analysis of TLC of the material obtained 
after initial flash chromatography showed no evidence for remaining the starting materials and 
analysis of the proton NMR spectrum of the crude obtained indicated the formation of a mixture 
of products, which was supported by the TLC observation. Separation was attempted by using 
various solvent conditions in flash chromatography. Fortunately, separation was achieved by 
running longer column chromatography, followed by crystallisations from (20% 
EtOAc/petroleum ether). The IR spectrum showed a broad peak around 1670 cm
-1 
from an amide 
(C=O) stretch, but from these analyses alone the actual structure remained elusive. Fortunately, 
single crystals were formed and the structures were confirmed by X-ray diffraction analysis 
showing one stereoisomer of a pyrrolidin-2-one (γ-lactam) cis-130. This was supported with X-
Ray diffraction analysis of a crystal of the stereoisomer trans-130 (Scheme 46 and Figure 22). 
 







Figure 22: X-Ray crystal structure of cis-130 and trans-130 with ellipsoids drawn at the 50 % probability level. X-Ray 
structure analysis performed by Dr. Louise Male at the University of Birmingham. 
In addition, with X-ray diffraction results in hand, the relative stereochemistry was more easily 
assigned for both isomers, using nuclear Over Hauser effect (nOe) experiments (Figure 23). To 
corroborate this, irradiation of H
a 
in compound cis-130a resulted in increasing the H
c
 signal and 
the proton of the hydroxyl group, but no nOe was observed between H
a
 and the phenyl protons. 
Correspondingly, irradiation of proton H
b 
in compound cis-130a led to an increase in the signal of 
the protons belonging to the methyl group and the phenyl protons, but not the proton of the 
hydroxyl group. Similarly, irradiation of H
c 









stereochemistry was found to be cis-130a and for the trans-130a was assigned by the same 
technique and supported by X-ray crystal structure. 
 
Figure 23: nOe experiments for compound cis-130a and trans-130a 
When the structure and the relative stereochemistry of the unexpected γ-lactam was confirmed, In 
addition to the literature reports on the significant roles of γ-lactams,
66
 particularly in the 
synthesis of alkaloids and pharmaceutical chemistry,
67 
then the separation of diastereomer was 
performed, followed by the reaction conditions optimisation, and the scope of the method was 
investigated. 
Reaction optimisation of γ-lactam synthesis was carried out by screening various solvents and 




Table 15: Base and solvent screening for synthesis of γ-lactam 
 
Entry Base Solvent % yieldb 









1 NaHCO3 CH3CN 35 35 35 30 57: 43 
2 Cs2CO3 CH3CN - 27 - 73 - 
3 NaOAc CH3CN 20 60 20 20 50: 50 
4 NaOH CH3CN 18 75 25 - 51: 49 
5 Na2CO3 CH3CN 20 43 27 30 60: 40 
6 K2CO3 CH3CN 25 33 30 37 43: 57 
7 Li2CO3 CH3CN 22 48 22 30 56: 44 
8 LiOH CH3CN 47 34 47 19 57: 43 
9 KOH CH3CN 21 53 22 25 54: 46 
10 -- CH3CN 25 65 30 5 56:44 
11 NaHCO3 MeCN:H2O
c 21 48 30 21 33: 67 
12 NaHCO3 EtOAc 89 0 >99 0 46: 54 
13 NaHCO3 Dry THF 60 10 60 30 38: 62 
14 NaHCO3 MeOH 10 43 40 17 45: 55 
15 NaHCO3 DCM 10 90 10 - 50: 50 
16 NaHCO3 Dry MeCN 20 60 20 20 48: 52 





From the reaction conditions optimisation study, it was found that ethyl acetate as a solvent and 
sodium bicarbonate as a base (Table 15, entry 12) shows a higher yield of cis-130a and trans-
130a after 24 hours and no by-products were observed. However, in all cases, the ratio of 
diastereomers was not improved significantly. Interestingly, the oxidation of the amine
68 
was 
noted when cesium carbonate was used as a base and acetonitrile as a solvent (Table 15, entry 2) 
and no product was observed; instead imine 131 was obtained as a major product (Scheme 48). 
Sodium acetate and sodium hydroxide (Table 15, entry 3 and 4) gave a 20-25% isolated yield 
respectively, with a nearly equal diastereomer ratio 1:1. The best diastereomer ratio (60:40) was 
achieved when sodium carbonate was used as a base (Table 15, entry 5). However, the isolated 
yield was low (20%). Potassium carbonate (Table 15, entry 6) resulted in a slight increase in the 
isolated yield 30% and diastereomer ratio also slightly changed to 43:57. Lithium carbonate and 
potassium carbonate (Table 15, entry 7 and 9) produced no significant change in the isolated yield 
and diasteroselectivity. Lithium hydroxide (Table 15, entry 8) increased the yield but did not 
affect the diastereomer ratio. In the case of three equivalents of iodine and no base (Table 15, 
entry 10), only 25% of γ-lactam was formed after 24 hours and 65% of starting material 47a was 
recovered. In the presence of a mixture of acetonitrile and water 1:1, the diastereomer ratio was 
improved to about 1:3, but the isolated yield was low. When tetrahydrofuran as a solvent (Table 
15, entry 13) was used the isolated yield was increased and the diasteroselectivity remained the 
same, which suggested that the diastereoselectivitiy is not a base nor a solvent dependant, rather 
the mechanism results in a non-selective cyclisation. What is noteworthy is that formation of 
compound 131 was found as a minor product in all cases except when sodium hydroxide in 
acetonitrile and sodium bicarbonate in dichloromethane (Table 15, entry 4 and 15). Cyclisation 




spectra showed a mixture of products, suggesting that none of these reagents is superior to 
molecular iodine. 
2.3.2.1 Expanding the scope of γ-lactam synthesis 
With satisfactory reaction conditions in hand, and having various 3-methyl substituted 
homoallylamines (47a-r) synthesised (section 2.3.1), the scope of the developed methodology 
was probed. Several novel γ-lactam derivatives were synthesised, and in all cases, γ-lactams as a 
















1 130a Ph Bn 89 54:46 
2 130b Ph 3-Picolyl 91 57:43 
3 130c Ph n-Pr 34 56:44 
4 130d Ph 2-Me-benzyl 43 60:40 
5 130e 3-Furyl Bn 72 54:46 
6 130f t-Bu Bn 67 55:45 
7 130g 3,4-OMe-Ph Bn 65 56:44 
8 130h Ph 4-OMe-benzyl 78 61:39 
9 130i Ph Admantyl
 
57 30:70 
10 130j 2-Thio Bn 73 36:64 
11 130k 2-Br-Ph Bn 55 67:33 
12 130l Ph 4-Cl-benzyl 64 60:40 
13 130m 4-NO2-Ph Bn 55 45:55 
14 130n 1-Naph Bn 72 24:76 
15 130o Ph Me 43 56:44 
16 130p 3-Pyr 4-OMe-benzyl
 
99 52:48 
17 130q 3-Pyr Me 68 53:47 
(a) isolated yield as a mixture of diastereomers, (b) determined by 1H NMR spectrum of the isolated products 
The γ-lactams 130a-q were obtained in moderate to high yields as the major products for all 
substrates tried. When phenyl substituent at R
1 
and a benzyl substituent at R
2
 was employed 




substituent amines (Table 16, entries 3, 15 and 17) can also be cyclised to deliver γ-lactams. 





Pr (Table 16, entry 3) the isolated yield was slightly low at 34%. In general, alkyl substituents at 
R
2 
gave lower yields compared to the alkyl substituent at R
1
=tert-butyl (Table 16, entry 6) that 
gave reasonable yields (67%), suggesting that alkyl group containing substrates are not very 
reactive under these reaction conditions. Para-substituted benzylic substituents at R
2
 were 
probed, such as 4-chlorobenzyl and 4-methoxybenzyl (Table 16, entries 8 and 12), they gave high 
yield (78 and 64%) respectively. An ortho-substituted benzylic substituent 2-tolylbenzyl at R
2
 
(Table 16, entry 4) led to a redution in the isolated yield (43%). An electronic effect of 
substituents at R
1
 was also employed (Table 16, entries 11 and 13), ortho- and para-substituents 
(2-bromophenyl and 4-nitrophenyl) and isolated yield was notably reduced to (55%). 
Heterocyclic substituents (3-furyl and 2-thienyl) were used at R
1
 (Table 16, entries 5 and 10) and 
the yield was improved to (72 and 73%) respectively. The diastereomer ratios of the products 




 substituents. The best diastereomer ratio (67:33 
d.r.) was achieved with 2-bromobenzyl substituent at R
1
 (Table 16, entry 11), but the isolated 
yield was low (55%). The diastereomer ratios of the synthesised compounds were calculated by 
comparison of signals in the analysis of 
1
H NMR spectra.  
Figure 24 gives a representative example of the spectrum of non-separated mixtures of 
diastereomer of compound 130q, which shows the two apparent triplets next to other at around 
4.42 and 4.70 ppm which belong to the (CH) of both diastereomer of the product. These are 




of the starting material (C=CH2) homoallylamine, and to another singlet at around 8.1 ppm which 
belongs to the single proton (CH=N) of compound 131. 
 
Figure 24: 1H NMR spectrum of a mixture of diastereoisomers of compound cis-130q and trans-130q 
Figure 25 provides an example on the separated mixture of diastereoisomers of the one 
synthesised compound 130o into single diastereoisomers. Single diastereoisomers were separated 
for all the synthesised mixtures by using column chromatography, and the correct solvent 







Figure 25: The 1H NMR spectra shown for a mixture and individual diastereoisomers of compound 130o 
The relative stereochemistry was assigned to some of the synthesised γ-lactam derivatives 
(experimental section) by single crystal X-ray diffraction. The crystals of compound trans-130d 
were grown in a mixture of ethyl acetate and hexane or ethyl acetate and petroleum ether, and the 






Figure 26: X-ray crystal structures of compound trans-130d 
Scheme 47 shows the suggested reaction mechanism for the formation of racemic γ-lactams. The 
reaction was start through the formation of iodonium intermediate b, followed by the formation 
of quaternary carbonium ion c, which could then be attacked by the nitrogen lone pair through 
SN1 mechanism to form azetidine intermediate d. The unstable intermediate is robustly 
transformed in to a five membered ring pyrrolidines f via azetidinium intermediate e, followed by 
a series of elimination and addition and finally oxidation of k to deliver γ-lactam o in the final 
step (Scheme 47). It is believed that the oxidation of g to produce i could cause racemisation to 





Scheme 47: Proposed mechanism pathway to form γ-lactams 
The mechanism for the formation of the minor product 131 shows in the Scheme 48, which ends 




Scheme 48: Mechanism pathway to form the corresponding oxidised form of imine 
Based on the proposed mechanism for the formation of γ-lactams, and in order to understand the 
reaction mechanism through the formation of the intermediate compounds shown in Scheme 47, 




obtained, but most of the starting material was recovered. When two equivalents of iodine were 
used, no product was observed and only 20% of the starting material was recovered. When iodine 
was used in excess (three, four and five equivalents), γ-lactams cis-130 and trans-130 as major 
products were obtained in more than 98% isolated yields, suggesting that the formation of γ-
lactams needs iodine in excess to help the oxidation of the proposed double bond containing 
intermediates, which are shown in the suggested reaction mechanism (Scheme 45). 











1 1 90 - 10 
2 2 20 - 80 
3 3 - 98 2 
4 4 - >99 0.5 







2.3.2.2 Modification of γ-lactams 
Methylation of the tertiary alcohol of the γ-lactam was attempted for two reasons; firstly to 
compare the ease of separation of diastereoisomers before and after methylation, and secondly to 
study the biological activity after methylation. Hence, the mixture of diastereoisomers of 
compound 130 has been methylated (Scheme 49), the hydroxyl group was deprotonated by 
treatment with sodium hydride and followed by O-methylation gave quantitative conversion to 
compound 132 as a mixture of diastereoisomers. The separation of diastereoisomers was 
attempted for the methylated product and no significant improvements were seen, the separation 
was as laborious with the parent OH. 
 
Scheme 49: Methylation of hydroxyl group of (cis/trans)-130a to give 132 
In order to modify hydroxyl group of γ-lactam, acetylation was carried out on a single 
diastereoisomer of compound cis-130p (based on the availability of single diastereoisomer of 
starting material) using acetic anhydride in the presence of DMAP as a nucleophilic catalyst, with 
triethylamine in dichloromethane as a solvent. The complete conversion was achieved giving a 





Scheme 50: Acetylation of cis-130a to give cis-133 
Trans-3-hydroxynicotine 135 has been reported to bind neuronal acetylcholine receptors and 
enhance cognition function.
69
 In order to generate the analogue of 135, the reduction of carbonyl 
group of compound 130q was performed. The carbonyl group in compound 130q was reduced. 
Initially, five equivalents of lithium aluminium hydride were used and only 56% of 134q was 
isolated, when the amount of reducing agent was increased to ten equivalents, the yield was 
improved to 89% isolated yield of 134q. The separation to get the single diastereoisomers was 
found to be more difficult compared to the starting material. The relative stereochemistry after 
reduction was confirmed for both single diastereoisomers by nOe experiment. 
 
Scheme 51: Reduction of carbonyl group of compound 130q 





 the hydrolysis of γ-lactam would deliver α-hydroxy-γ-amino acids 136. 




only the starting material was recovered. These results suggest the stability of the synthesised γ-
lactams to acid and base conditions. 
 
Scheme 52: Acid and base catalysed ring-opening attempts of γ-lactam 130a 
Further work could be done to make the reaction work, such as increasing the reaction 
temperature, changing the solvent, and controlling the reaction time. 
Deprotection of nitrogen group could be important to generate a new version of pyrrolidine 
compound 137 bearing free nitrogen atom that helps to coordinate better with metal ions. CAN 
was previously reported as the most widely used reagent for oxidative cleavage of N-4-
methoxybenzyl group.
72 
In order to generate compound 137, deprotection of N-4-methoxybenzyl 
group from compound 130h was attempted in the presence of five to ten equivalents of CAN 
using literature protocol.
45
 The reaction was tried several times by changing reaction conditions, 
such as changing the equivalents of CAN or the ratio of water to acetonitrile, but the product 137 
was not observed (Scheme 53). However, the TLC analysis showed consumption of all starting 
material. The reason for this result is not clear, but it could be a result of degradation of the 
molecule because of deprotection. The same procedure was applied on the reduced version of 





Scheme 53: Deprotection attempt of 4-Methoxybenzyl group from γ-lactam 130h 
After several modifications were performed on some of the synthesised γ-lactams, and in order to 
test the possibility of the preparation of enantiopure γ-lactam compound, attention was then 
turned in to synthesis of enantiopure homoallylamines first, and cyclisation later on.  
2.3.3 Cyclisation of enantio enriched 3-methyl substituted homoallylamines 
The chiral amine auxiliary protocol was used in order to synthesise non-racemic γ-lactams. The 
reaction was attempted by the synthesis of enantiopure imine, followed by selective allylation in 
the presence of indium triflate to form (2R, 4R)-138a. Then the chiral auxiliary was removed to 
form enantiopure allyl amine R-138b in 64% isolated yield and 83% ee, followed by 
condensation with an aldehyde and subsequent reductive amination with sodium borohydride to 





Scheme 54: Attempted to synthesis of enantiopure γ-lactam from enantiopure homoallylamine gave racemic products 
The cyclisation of compound 139 was attempted using the iodocyclisation protocol for synthesis 
of non-racemic γ-lactams. The product was purified and crystallised. The X-ray single crystal 
structure and optical rotation measurements all showed the formation of racemic γ-lactams cis-
130a and trans-130a. 
 
 
Figure 27: Analytical HPLC spectra showed racemic formation of γ-lactam 
Non-racemic starting material (left hand) and racemic product after 




The products 130a and 130b were found to have zero optical rotation on polarimeter, this mean 
that the product is not be enantiopure, this is also confirmed by X-ray diffraction technique which 
shows molecule as centrosymmetric, which contains an inversion centre, and two of four 
molecules in the unit cell are (S) and the other two are (R). For further proving racemisation, the 
HPLC was run for the starting material and the product, the HPLC spectrum also shows two 
peaks for the product, while the staring material homoallylamine was found as enantio enriched 
with 83% ee (Figure 27). The reason for such racemisation is defined by the suggested reaction 
mechanism from the oxidation step to form imine intermediate with the defined stereocentre 
hydrogen atom (Scheme 47, j). 
A new efficient synthetic route for the synthesis of 1,3,5-trisubstituted-pyrrolidin-2-one bearing 
functionalised hydroxylated quaternary carbon centre 130a-q in a moderate to good yield via 
iodine mediated cyclisation of 3-methyl substituted homoallylamines at room temperature has 
been presented. Although the mixture of diastereomers are obtained, this method has several 
promising features; three simple steps, readily available and inexpensive starting materials, and 
finally, good yields with low by-products. 
To expand the scope of this new route, and to improve the selectivity of the developed method to 
synthesis of γ-lactams, the generation of 3-phenyl substituted pyrrolidine-2-ones (instead of 3-






2.4 Furan bis-pyrrolidine synthesis 
The cyclisation of phenyl substituted homoallylamine was studied in order to expand the scope of 
the γ-lactam synthesis (Scheme 55). 
 
Scheme 55: General scheme for the synthesis of furan bispyrrolidine 
2.4.1 Synthesis of 3-phenyl substituted homoallylamines intermediates 
The cyclisation of 3-phenyl substituted homoallylamines was tried to expand the scope of γ-
lactam synthesis. It was believed that the cyclisation of such homoallylamines could furnish γ-
lactams bearing phenyl substitution at 3-position. We also believed that the phenyl group would 
improve selectivity of the method for the synthesis of azetidine or pyrrolidine or single 
diastereoisomer of γ-lactam based on the steric effect produced compared to methyl group. In 
order to understand this hypothesis, the synthesis of 3-phenyl substituted homoallylamine was 
attempted. Initially, the search for the existence of compound 140 was started either for readily 
availability or for synthetic procedure, only two literature references were found for the synthetic 








The synthesis of 3-phenyl substituted homoallylamines 140 was attempted, from zinc-mediated 
allylation of imines in dry THF at reflux, using phenallylbromide 142. Phenallylbromide was 
prepared by using literature procedure,
73
 by the addition of NBS to α-methyl styrene 141 under 
reflux, in the presence of p-toluene sulfonic acid to give the desired phenallylbromide product 
142 in a 62% isolated yield (Scheme 57). The first attempt in the absence of TsOH, utilising 
literature protocol
74 
was unsuccessful, this suggests that the radical initiator TsOH is required.
73 
 
Scheme 56: Preparation of phenallylbromide in the absence of radical initiator 
 
Scheme 57: Preparation of phenallylbromide via bromination of α-methyl styrene 
A racemic mixture of 140 was obtained in a high yield from treatment of imine 8 with phenallyl 
zinc reagent prepared in situ from 142 in dry THF at reflux temperature. The reaction between 
imine and phenallyl zinc reagents was not observed at room temperature, however, heating the 












1 140a Ph Bn 72 
2 140b Ph 4-Methoxybenzyl 82 
3 140c Ph Me 91 
(a) isolated yield after purification 
When phenyl substituent was used at R
1 
and benzyl at R
2
, the product was obtained in 72% 
(Table 18, entry 1). When electron releasing substituent at R
2
 (4-methoxybenzyl) was used (Table 
18, entry 2), the isolated yield of 140b increased to 82%. When alkyl substituent at R
2
 was used 
(Table 18, entry 3), the isolated yield of 140c was much higher (91%). Then the cyclisation was 
investigated. 
2.4.2 Cyclisation of 3–phenyl substituted homoallylamines 
Compound 140a underwent iodocyclisation using the developed procedure for the synthesis of γ-
lactam (Section 2.3, page 55). Analysis by TLC showed formation of the product after 24 hours. 
After workup, it was found the product could be easily crystallised from hexane or petroleum 
ether alone. The analysis of proton NMR spectra of the crude mixture showed no evidence for the 






Scheme 58: Iodocyclisation of 3-phenyl substituted homoallylamine 
Crystallisation of the product from petroleum ether gave a single crystal for X-ray crystal 
structure determination. The structure was shown to be a novel fused tricyclic furan 
bispyrrolidine 143a. 
 




Unexpectedly, Furan bispyrrolidine 143a was formed as a C2-racemate of the single 
diastereoisomer, as shown in Figure 29, in an acceptable yield (48%), from oxidative 
dimerisation of 3-phenyl substituted homoallylamine 140a. 
Compound 140a was used as a typical substrate for the optimisation of reaction conditions in 
order to improve the product yield of tricyclic compound 143a. Several bases and solvents were 
screened in addition to changing temperature and reagents, the standard reaction condition (Table 





Table 19: Study and optimisation of reaction condition for fused tricyclic compound 
 
 











1 EtOAc NaHCO3 r.t. 24 I2 52 48 - 
2 EtOAc NaHCO3 Reflux 24 I2 81 19 - 
3 EtOAc NaHCO3 r.t 48 I2 83 17 - 
4 EtOAc NaHCO3 r.t 72 I2 89 11 - 
5 EtOAc LiOH r.t 24 I2 80 20 - 
6 EtOH NaHCO3 r.t 24 I2 >50  -
 b
 - 
7 MeCN NaHCO3 r.t 48 I2 69 31 - 
8 EtOAc Cs2CO3 r.t 24 I2 -
 
- >99 
9 EtOAc NaHCO3 r.t 24 NIS 73 27 - 
10 EtOAc NaHCO3 r.t 24 Br2 82 18 - 
11 MeCN LiOH r.t 24 I2 67 33 - 
12 CHCl3 NaHCO3 r.t 24 I2 >99 - - 
13 THF NaHCO3 r.t 24 I2 81 19 - 




When leaving the reaction longer and increasing the reaction temperature to reflux, this led to a 
decrease in the isolated yield to 19-11% (Table 19, entry 2, 3 and 4), suggesting that the 
remaining product in the reaction vessel for a longer time could cause degradation of the 
molecule. Lithium hydroxide (Table 19, entry 5) did not alter the isolated yield of the product. In 
the presence of protic solvent ethanol (Table 19, entry 6), compound 143a was not found, instead, 
the unidentified product was obtained with recovering >50% of the compound 140a. Using 
acetonitrile as a solvent (Table 19, entry 7) gave lower yield 31%. Cesium carbonate (Table 19, 
entry 8) did not deliver compound 143a as expected; instead, the corresponding oxidised form of 
starting material 147 was obtained. Using different cyclisation reagents NIS and Br2 (Table 19, 
entry 9 and 10) did not help to improve the product yield. When LiOH in acetonitrile was 
employed (Table 19, entry 11), no significant improve in the yield was obtained. Employing 
halogenated solvent chloroform (Table 19, entry 12) led to recovering all of the starting material. 
The proposed mechanism suggested the oxidative coupling of the enamine intermediates g 
produced after basic elimination of proton from pyrrolidinium intermediate f followed by 
nucleophilic attack from the nucleophilic carbon of pyrrolidines ring to form h,
 
finally cyclisation 





Scheme 59: Suggested reaction mechanism for the formation of furan bispyrrolidine. 
In order to determine the possibility of the formation of the fused tricyclic product from different 
substrate, the cyclisation of compound 140b and 140c were tried, using the same strategy. 
Compound 143b and 143c were obtained in 20% and 21% isolated yields respectively, (Scheme 
60). 
 
Scheme 60: Synthesis of fused tricyclic furan bispyrrolidine derivatives 
From the results obtained, it was found that compound 143a-c were obtained as major products. 




yields, but the selectivity was already solved for all substrates, as only single diastereoisomers 
were formed in each case.  
In conclusion, a new synthetic procedure developed from the cyclisation of phenyl substituted 
homoallylamine for the preparation of fused tricyclic furan bispyrrolidines functionalised in three 
positions on each pyrrolidine ring via oxidative dimerisation of phenyl-substituted 
homoallylamines using the iodocyclisation procedure. Suggesting that the synthesis of γ-lactam 
bearing phenyl substituent instead of methyl substituent at 3- position was not possible using this 
strategy. 
Further work in our research group is ongoing to expand the scope of this discovery, such as 
changing phenyl group and expanding scope of R to include heterocyclic groups and substituted 
phenyl groups. Additionally, investigation in to the synthesis of enantiopure furan bispyrrolidine 













Result and discussion 





2.5 Synthesis of 3-gem-dimethyl substituted azetidine 
For further study on the cyclisation, the synthesis of 3-gem-dimethyl substituted azetidine from 
cyclisation of gem-dimethyl substituted homoallylamine was then investigated. 
 
Scheme 61: General scheme for the synthesis of 3-gem-dimethylazetidine 
2.5.1 Attempt toward synthesis of 4-gem-dimethyl substituted homoallylamine 
The synthesis of 4-gem-dimethyl substituted homoallylamines 48a was previously reported that 
could be obtained regioselectively as a thermodynamic product, through treatment of imine with 
prenyl zinc bromide in the presence of THF and then DMI according to literature procedure.
75 
In 
order to obtain 48a, the allylation of imine 8a was tried using prenyl zinc bromide in situ 
prepared in dry THF and DMI for 24 h. The product 48b was formed in a 50% yield and 
recovering 40% of the starting material. 
 
Scheme 62: Synthesis of 2-gem-dimethyl substituted homoallylamine 
The expected reaction mechanism suggested for this reaction according to the literature, involves 
allylic rearrangement,
76




the homoallylamines 48a to 48b in the presence of DMI and another imine molecule because of 
high temperature, but the formation of only 48b suggests that the isomerisation did not occur. 
 
Scheme 63: Transition state and mechanism of synthesis of 2-gem-dimethallylamine 
The zinc mediated allylation of imine 8a to generate 4-gem-dimethyl substituted 
homoallylamines 48a was unsuccessful due to the formation of 48b being faster than 48a. With 
50% of 48b in hand, then the cyclisation was attempted. 
2.5.2 Cyclisation of 2-gem-dimethyl substituted homoallylamines 
The iodocyclisation of 2-gem-dimethyl substituted homoallylamines was believed to furnish 2-
gem-dimethylazetidines. Despite the difficulties faced during the synthesis of 48b (section 2.5.1), 
cyclisation was attempted. After the reaction completed and analysis of the crude 
1
H NMR 
spectrum revealed the formation of a mixture of equal amount of iodoazetidine 148 and 




resulted in the recovery of the aminoazetidine 150 in a 50% isolated yield, but purification of 
aminopyrrolidine was not successful. 
 
Scheme 64: Iodocyclisation of 2-gem-dimethylsubstitutedhomoallylamine 
The synthesis of 2-gem-dimethyl substituted azetidines proved to be problematic by this strategy. 
Further work is ongoing in our research group towards discovering a new procedure for the 




2.6 Towards the synthesis of 3-substituted azetidines 
In order to study the cyclisation of 3-methyl substituted homoallylamine and the possibility of the 
synthesis of chiral 3-methyl substituted azetidine, the iodocyclisation of 2-methyl substituted 
homoallylamine was investigated. 
 
Scheme 65: Suggested general scheme for the synthesis of 3-methylazetidines 
2.6.1 Synthesis of 2-methyl substituted homoallylamine intermediate 
The zinc-mediated allylation of imines 8a utilising crotylbromide can afford 49a and 49b as a 
mixture of diastereomer (syn/anti) in a (7:3) ratio. The reaction was conducted using a 
combination of two literature procedures,
 57,75 
treatment of imine 8a with the in situ generated 
allyl zinc reagent, which was prepared by using two equivalents of crotylbromide and 2.5 
equivalents of zinc in dry THF in the presence of indium triflate. A mixture of diastereomers 49a 
and 49b were obtained (dr 67:33) in a 43% isolated yield.  
 




Several column chromatography methods were attempted for separation, but unfortunately, it was 
impossible to successfully separate the diastereomers. Analysis of the crude 
1
H NMR spectrum of 
the product revealed a mixture of two diastereoisomers in a ratio of 67:33 (syn/anti). The ratio is 
due to the allylic rearrangement that resulted from the resonance of the transition state (Figure 
30), which resulted in a decrease in the ratio of syn isomer compared to the anti isomer. As a 
result of the difficulties encountered during the separation of diastereoisomers, the compound 
was taken forward to the cyclisation step as a mixture of diastereoisomers.  
 
Figure 30: Transition state of 2-methyl homoallylamine formation 
2.6.2 Cyclisation attempt of 2-methyl substituted homoallylamines 
The cyclisation of 2-methyl substituted homoallylamine 49 was thought to give an azetidine with 
one extra chiral centre at the position 3 (151). The diastereometric mixtures of compound 49 
were mixed with three equivalents of iodine and five equivalents of sodium bicarbonate in 
acetonitrile at room temperature. Analysis of the result confirmed that azetidine 151 was not 






Scheme 67:Iodocyclisation of 2-methyl substituted homoallylamine 
In conclusion, based on the results obtained from the cyclisation of 2-methyl substituted 
homoallylamine, it is proved that the synthesis of chiral 3-substituted azetidine is not possible by 
using this method. For further investigation, the reaction conditions optimisation could be 
considered or finding another synthetic route. 
2.7 Cyclisation attempt of cyclic homoallylamine 
The study on the cyclisation of cyclic homoallylamine to obtain ring fused azetidine was 
attempted. 
 
Scheme 68: Suggested general scheme for the synthesis of fused azetidines 
 
The syntheses of ring-fused azetidines were another goal that was expected that could be 
achieved from the cyclisation of cyclic homoallylamine 152a (Scheme 70). In order to achieve 
this goal, the synthesis of cyclic homoallylamine 152a was attempted. Homoallylamine 152a was 
prepared in a 63% isolated yield, using the standard literature procedure,
 57 




8a with in situ prepared cyclohex-2-en-1-ylzinc bromide reagent, followed by an aqueous workup 
to give the crude product in complete conversion. Purifying 152a using column chromatography 
causes degradation of the product. After numerous attempts for purification through traditional 
chromatographic techniques, including gravity and flash column chromatography utilising 
several solvent systems and eluent, such as ethyl acetate and hexane, it was found that triturating 
the crude compound in water overnight resulted in a pure product. 
 
Scheme 69: Synthesis of cyclohexenylallylamine 
Cyclisation of 152a was attempted utilising the iodine mediated cyclisation strategy.
22 
Analysis 
of TLC showed that all the starting material was consumed. The proton NMR spectrum showed 
no evidence for the formation of the desired fused azetidine 154. Instead the secondary amine 






Scheme 70: Iodocyclisation of cyclic homoallylamine 
The two possible transition states are proposed TS I and TS II (Figure 31). The formation of 
unfavourable high-energy transition state TS I, due to 1,3-diaxial interaction, prevented the 
cyclisation from delivering the desired fused azetidine154. 
 
Figure 31: Unfavourable high-energy transition states 
In conclusion, the cyclisation of cyclic homoallylamine was unsuccessful to deliver ring fused 
azetidine, suggests that the synthesis of ring fused azetidine need further servey and study to find 
a good method. For example, using terminal alkene bonded to aliphatic ring (Scheme 71). This 

















Results and Discussion 































































































































In conclusion, the synthesis of a symmetric chiral cis-2,4-azetidines in 50-83% yields and up to 
99% ee from cyclisation of enantiopure homoallylamines was reported, employing iodine-
mediated cyclisation methodology established by the Fossey research group for the synthesis of 
racemic cis-2,4-azetidine. The substrate scope of the previous methodology was also expanded. 
An efficient new procedure for the synthesis of γ-lactams, as a mixture of diastereomers in 34-
99% yields has been developed from the cyclisation of 3-methyl substituted homoallylamines, 
using three equivalents of iodine and five equivalents of sodium bicarbonate in ethyl acetate at 
room temperature. Single diastereomers were separated using column chromatography. In 
addition, some modifications were made in the synthesis of nicotine analogues. As a result, a new 
class of the hydroxylated pyrrolidine derivatives was  generated from the reduction of pyrrolidin-
2-ones. The optimisation of the reaction conditions for the synthesis of γ-lactam, led to another 
important route for oxidation of secondary amines using caesium carbonate as a base with iodine 
in ethyl acetate. 
Biological activity tests for the synthesised γ-lactam derivatives, such as cis+trans-130a and 
cis+trans-130j have shown intriguing activities, particularly in the brain and liver of zebrafish 
embryos. Anti-inflammatory activity was investigated for some of the synthesised γ-lactam 
derivatives, such as 130a, 130g, 130h, 130k, 130m and 130n and only compounds 130g and 
130n showed to have anti-inflammation activity. Anti-bacterial activity for a mixture of 
diastereomers of compounds 130a, 130g, 130n, and 130j was measured, and interestingly, 130g 




A new efficient methodology was established for the synthesis of fused tricyclic furan 
bispyrrolidines stereoselectively in 20-48% yields, from iodine-mediated cyclisation of 3-phenyl 
substituted homoallylamines, using the same protocol as for the synthesis of γ-lactams. 
The generation of gem-dimethyl substituted azetidine was found to be problematic when using 
this strategy, because of the difficulties faced in the synthesis of the starting materials. In 
addition, the iodocyclisation of cyclic homoallylamine for the synthesis of fused azetidine was 
investigated and it was found that obtaining azetidine was not possible and the cyclisation was 
not successful, instead the starting material was oxidised to form the corresponding imine in 
>87% conversion. 
Finally, a new straightforward route for the preparation of novel 2-pyrazoline derivatives was 
designed from cyclisation of homoallylhydrazines, using three equivalents of iodine and five 
equivalents of sodium bicarbonate in acetonitrile, at room temperature. A library of novel 
aminopyrazoline derivatives has been prepared in 61-86% yields. The study found evidence for 
the fluorescence property of the synthesised pyrazoline derivatives and proved the role of 
substituents on the fluorescence property. 
The application of the synthesised compounds in biology and catalytic activity are under 
investigation by the Fossey research group. In addition, some of the synthesised γ-lactams and 
pyrazoline molecules were sent to Syngenta and are currently under investigation in 
agrochemistry. Several of the synthesised pyrazoline and γ-lactam compounds were submitted for 


















5. Future work 
2-pyrazoline derivatives bearing stereogenic quaternary carbon centre could be obtained from the 
iodocyclisation of 3-Methyl substituted homoallylhydrazine 159, which could be synthesised 
from zinc mediated allylation of imine. 
 
In addition, a click-reaction could be performed to displace iodine from the synthesised 
iodopyrazoline to form triazole linked with pyrazoline. 
 
From the proved fluorescence properties of pyrazoline derivatives,
54
 the comprehensive study 
could be undertaken to investigate their uses as a selective sensor.  
Synthesis of enantiopure pyrazoline derivatives could be attempted by using chiral auxiliary 






and applying a similar protocol on cyclisation of homoallylhydrazines to access 
the synthesis of enantiopure pyrazoline. 
 
Biological activity could be investigated for the synthesised 2-pyrazoline derivatives through 
screening zebrafish embryos developmental assays, and the structure activity relationships (SAR) 

















6. Experimental Part 
All reagents and solvents used are commercially available, from Sigma-Aldrich or Fisher, unless 
otherwise stated. 
1
HNMR spectroscopy was performed at 300 MHz on a Bruker AVIII300 NMR 
spectrometer, and at 400 MHz on an AV400 NMR spectrometer. Proton decoupled 
13
CNMR 
spectroscopy was recorded at 10 MHz on a Bruker AVIII400 NMR spectrometer at room 
temperature. Chemical shifts (δ) were recorded in ppm relative to TMS (δ 0.00) for 
1
HNMR or 
residual solvent and to chloroform (δ 77.0) for the 
13
CNMR measurements, coupling constant J 
are expressed in Hertz. The PENDANT technique was used to aid 
13
CNMR assignment in some 
cases. Mass spectra were recorded by Electrospray MS waters LCT Time of flight Mass 
Spectrometer and with EI (GC/MS) waters GCT premier time of flight mass spectrometer. IR 
spectroscopy was recorded on a PerkinElmer 100FT-IR spectrometer at room temperature. 
Column chromatogram was obtained from combiflash machine Rf300. Melting points were 
measured by the Stuart
TM 
digital melting point apparatus (SMP10). 
General Procedures 
General procedure for preparation of imines (a1) 
Aldehyde (1 equiv.) and amine (1.1 equiv.) were mixed in ethanol (30 mL) and the reaction 
mixture was stirred at reflux temperature for six hours. After the reaction was completed, then the 





General procedure for preparation of hydrazone imines (a2) 
Aldehyde (1 equiv.) and phenylhydrazine (1.05 equiv.) were mixed in ethanol (10 mL) and the 
reaction mixture was stirred at room temperature for two hours (if the reaction did not start, it 
needed to be refluxed for 2 hours). After the reaction was completed, the reaction mixture was 
cooled to room temperature, it was filtered under vacuum, and the solid products were collected 
and dried under vacuum. 
General procedure for preparation of homoallylamines (b1) 
Magnesium turning (2 equiv.) under nitrogen, was mixed with ally bromide (1.5 equiv.) in dry 
THF (10 mL) and stirred at room temperature for 30 minutes. An appropriate amount of imines 
(1 equiv.) in dry THF (2 mL) was added. The reaction mixture was stirred for 16 hours at room 
temperature. After the reaction was completed, it was quenched with a saturated solution of 
sodium bicarbonate (5mL) and was extracted with ethyl acetate (3x 20 mL), the product was 
obtained after column chromatography (ethyl acetate/ hexane 1:9). 
General procedure for preparation of homoallylamines (b2) 
Imine (1 equiv.) in dichloromethane (20 mL) was mixed with boron triflouride diethyl etherate (3 
equiv.) and the reaction mixture was stirred at room temperature for 30 minutes. Then 
allyltributyltin (1.5 equiv.) was added. The reaction mixture was stirred for 16 hours at room 
temperature with TLC monitoring, when the reaction was completed, it was quenched with brine 
and was extracted with (3x 20 mL) ethyl acetate, the combined organic layers were concentrated 
in vacue and dried with MgSO4, and the crude was purified with column chromatography ethyl 




General procedure for preparation of enantiopure Ellman homoallylamines (c1) 
Activated zinc powder (3 equiv.) under nitrogen, was mixed with indium triflate (2 equiv.) and 
ally bromide (2 equiv.) in dry THF (10 mL), and then stirred for 30 minutes at room temperature. 
(R)-(+)-tert-butaylsulfinimine (1 equiv.) in dry THF (10 mL) was added, the reaction mixture 
was stirred at room temperature for 24 hours with TLC monitoring. After the reaction was 
completed then the reaction was quenched with brine and extracted with ethyl acetate (3x 20 
mL), the pure product was obtained after column chromatography ethyl acetate/ hexane 1:9. 
General procedure for preparation of enantiopure amine (deprotection of Ellman auxiliary) 
(c2) 
Ellman homoallylamine (1 equiv.) was mixed with (2 equiv.) of (1:1) 4M hydrochloric acid in 
dioxane and methanol prepared in situ. The reaction mixture was stirred for 24 hours at room 
temperature. Afetr the reaction was completed then the solvent was removed in vacue, the residue 
was washed with diethyl ether (3x 5mL), the aqueous layer was neutralized and re-extracted with 
diethyl ether (3x 10 mL), the combined organic layers were dried using MgSO4 and the solvent 
was removed in vacuo. 
General procedure for preparation of enantiopure homoallylamines (c3) 
Aldehyde (1 equiv.) in methanol (10 mL) was mixed with (1.1 equiv.) of enantiopure amine 
stirred at reflux temperature for 6 hours and cooled at room temperature, then sodium 
borohydried (2 equiv.) was added and stirred for 24 hours at room temperature. Methanol was 




organic layers were dried with MgSO4. The pure product was obtained after column 
chromatography (ethyl acetate/ hexane 2/8). 
General procedure for preparation of 3-methyl-substituted homoallylamines (d) 
Activated zinc powder (2 equiv.) under nitrogen, was mixed with methallylbromide (1.5 equiv.) 
in dry THF (10 mL) and stirred for 30 minutes at room temperature. An appropriate amount of 
imines (1 equiv.) in dry THF (2 mL) was added and the reaction mixture was stirred for 16 hours 
at room temperature. After the reaction was completed as judged by TLC, it was quenched with a 
saturated solution of sodium bicarbonate (5 mL) and extracted with ethyl acetate (3x 20 mL), the 
combined organic layers were concentrated in vacuo and the product was purified by column 
chromatography ethyl acetate/ hexane 1:9. 
General procedure for preparation of 3-phenyl-substituted homoallylamines (e) 
Activated zinc powder (2 equiv.) under nitrogen, was mixed with phenyl-substituted allybromide 
(2.5 equiv.) in dry THF (10 mL) and stirred for 30 minutes (heat to 50 
°
C). An appropriate 
amount of imines (1 equiv.) in dry THF (2 mL) was added. The reaction mixture was heated at 
reflux temperature for one hour, and then the reflux was removed and was stirred for another 16 
hours at room temperature. After the reaction was completed as judged by TLC, it was quenched 
with a saturated solution of sodium bicarbonate (5mL) and extracted with ethyl acetate (3x 20 
mL), the combined organic layers were combined and concentrated in vacuo and the pure product 





General procedure for preparation of homoallylhydrazines (f) 
Activated zinc powder (2 equiv.) under nitrogen, was mixed with ally bromide (2.5 equiv.) in dry 
THF (10 mL) and was stirred for 30 minutes. An appropriate amount of hydrazone imines (1 
equiv.) in dry THF (2 mL) was added. The reaction mixture was stirred for 6 hours at room 
temperature. After the reaction was completed as judged by TLC, it was quenched with a 
saturated solution of sodium bicarbonate (5 mL) and extracted with ethyl acetate (3x 20 mL), the 
combined organic layers were concentrated in vacuo and the pure product was obtained after 
column chromatography ethyl acetate/hexane 1:1. 
General procedure for preparation of 2-gem-dimethyl-substituted homoallylamines (g) 
Activated zinc powder (2 equiv.) under nitrogen, was mixed with prenyl bromide (2.5 equiv.) in 
dry THF (10 mL) and was stirred for 30 minutes at room temperature. An appropriate amount of 
imines (1 equiv.) in dry THF (2 mL) was added. The reaction mixture was stirred for an hour. 
Then DMI (5mL) was added and the mixture was heated to 120 
°
C for overnight. After the 
reaction was completed as judged by TLC, it was quenched with a saturated solution of sodium 
bicarbonate (5mL) and extracted with (3x 20 mL) ethyl acetate, the pure product was obtained 
after column chromatography ethyl acetate/hexane 1:9. 
General procedure for azetidines synthesis (h) 
Homoallylamines (1 equiv.) in acetonitrile (50 mL), were mixed with iodine (3 equiv.) and 
sodium bicarbonate (5 equiv.) and was stirred for 16 hours at 0-20 
°
C. After the reaction was 
completed, the the reaction was quenched by a saturated solution of sodium thiosulfate, then 




then dried by MgSO4. The crude iodoazetidine was mixed with excess of amine (3 mL) in neat, 
and was stirring at room temperature for 48 hours, the reaction was quenched by (2M NaOH) 
solution, and extracted with dichloromethane and washed with brine and water, the product was 
obtained after column chromatography. 
General procedure for synthesis of γ-lactams (i) 
Methyl substituted homoallylamines (1 equiv.) in ethyl acetate (25 mL) were mixed with iodine 
(3 equiv.) and sodium bicarbonate (5 equiv.), the mixture was stirred at room temperature for 24 
hours. After the reaction was completed as judged by TLC, then it was quenched with sodium 
thiosulfate (5mL) and extracted with ethyl acetate (3x20 mL). The combined organic layers were 
concentrated in vacuo and purified by column chromatography. Separation of diastereomers was 
performed by further column chromatography. 
General procedure for synthesis of furan bispyrrolidines (j) 
Phenyl substituted homoallylamines (1 equiv.) in ethyl acetate (25 mL) were mixed with iodine 
(3 equiv.) and sodium bicarbonate (5 equiv.), the reaction mixture was stirred at room 
temperature for 24 hours. After the reaction was completed as judged by TLC, then it was 
quenched with sodium thiosulfate (5mL) and extracted with ethyl acetate (3x20 mL). The 






General procedure for synthesis of iodopyrazolines (k) 
Homoallylhydrazines (1 equiv.) in acetonitrile (25 mL) were mixed with iodine (3quiv.) and 
sodium bicarbonate (5 equiv.), the reaction mixture was stirred at room temperature for 24 hours, 
After the reaction was completed as judged by TLC, then it was quenched with sodium 
thiosulfate (5mL) and extracted with ethyl acetate (3x20 mL). The combined organic layers were 
concentrated under reduced pressure. 
General procedure for synthesis of aminopyrazolines (l) 
The crude iodopyrazolines were mixed in neat with an excess amount of amines, the reaction 
mixture was stirred at room temperature for 48 hours with TLC monitoring, then it was quenched 
with 2M NaOH, and extracted with dichloromethane (3x20 mL) and washed with brine (3x10 
mL), and the combined organic layers were concentrated in vacuo, and dried over MgSO4. The 







General procedure (a1) was used, benzaldehyde (1.0 gm, 9.40 mmol), 
benzylamine (1.1 gm, 9.00 mmol), colourless oil, 180 mg 99% yield. IR 
3084, 3063, 2795, 1652, 1576, 1478, 1450, 1422, 1379, 1308, 1283, 1224, 1166, 1026, 834, 725, 
670.
1
H NMR (δ; 300 MHz, CDCl3); 4.83 (2H, s, CH2), 7.20- 7.35 (8H, m, ArCH), 7.71-7.82 (2H, 
m, ArCH), 8.45 (1H,s, CH=N).
13
C NMR (δ; 100 MHz CDCl3); 65.2 (CH2), 127.2 (ArCH), 128.2 
(ArCH), 128.6 (ArCH), 131.5 (ArC), 139.0 (ArC), 162.5 (CH=N). MS (ES+) calculated for 




General procedure (a1) was used, pivaldehyde (1.0 gm, 11.6 mmol), 
benzylamine (0.8 gm, 6.00 mmol), yellow oil, 174 mg 91% yield. IR 2889, 
1890, 1642, 1430, 1023.
1
H NMR (δ; 300 MHz, CDCl3); 1.05 (9H, s,CH3), 4.45 (2H, s, ArCH2), 
7.10-7.25 (5H, m, ArCH), 7.55 (1H, s, CH=N).
13
C NMR (δ; 100 MHz, CDCl3); 12.6 (3CH3), 
27.1 (CH), 45.6 (CH2), 126.9 (2ArCH), 127.5 (2ArCH), 1128.1 (ArCH), 133.3 (ArC), 151.9 




General procedure (a1) was used, 3-Pyridinecarboxaldehyde (1.0 gm, 
9.30 mmol), benzylamine (1.0 gm, 9.00 mmol), pale yellow oil, 168 mg 
90% yield. IR; 3060, 3029, 2882, 1646, 1586, 1567, 1467, 1435, 1364, 992, 771, 739, 698.
1
H 




J7.6, 1.5, PyrCH), 8.44 (1H, d, J 7.9, PyrCH), 8.68 (1H, d, J 7.1, PyrCH), 8.9 (1H, s, CH=N),
 13
C 
NMR (δ; 100 MHz, CDCl3); 55.3 (CH3), 64.7 (CH2), 113.9 (2ArCH), 123.7 (ArCH), 129.3 
(2ArCH), 130.8 (ArC), 131.8 (PyrC), 134.6 (PyrCH), 150.3 (PyrCH), 151.5 (PyrCH), 158.5 
(CH=N), 158.8 (PyrCH). MS (ES+) calculated for formula C13H12N2
+
: 197.2; found: 197.2. The 




General procedure (a1) was used, benzaldehyde (1.0 gm, 9.40 
mmol), 4-methoxybenzylamine (1.2 gm, 6.90 mmol), yellow oil, 
172 mg 94% yield. IR 3016, 2664, 1602, 1525, 1459, 1395, 1389, 1356, 1308, 1285, 1222, 1190, 
1134, 1087, 1035, 896, 890, 868, 814, 777, 763, 710, 680. 
1
H NMR (δ; 300 MHz, CDCl3); 3.75 
(3H, s, OCH3), 4.75 ( 2H, s, ArCH2), 6.85 (2H, dd, J 15, 1.3, ArCH), 7.25 (2H, dd, J 15, 1.8, 
ArCH), 7.35 (5H, m, ArCH), 8.25 (1H, s, CH=N).
13
C NMR (δ; 100 MHz, CDCl3); 55.3 (OCH3), 
64.5 (CH2), 114.0 (2ArCH), 128.3 (2ArCH), 128.6 (2ArCH), 129.3 (2ArCH), 130.8 (ArCH), 





General procedure (a1) was used, thiophencarboxaldehyde (1.0 gm, 9.0 
mmol), benzylamine (1.2 gm, 10.0 mmol), brown yellow oil, 175 mg 92% 
yield. IR 3063, 3027, 2869, 1631, 1495, 1430, 1345, 1219, 1044, 835, 697.
1
H NMR (δ; 300 
MHz, CDCl3); 4.83 (2H, s, ArCH2), 7.11 (1H, dd, J 5.0, 3.6, ThioCH), 7.26- 7.45 (7H, m, ArCH, 
ThioCH), 8.49 (1H, s, CH=N).
13




127.4 (ArCH), 128.0 (2ArCH), 128.5 (2ArCH), 129.0 (ThioCH), 130.7 (ThioCH), 139.0 
(ThioC), 142.4 (ArC), 155.2 (CH=N). MS (ES+) calculated for formula C12H12NS: 202.1; found: 




General procedure (a1) was used, benzaldehyde (1.0 gm, 9.40 mmol), 
propylamine (50 mg, 9.40 mmol), yellow oil, 121 mg 92% yield. IR 3027, 
3062, 2960, 2930, 2873, 2832, 1646. 
1
H NMR (δ; 300 MHz, CDCl3); 0.96 (3H, t, J 17.0,  CH3), 
1.75 (2H, m, CH2), 3.58 (2H, t, J 9.0, CH2), 7.35-7.45 (2H, m, ArCH), 7.65-7.72 (3H, m, ArCH), 
8.25 (1H, s, CH=N).
13
C NMR (δ; 100 MHz, CDCl3); 11.9 (CH3), 24.1 (CH2), 63.5 (CH2), 128.1 




General procedure (a1) was used, benzaldehyde (1.0 gm, 9.40 mmol), 2-
methylbenzylamine (1.1 gm, 9.40 mmol), pale yellow oil, 178 mg 90% 
yield. IR 2835, 2823, 1605, 1576, 1492, 1364, 1311, 1127, 1035, 898, 830, 762, 704, 689.
1
H 
NMR (δ; 300 MHz, CDCl3); 2.35 (3H, s, CH3), 4.35 (2H, s, ArCH2), 7.25-7.55 ( 8H, m, ArCH), 
7.75 (1H, d, J 4.5, ArCH), 8.35 (1H, s, CH=N).
13
C NMR (δ; 100 MHz CDCl3); 19.4 (CH3), 62.7 
(CH2), 126.2 (ArCH), 127.2 (ArCH), 128.3 (2ArCH), 128.5 (ArCH), 128.7 (2ArCH), 130.2 
(ArCH), 130.8 (ArCH), 136.3 (ArC), 137.6 (ArC), 161.9 (CH=N). MS (ES+) m/z= 192.1. The 






N- benzylidene-1-pyridine-3-yl)methanamine (8k) 
General procedure (a1) was used, benzaldehyde (1.0 gm, 9.40 mmol), 3-
picolylamine (1.1 gm, 9.40 mmol), yellow oil, 170 mg, 95% yield. IR 
3027, 2844, 1642, 1576, 1478, 1450, 1422, 1379, 1308, 1293, 1217, 1170, 1124, 1066, 1025, 
963, 923, 858, 824, 787, 753, 711, 692. 
1
H NMR (δ; 300 MHz, CDCl3); 4.75 (2H, s, PyrCH2), 
7.22-7.45 (5H, m, ArCH), 7.65 (1H, d, J 13.1, PyrCH), 8.45 (1H, s, PyrCH), 8.51 (1H, dd, J 6.1, 
2.0, PyrCH), 8.65 (CH=N).
13
C NMR (δ; 100MHz, CDCl3); 62.3 (CH2), 123.4 (PyrCH), 128.3 
(2ArCH), 128.7 (2ArCH), 131.0 (ArCH), 134.9 (PyrCH), 135.5 (ArC), 135.9 (PyrC), 148.4 




General procedure (a1) was used, furancarboxaldehyde (1 gm, 10.0 
mmol), benzylamine (1.2 gm, 10.0 mmol), brown oil, 172 mg 95% yield.
 
1
H NMR (δ; 300 MHz, CDCl3); 4.73 (2H, s, ArCH2), 6.85 (1H, s, FurCH), 7.72 (1H, s, FurCH), 
7.41 (1H,s, FurCH), 7.22-7.38 (5H, m, ArCH), 8.33 (1H, s, CH=N).
13
C NMR (δ; 100 MHz, 
CDCl3); 65.2 (CH2), 108.0 (FurCH), 125.5 (FurC), 127.0 (ArCH). 128.0 (2ArCH), 128.4 
(2ArCH), 139.2 (ArC), 144.1 (FurCH), 145.4 (FurCH), 153.6 (CH=N). MS (ES+) m/z= 185.1. 







General procedure (a1) was used, benzaldehyde (1.0 gm, 9.40 mmol), 
4-chlorobenzylamine (1 gm, 9.40 mmol), yellow oil, 195 mg 92% 
yield. IR 3027, 2841, 1892, 1643, 1490, 1090, 1014, 798, 753, 691.
1
H NMR (δ; 300 MHz, 
CDCl3); 4.76 (2H, s, ArCH2), 7.22-7.38 (5H, m, ArCH), 7.35-7.45 (2H, m, ArCH), 7.72- 7.78 
(2H, m, ArCH), 8.35 (1H, s, CH=N).
13
C NMR (δ; 100 MHz, CDCl3); 64.2 (CH2), 128.4 
(2ArCH), 128.6 (2ArCH), 129.0 (2ArCH), 129.5 (2ArCH), 131.0 (ArCH), 132.8 (ArC), 136.0 




General procedure (a1) was used, 1-naphthalenecarboxaldehyde (1 gm, 
6.40 mmol), benzylamine (1.2 gm, 6.4 mmol), yellow oil, 149 mg 95% 
yield. IR 3023, 2860, 1631, 1587, 1497, 1411, 1302, 1355, 1315, 1302, 1342, 1224, 1119, 1090, 
1024, 875, 850, 810, 755, 730, 710, 680.
1
H NMR (δ; 300 MHz, CDCl3); 5.02 (2H, s, ArCH2), 
7.28-7.71 ( 4H, m, ArCH), 7.90-8.06 (2H, m, ArCH), 9.05 (1H, d, J 8.4, ArCH), 9.10 (1H, s, 
CH=N).
13
C NMR (δ; 100 MHz, CDCl3); 66.1 (CH2), 124.4 (ArCH), 125.3 (ArCH), 126.1 
(ArCH), 127.0 (ArCH), 127.1 (ArCH), 127.2 (ArCH), 128.0 (ArCH), 128.6 (ArCH), 128.7 
(ArCH), 129.2 (ArCH), 131.2 (ArCH), 131.4 (ArCH), 131.6 (ArC), 133.9 (ArC), 139.6 (ArC), 







General procedure (a1) was used, 3,4- methoxycarboxaldehyde (1 
gm, 7.20 mmol), benzylamine (1.1 gm, 6.02 mmol), yellow oil, 
140 mg 92% yield.
1
H NMR (δ; 300 MHz, CDCl3); 3.93 (3H, s, OCH3), 3.95 (3H, s, OCH3), 4.83 
(2H, s, ArCH2), 6.89 (1H, s, ArCH), 6.91 (1H, s, ArCH), 7.21 (1H, dd, J 8.2, 1.9, ArCH), 7.28-
7.41 ( 2H, m, ArCH), 7.52 (1H, d, J 1.9, ArCH), 8.32 (1H, s, CH=N).
13
C NMR (δ; 100 MHz, 
CDCl3); 55.9 (2CH3), 64.9 (CH2), 108.8 (ArCH), 110..4 (ArCH), 123.3 (ArCH), 126.9 (ArCH), 
127.0 (ArCH), 128.0 (ArCH), 128.4 (ArCH), 129.4 (ArC), 139.4 (ArC), 149.3 (ArC), 151.4 
(ArC), 161.5 (CH=N). MS (ES
+
) m/z 256 (M+H
+





General procedure (a1) was used, 4-nitrocarboxaldehyde (1.0 gm, 
6.30 mmol), benzylamine (1.1 gm, 6.30 mmol), brown oil, 133 mg 
92% yield. IR 3063, 3029, 2850, 1644, 1600, 1517, 1375, 1339, 1107, 1027, 838, 698.
1
H NMR 
(δ; 300 MHz, CDCl3); 4.88 (2H, s, ArCH2), 7.22-7.39 (5H, m, ArCH), 7.92 (2H, dd, J 7.8, 2.0, 
ArCH), 8.24 (2H, dd, J 7.9, 1.9, ArCH), 8.46 (1H, s, CH=N).
13
C NMR (δ; 100 MHz, CDCl3); 
65.2 (CH2), 123.9 (2ArCH), 127.3(ArCH), 128.1 (2ArCH), 128.7 (2ArCH), 129.0 (2ArCH), 
138.5 (ArC), 141.6 (ArC), 149.1 (ArCNO2), 159.5 (CH=N). MS (ES
+








General procedure (a1) was used, 2-bromocarboxaldehyde (1.0 gm, 
mmol), benzylamine (1.0 gm, 6.4 mmol), yellow oil, 124 mg 92% yield.
 
1
H NMR (δ; 300 MHz, CDCl3); 4.76 (2H, s, ArCH2), 7.13-7.26 (7H, m, ArCH), 7.45-7.48 (1H, 
m, ArCH), 7.97 (1H, dd, J 7.7, 1.9, ArCH), 8.68 (1H, s, CH=N).
13
C NMR (δ; 100 MHz, CDCl3); 
66.2 (CH2), 125.2 (ArCH), 127.1(ArCH), 128.0 (ArCH), 128.2 (ArCH), 128.5 (ArCH), 131.9 
(ArCH), 133.0 (ArCH), 134.5 (ArC), 139.0 (ArC), 161.0 (CH=N). MS (ES
+
) m/z 273.0 (M+H
+
). 




General procedure (a1) was used, benzaldehyde (1 gm, 9.40 mmol), 
admatamine (1.2 gm, 9.80 mmol), white precipitate, 146 mg 93% yield. 
IR 3027, 2841, 1892, 1643, 1490, 1090, 1014, 798, 753, 691.
1
H NMR (δ; 
300 MHz, CDCl3); 1.66-1.81 (15H, m, 6CH2, 3CH), 7.35-7.45 (2H, m, ArCH), 7.70-7.80 (3H, m, 
ArCH), 8.8.29 (1H, s, CH=N).
13
C NMR (δ; 100 MHz, CDCl3); 29.6 (3CH), 36.6 (3CH2), 43.2 
(3CH2), 57.5 (C), 127.9 (2ArCH), 128.5 (2ArCH), 130.1 (ArCH), 137.3 (ArC), 155.0 (CH=N). 
HRMS [M+H]
+
 calculated for formula C17H22N: 240.1752; found: 240.1752. 
N-(4-methoxybenzyl)-1-(pyridin-3-yl)methanimine (8s) 
General procedure (a1) was used, 3-pyridinecarboxaldehyde (1 gm, 
9.30 mmol), 4-methoxybenzylamine (1.2 gm, 9.30 mmol), yellow 
oil 90% yield. IR 3386, 2958, 2836, 1610, 1589, 1511, 1246, 1029, 817, 706.
1
H NMR (δ; 300 




(2H, m, ArCH), 7.7 (1H, d, J 7.1, PyrCH), 7.75 (1H, m, PyrCH), 8.4 (1H, s, PyrCH), 8.5 (1H, d, 
J 6.9, PyrCH), 8.55 (CH=N).
13
C NMR (δ; 100 MHz, CDCl3); 55.3 (CH3), 64.7 (CH2), 113.9 
(2ArCH), 123.7 (PyrCH), 129.2 (2ArCH), 131.8 (ArC), 132.0 (PyrC), 134.6 (PyrCH), 150.3 
(PyrCH), 151.5 (PyrCH), 158.5 (CH=N), 158.8 (ArCOMe). HRMS (M+H
+
) calculated for 
formula C14H15N2O
+





Benzaldehyde (1gm, 9.4 mmol) was mixed with methylamine solution (5 mL) 
and stirred at room temperature for 24 hours, the solvent was removed to give 
pure imine. Pale yellow oil, 110 mg 99% yield.
1
H NMR (δ; 300 MHz, CDCl3); 3.51 (3H, s, CH3), 
7.39-7.41 (3H, m, ArCH), 7.69-7.72 (2H, m, ArCH), 8.26 (1H, s, CH=N).
13
C NMR (δ; 100 MHz, 
CDCl3); 48.2 (CH3), 127.9 (ArCH), 128.2 (ArCH), 128.6 (ArCH), 129.7 (ArCH), 130.5 (ArCH), 
136.2 (ArC), 162.6  (CH=N). MS (ES+) calculated for formula C14H13N: 120.1; found: 120.1. 
The spectral data are comparable with literature.
90 
N-methyl-1-(pyridin-3-yl)methanimine (8u) 
3-Pyridinecarboxaldehyde (1gm, 9.30 mmol) was mixed with methylamine 
solution (5 mL) and stirred at room temperature for 24 hours, the solvent was 
removed to give pure imine, yellow oil, 115 mg 99% yield. 
1
H NMR (δ; 300 MHz, CDCl3); 3.55 
(3H, s, CH3), 7.32-7.36 (1H, m, PyrCH), 8.06-8.09 (1H, m, PyrCH), 8.32 (1H, s, PyrCH), 8.63-
8.65 (1H, m, PyrCH), 8.86 (1H, s, CH=N).
13
C NMR (δ; 100 MHz, CDCl3); 48.4 (CH3), 123.6 




(ES+) calculated for formula C14H13N: 121.1; found: 121.1. The spectral data are comparable 
with literature.
91 
N-benzyl-1-((2S, 4R)-4-phenyl-1-(pyridin-3-ylmethyl)azetidin-2-yl)methanamine (44a) 
General procedure (h) was used, 1-phenyl-N-(pyridin-3-
ylmethyl)but-3-en-1-amine (280 mg, 0.83 mmol), flash 
chromatography (DCM/Methanol= 9.5/0.5), yellow brown oil, 200 
mg 65% yield. IR 3020, 2822, 1670, 1567, 1470, 1454, 1421, 
1354, 1260.
1
H NMR (δ; 300 MHz, CDCl3); 2.01 (2H, dd, J 18.8, 8.7, CHCHHN), 2.39-2.49 (2H, 
m, CHCHHCH), 2.56 (1H, dd, J 12.1, 4.3, CH), 3.32 (1H, m, CH), 3.67 (ABq, 2H, JAB13.2, 
JAB13.2, PyrCH2), 3.64 (2H, s, ArCH2), 3.99 (1H, app.t, J 8.2,  CHCHH), 7.08 (2H, ddd, J 7.7, 
4.8, 0.6, ArCH), 7.13-7.44 (10H, overlapping m, ArCH, PyrCH), 8.39 (1H, dd, J 4.8, 1.6, 
PyrCH), 8.49 (1H, d, J 1.8, PyrCH).
13
C NMR (δ; 100 MHz, CDCl3), 31.3 (CH2), 53.3 (CH2), 
54.0 (CH2), 58.8 (CH2), 62.6 (CH), 65.8 (CH), 123 (PyrCH), 126.9 (2ArCH), 127.2 (ArCH), 
127.2 (ArCH), 128.2 (2ArCH), 128.4 (2ArCH), 128.7 (2ArCH), 134.1 (ArC), 136.7 (PyrCH), 
140.0 (PyrC), 143.0 (ArC), 148.5 (PyrCH), 150.2 (PyrCH).HRMS [M+H]
+
calculated for formula 
C23H26N3
+
344.2120; found 344.2121. 
3-((2-Phenyl-4-(piperidin-1-ylmethyl)azetidin-1-yl)methyl)pyridine (44b) 
General procedure (h) was used, 1-phenyl-N-(pyridin-3-ylmethyl)but-3-
en-1-amine (130 mg, 0.53 mmol), flash chromatography 
(DCM/Methanol= 9.5/0.5 and 9/1), 100 mg 76% yield. IR 3028, 2934, 




1026, 998, 860, 752, 714, 699.
1
H NMR (δ; 300 MHz, CDCl3); 0.91 (2H, dd, J 13.0, 5.8, 
CH2CH2CH2), 1.23-1.49 (4H, m, 2x CH2), 1.60 (4H, dt, J 10.9, 5.4, 2x CH2), 1.80 (2H, dt, J 10.1, 
8.5, NCH2CH), 3.46 (1H, dt, J 13.6, 6.9, CH2CHCH2), 3.72 (2H, d, J 2.6, PyrCH2), 4.00 (1H, 
app.t, J 8.1, CHCHH), 7.10 (2H, dd, J 7.4, 4.8, ArCH), 7.15-7.39 (3H, m, ArCH), 7.59 (1H, dt, J 
7.8, 1.8, PyrCH), 8.39 (1H, dd, J 4.8, 1.4, PyrCH), 8.49 (1H, d, J 1.5, PyrCH).
13
C NMR (δ; 100 
MHz, CDCl3), 23.7 (CH2), 25.2 (2CH2), 35.4 (CH2), 54.9 (2CH2), 58.5 (CH2), 60.3 (CH), 64.8 
(CH2), 66.3 (CH), 123.0 (PyrCH), 126.8 (2ArCH), 127.2 (ArCH), 128.2 (2ArCH), 133.8 (PyrC), 
137.0 (PyrCH), 142.9 (ArC), 148.3 (PyrCH), 150.4 (PyrCH). High resolution MS [M+H
+
] 
calculated for formula C21H27N3
+
: 321.2205 found 321.2207. 
N-(((2S,4R)-1-benzyl-4-(naphthalen-1-yl)azetidin-2-yl)methyl)-N-propylpropan-1-amine (44c) 
General procedure (h) was used, N-benzyl-1-(naphthalen-1-yl)but-
3-en-1-amine (210 mg, 0.72 mmol), flash chromatography (Ethyl 
acetate/Hexane= 1/1), yellow brown oil, 120 mg 50% yield. IR 
2956, 2924, 1666, 1454, 799, 778, 699.
1
H-NMR (δ; 300 MHz, 
CDCl3); 0.80 (3H, t, J 7.3, CH3), 1.25 ( 3H, t, J 8.9, CH3), 1.22-1.43 (4H, m, 2x CH2CH3), 1.76 
(2H, dd, J 18.6, 8.6, CHCH2N), 2.16-2.40 (4H, m, 2x NCH2CH2CH3), 2.8-2.97 (1H, m, 
CH2CHCH2), 3.81 (ABq, 2H, JAB12.6, JAB12.6, ArCH2), 4.73 (1H, app.t, J 8.5, CHCHH), 7.55-
7.57 (10H, m, ArCH), 7.74 (2H, d, ArCH).
13
CNMR (δ; 100 MHz, CDCl3), 11.9 (2CH3), 20.1 
(CH2), 29.7 (2CH2), 35.2 (2CH2), 56.9 (2CH2), 60.0 (CH), 62.0 (CH), 62.3 (CH2), 62.7 (2CH), 
122.9 (ArCH), 123.0 (ArCH), 124.4 (ArCH), 124.9 (ArCH), 125.4 (ArCH), 125.6 (ArCH), 125.8 




(2ArC), 138.8 (ArC), 139.6 (ArC). High resolution MS [M+H
+
] calculated for formula 
C27H35N2
+
: 387.2800 found 387.2819. 
N-(((2S,4R)-1-benzyl-4-phenylazetidin-2-yl)methyl)-N-ethylethanamine (44e) 
General procedure (f) was used, N-benzyl-1-phenylbut-3-en-1-amine 
(200 mg, 8.5 mmol), flash chromatography (DCM/Methanol= 9.5/0.5), 
yellow brown oil, 80 mg 65% yield. IR 3024, 2820, 1666, 1523, 1450, 
1342, 1260.
1
H NMR (δ; 300 MHz, CDCl3); 0.93 (6H, t, J 7.1, 2x CH3), 1.78 (2H, dd, J 17.9, 9.3, 
CH2CH3), 2.29 (1H, dd, J 13.2, 3.5, CH2CHCH2), 2.36-2.52 (2H, m, CH2CH3), 2.61 (2H, dt, J 
10.1, 7.4, CHCHHCH), 3.70 (ABq, 2H, JAB12.8, JAB12.8, ArCH2), 4.01 (1H, app.t, J 8.2, 
CHCHH), 7.20-7.47 (10H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3), 21.1 (2CH3), 31.3 (CH2), 
50.0 (CH2), 54.8 (CH2), 58.2 (CH), 64.1 (CH), 64.5 (CH), 124.3 (ArCH), 124.9 (ArCH), 126.9 
(2ArCH), 127.1 (2ArCH), 127.5 (2ArCH), 128.1 (2ArCH), 142.1 (ArC), 143.5 (ArC).HRMS 
[M+H]
+
calculated for formula C21H29N2
+
309.4116; found 309.4119. 
(R)-N-benzyl-1-phenylbut-3-en-1-amine (46a) 
General procedure (c3) was used. N-benzyl-1-phenylbut-3-en-1-amine (1 
gm, 2.40 mmol), 3-bromo-1-propene (1.2 gm, 10.0 mmol) and zinc 
powder (400 mg, 7.2 mmol) in dry THF (10 mL), pale yellow oil, 1.45 
gm 91% yield.
1
H NMR (δ; 300 MHz, CDCl3);1.82 (1H, s, NH), 2.25-2.35 (1H, m, NHCHCHH), 
3.41 (1H, d, J13.3, PhCHH), 3.56-3.61 (ABq, 2H, m, PhCHH),4.90-5.10 (2H, m, olefine CHH), 
5.50-5.60 (1H, m, CH=CH2), 7.05-7.25 (10H, m, ArCH).
13
C NMR (δ; 100MHz , CDCl3); 43.3 




(2ArCH), 128.4 (2ArCH), 128.5 (2ArCH), 128.7 (2ArCH), 135.6 (ArC), 141.0 (ArC), 144.0 (C). 
HRMS [M+H]
+ 
calculated for the formula C17H20N
+
 238.1592; found 238.1584. [α]
20
D= +56.5 (C 
5, CHCl3) (lit. +55.4). >99% ee.
23 
(R)-N-neopentyl-1-phenylbut-3-en-1-amine (46b) 
General procedure (c3) was used. N-neopentyl-1-phenylmethanimine (1 gm, 
5.70 mmol), 3-bromo-1-propene (1.3 gm, 11.4 mmol) and zinc powder (900 
mg,14.2 mmol) in dry THF (10 mL), pale yellow oil, 985 mg 93% yield.
1
H 
NMR (δ; 300 MHz, CDCl3);1.52 (9H, s, CH3), 2.22-2.32 (1H, m, NHCHCHH), 3.46 (2H, d, 
J12.4, CCHH),5.10-5.25 (2H, m, olefine CHH), 5.60-5.80 (1H, m, CH=CH2), 7.15-7.20 (5H, m, 
ArCH).
13
C NMR (δ; 100MHz , CDCl3); 23.1 (CH3), 23.1 (CH3), 23.1 (CH3), 43.3 (CH2), 51.5 
(CH2), 61.5 (CH), 117.7 (CH2), 128.5 (2ArCH), 128.7 (ArCH), 135.6 (ArCH), 140.5 (ArC), 
144.0 (C). HRMS [M+H]
+
calculated for the formula C15H24N
+
 218.1832; found 218.1824. 
[α]
20
D=+26.5 (c 5, DCM). HPLC (AD column), hexane/isopropanol 99:1, flow rate=0.2 mL/ 
minutes, 91% ee. 
 





General procedure (c3) was used, 1-phenyl-N-(pyridin-3-
ylmethyl)methanimine (1 gm, 2.40 mmol), 3-bromo-1-propene (1.2 gm, 
10.0 mmol) and zinc powder (400 mg,7.2 mmol) in dry THF (10 mL), 
yellow oil, 1.40 gm 92% yield.
1
H NMR (δ; 300 MHz, CDCl3);1.80 (1H, s, NH), 2.42-2.45 (1H, 
m, NHCHCHH), 3.42 (1H, d, J13.1, PhCHH), 3.26-3.41 (2H, m, PhCHH), 4.86-5.00 (2H, m, 
olefine CHH), 5.40-5.50 (1H, m, CH=CH2), 7.05-7.25 (6H, m, ArCH), 8.35-8.45 (2H, m, PyCH), 
8.50 (1H, s, PyCH).
13
C NMR (δ; 100MHz , CDCl3); 43.3 (CH2), 51.5 (CH2), 61.5 (CH), 117.7 
(CH2), 126.9 (CH), 127.2 (ArCH), 128.2 (ArCH), 128.3 (2ArCH), 128.4 (ArCH), 128.5 (PyrCH), 
128.7 (PyrCH), 135.6 (ArC), 141.0 (PyrC). HRMS [M+H]
+ 
calculated for the formula C16H19N2
+
 
239.1502; found 239.1504. [α]
20
D=+41.3 (C 5, DCM). HPLC (AD column), hexane/isopropanol 
99:1, flow rate=0.2 mL/minutes, >93% ee. 
 






General procedure (d) was used. N-benzylidene-1-phenylmethanamine 
(1000 mg, 5.0 mmol), 3-bromo-2-methylprop-2-ene (1000 mg, 10 mmol) 
and zinc powder (838 mg, 10 mmol) in dry THF (10 mL). Pale yellow oil, 
2.0 gm 99% yield. IR 3450, 3026, 2933, 1492. 
1
H NMR (δ; 300 MHz, CDCl3) ;1.72 (3H, s, 
CH3),1.85 ( 1H, s, NH), 2.37 (1H, dd, Jab14.0, Jac4.7, CHCHH), 2.45 (1H, dd, Jab14.0, Jbc 9.5, 
CHCHH), 3.56 (ABq, 1H, JAB13.5, ArCHH), 3.78 (ABq, 1H, JAB13.5, ArCHH), 3.84 (1H, dd, 
Jbc9.5, Jac4.7, NCHCHH), 4.84 (1H, s, olefine CHH), 4.88 (1H, s, olefine CHH), 7.25-7.50 (10H, 
m, ArCH).
13
C NMR (δ; 100MHz , CDCl3); 22.1 (CH3), 47.6 (CH2), 51.5 (CH2), 59.3 (CH), 113.4 
(CH2), 126.8 (2ArCH), 127.0 (2ArCH), 127.3 (2ArCH), 128.1 (2ArCH), 128.3 (ArCH), 128.4 
(ArCH), 140.6 (ArC), 142.7 (ArC), 144.3 (C). HRMS [M+H]
+ 
calculated for the formula 
C18H22N
+
 252.1762; found 252.1752.
92 
3-Methyl-1-phenyl-N-(pyridin-3-ylmethyl)but-3-en-1-amine (47b) 
General procedure (d) was used. N-benzyl-1-(pyridin-3-
yl)methanimine(1.0 gm, 5.0 mmol), 3-bromo-2-methylprop-2-ene (1.0 
gm, 10 mmol) and zinc powder (838 mg, 10 mmol) in dry THF (10 mL), 
yellow oil, 0.7 gm 74% yield. IR 3319, 3061, 3028, 2968, 2844, 1645, 1576, 1453, 1423, 1026, 
892, 757, 701.
1
H NMR (δ; 300MHz, CDCl3); 1.68 (3H, s, CH3), 2.24-2.45 (2H, m, CHCHH), 
3.61 (ABq, 2H, JAB13.7, JAB13.7, PyrCHH), 3.75 (1H, dd, J8.2, 4.1, NCHCHH), 4.77 (1H, s, 
olefine CHH), 4.83 (1H, s, olefine CHH), 7.15-7.47 (6H, m, ArCH), 7.55 (2H, d, J 13.0, PyrCH), 
8.47 (2H, d, J 8.3, PyrCH).
13




59.5 (CH), 113.6 (=CH2), 123.3 (PyrCH), 127.2 (3ArCH), 128.5 (2ArCH), 135.8 (PyrCH), 135.9 





; 253.1705; found 253.1709. 
3-Methyl-1-phenyl-N-propylbut-3-en-1-amine (47c) 
General procedure (d) was used. 1-phenyl-N-propylmethanimine(1.0 gm, 5.0 
mmol), 3-bromo-2-methylprop-2-ene (1.0 gm, 10 mmol) and zinc powder 
(838 mg, 10 mmol) in dry THF (10 mL), yellow oil, 0.6 gm 41% yield. IR 
3066, 3026, 3028, 2960, 2866 , 1646, 1602, 1454, 1375, 1309, 1142, 8, 893, 755.
1
H NMR (δ; 300 
MHz, CDCl3) ; 0.85 (3H, t, J 7.4, CH3), 1.38-1.55 ( 2H, m, CHCHH), 1.74 (3H, s, CH3), 4.24-
4.46 (4H, m, 2CH2), 3.75 (1H, dd, J 14.4, 1.2, NCHCHH), 4.72 (1H, s, olefine CHH), 4.80 (1H, 
s, olefine CHH), 7.16-7.39 (5H, m, ArCH).
13
C NMR (δ; 100MHz , CDCl3); 11.8 (CH3), 22.2 
(CH3), 23.1 (CH2), 47.4 (CH2), 49.9 (CH2), 60.7 (CH), 113.4 (=CH2), 127.0 (ArCH), 127.2 
(2ArCH), 128.3 (2ArCH), 142.7 (ArC), 144.3 (C). HRMS [M+H
+
] calculated for formula 
C14H22N
+
; 204.1752; found 204.1753. 
3-Methyl-N-(2-methylbenzyl)-1-phenylbut-3-en-1-amine (47e) 
General procedure (d) was used. N-(2-methylbenzyl)-1-
phenylmethanimine (1.0 gm, 5.0 mmol), 3-bromo-2-methylprop-2-ene 
(1.0 gm, 10.0 mmol) and zinc powder (838 mg, 10 mmol) in dry THF (10 
mL). Pale yellow oil, 1.6 gm 91% yield. IR 3061, 2940, 1635, 1453, 890, 698.
1
H NMR (δ; 300 
MHz, CDCl3); 1.69 (3H, s, CH3), 2.26 (3H, s, CH3), 2.32-2.52 (3H, m, overlapping NH, CH2), 




olefine CHH),4.72 (1H, s, olefine CHH), 7.15-7.49 (9H, m, ArCH).
13
C NMR (δ; 100 MHz, 
CDCl3); 18.9 (CH3), 22.0 (CH3), 47.4 (CH2), 49.4 (CH2), 59.9 (CH), 113.6 (=CH2), 125.8 
(ArCH), 127.1 (ArCH), 127.3 (2ArCH), 128.3 (2ArCH), 128.9 (2ArCH), 130.3 (ArCH), 136.5 
(ArCCH3), 138.0 (ArC), 142.7 (ArC), 144.0 (C). HRMS [M+H
+
] calculated for formula 
C19H24N
+
; 266.1909; found 266.1907. 
N-benzyl-1-(furan-3-yl)-3-methylbut-3-en-1-amine (47f) 
General procedure (d) was used, N-benzyl-1-(furan-3-yl)methanimine(1 
gm, 5.4 mmol), brown oil, 110 mg, 84% yield. IR 3063, 2950, 1450, 
1369, 889, 678.
1
H NMR (δ; 300 MHz, CDCl3); 1.65 (3H, s, CH3), 2.21-
2.52 (2H, m, CHCHH), 3.52-3.84 (3H, m, CH overlapping CH2), 4.78 (1H, s, olefine CHH), 4.81 
(1H, s, olefine CHH), 6.47 (1H, s, FurCH), 7.22-7.46 (7H, m, ArCH overlapping FurCH).
13
C 
NMR (δ; 100 MHz, CDCl3); 22.0 (CH3), 45.9 (CH2), 50.4 (CH), 51.2 (CH2), 109.1 (FurCH), 
113.5 (=CH2), 126.9 (ArCH), 127.0 (2ArCH), 127.2 (2ArCH), 128.2 (C), 139.8 (FurCH), 140.5 
(ArC), 142.5 (FurC), 143.2 (FurCH). HRMS [M+H
+
] calculated for formula C16H20NO
+
; 
242.1545; found 242.1543. 
N-benzyl-2,2,5-trimethylhex-5-en-3-amine (47g) 
General procedure (d) was used, pale yellow oil 82% yield. IR 3064, 
3031, 2946, 1646, 1453, 1374, 890, 698.
1
H NMR (δ; 300 MHz, CDCl3); 
0.89 (9H, s, CH3), 1.62 (3H, s, CH3), 1.85 (1H, dd, Jab13.6, Jac6.9, CHH), 
2.33 (1H, dd, Jab13.6, Jbc6.7, CHH), 3.55 (ABq, 2H, JAB12.9, JAB12.9, ArCH2), 3.72 (1H, dd, 






C NMR (δ; 100 MHz, CDCl3); 22.0 (CH3), 26.9 (3CH3), 40.7 (CH2), 47.6 (CH2), 51.5 
(C), 64.1 (CH), 112.8 (CH2), 126.8 (ArCH), 127.9 (ArCH), 128.2 (2ArCH), 128.3 (2ArCH), 
140.6 (ArC), 141.4 (C). HRMS [M+H
+
] calculated for formula C16H26N
+
; 232.2065; found 
232.2064. 
N-benzyl-1-(3,4-dimethoxyphenyl)-3-methylbut-3-en-1-amine (47h) 
General procedure (d) was used, N-benzyl-1-(3,4-
dimethoxyphenyl)methanimine (50 mg, 0.25 mmol), pale yellow oil, 62 
mg 66% yield. 
1
H NMR (δ; 300 MHz, CDCl3); 1.45 (3H, s, CH3), 1.88 
(1H, s, NH), 2.13-2.38 (2H, m, CHCHH), 3.60 (ABq, 2H, JAB14.1, 
JAB14.1, PhCHH), 3.75 (1H, dd, J 13.1, 8.6, CHCHH), 4.64 (1H, s, olefine CHH), 4.70 (1H, s, 
olefine CHH), 6.71 (2H, m, ArCH), 6.88 (1H, s, ArCH), 7.05- 7.18 (5H, m, ArCH).
 13
C NMR (δ; 
100 MHz, CDCl3); 22.1 (CH3), 47.8 (CH2), 51.4 (CH2), 55.9 (2OCH3), 58.9 (CH),), 110.0 
(ArCH), 111.0 (ArCH), 113.5 (=CH2), 119.5 (2ArCH), 126.9 (ArCH), 128.0 (2ArCH), 128.2 
(2ArCH), 136.9 (ArC), 140.6 (ArC), 142.8 (C), 148.0 (ArCOMe), 149.2 (ArCOMe). HRMS 
[M+H
+
] calculated for formula C20H25NO2Na
+
; 334.1783; found 334.1788. 
N-(4-methoxybenzyl)-3-methyl-1-phenylbut-3-en-1-amine (47i) 
General procedure (d) was used, yellow oil 73% yield. IR 2926, 
1611, 1511, 1453, 1301, 1245, 1036, 701. 
1
H NMR (δ; 300 MHz, 
CDCl3); 1.66 (3H, s, CH3), 1.78 (1H, s, NH), 2.25-2.42 (2H, m, 
CHCHH), 3.59 (ABq, 2H, JAB13.7, JAB13.7, ArCHH), 3.74 (1H, 




m, ArCH), 7.56-7.60 (1H, m, ArCH), 8.51 (1H, s, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 22.1 
(CH3), 47.6 (CH2), 50.9 (CH2), 55.3 (CH), 59.2 (CH), 113.4 (=CH2), 113.7 (2ArCH), 127.0 
(ArCH), 127.3  (2ArCH), 128.4 (2ArCH), 129.3 (2ArCH), 132.8 (ArCOMe), 142.8 (ArC), 144.4 
(ArC), 158.6 (C). HRMS [M+H
+
] calculated for formula C19H24NO
+
; 282.1858; found 282.1856. 
N-benzyl-3-methyl-1-(thiophen-2-yl)but-3-en-1-amine (47j) 
General procedure (d) was used, N-benzyl-1-(thiophen-2-yl)methanimine 
(1 gm, 5.6 mmol), yellow oil, 1.2 mg, 93% yield. IR 2922, 1645, 1494, 
1453, 1373, 1317, 1109, 894, 695.
1
H NMR (δ; 300 MHz, CDCl3); 1.64 
(3H, s, CH3), 2.35-2.51 (2H, m, CHCHH), 3.7 (ABq, 2H, JAB12.9, JAB12.9, ArCH2), 4.15 (1H, dd, 
Jbc7.9, Jac4.4, CHCHH), 4.74 (1H, s, olefine CHH), 4.80 (1H, s, olefine CHH), 6.94-7.03 (3H, m, 
3xThioCH), 7.15-7.42 (5H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 21.9 (CH3), 47.9 (CH2), 
51.1 (CH2), 54.9 (CH), 113.9 (=CH2), 124.1 (ThioCH), 124.4 (ThioCH), 126.4 (ThioCH), 127.1 
(ArCH), 128.4 (4ArCH), 138.9 (ThioC), 142.1 (C), 142.1 (ArC). HRMS [M+H] calculated for 
formula C16H20NS
+ 
258.1316; found 258.1315. 
N-benzyl-3-methyl-1-(naphthalen-1-yl)but-3-en-1-amine (47k) 
General procedure (d) was used, white solid precipitate, 0.3 gm 19%. 
yield.
1
H NMR (δ; 300 MHz, CDCl3); 1.84 (3H, s, CH3), 2.10 (1H, s, 
NH), 2.55 (2H, ddd, J 24.4, 14.2, 6.9, CHCHH), 3.75 (ABq, 2H, JAB13.4, 
JAB13.4, ArCHH), 4.75 (1H, dd, J10.1, J3.3, CHCHH), 4.95 (1H, d, J 6.7, CHCHH), 7.30-7.43 
(3H, m, ArCH), 7.52-7.65 (2H, m, ArCH), 7.86 (1H, d, J 8.1, naphCH), 7.93-8.06 (2H, m, 
naphCH), 8.26 (1H, d, J 4.7, naphCH).
13




51.8 (CH2), 113.6 (=CH2), 122.8 (ArCH), 123.9 (ArCH), 125.3 (ArCH), 125.8 (ArCH), 125.9 
(ArCH), 126.9 (ArCH), 127.4 (ArCH), 128.3 (ArCH), 128.4 (ArCH), 129.2 (ArCH), 131.6 
(ArC), 134.2 (ArC), 139.5 (ArC), 140.7 (ArC), 143.0 (C). HRMS [M+H
+
] calculated for formula 
C22H24N
+
; 302.1909; found 302.1908. 
N-(3-methyl-1-phenylbut-3-en-1-yl)adamantan-1-amine (47l) 
General procedure (d) was used, white solid precipitate 81% yield. IR 
2904, 2848, 1645, 1452,700.
1
H NMR (δ; 300 MHz, CDCl3); 1.30-2.20 
(15H, overlapping m, 6xCH2 & 3x admantyl CH), 4.03 (1H, dd, J9.9, 
J4.1, CHCHH), 4.78 (1H, s, olefine CHH), 4.83 (1H, s, olefine CHH), 7.15-7.48 (5H, m, 
ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 21.8 (CH3), 29.6 (3CH), 35.8 (CH2), 36.6 (3CH2), 43.8 
(2CH2), 49.7 (CH2), 51.1 (C), 52.6 (CH), 114.0 (=CH2), 126.3 (ArCH), 126.9 (2ArCH), 128.0 
(2ArCH), 143.1 (ArC), 148.5 (C). HRMS [M+H
+





General procedure (d) was used, N-benzyl-1-(2-
bromophenyl)methanimine (1 gm, 3.6 mmol), pale yellow oil, 0.58 gm 
47% yield. IR 3064, 3027, 2918, 2850, 1645, 1566, 1454, 1121, 1022, 
895, 753, 698.
1
H NMR (δ; 300 MHz, CDCl3); 1.69 (3H, s, CH3), 1.86 (1H, s, NH), 2.09 (1H, dd, 
Jab14.1, Jac4.0, CHCHH), 2.40 (1H, dd, Jab14.1, Jbc 4.7, CHCHH), 3.58 (ABq, 2H, JAB13.7, 
JAB13.7, ArCHH), 4.25 (1H, dd, Jac4.0, Jbc4.7, CHCHH), 4.78 (1H, s,olefine CHH), 4.82 (1H, s, 




7.75 (1H, d, J 8.7, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 21.6 (CH3), 45.9 (CH2), 51.7 (CH2), 
57.7 (CH), 113.7 (=CH2), 124.0 (ArCBr), 126.9 (ArCH), 127.8 (ArCH), 128.2 (ArCH), 128.3 
(2ArCH), 128.4 (ArCH), 132.8 (ArCH), 140.5 (C), 142.8 (ArC), 142.8 (ArC). HRMS [M+H
+
] 
calculated for formula C18H21NBr
+
; 331.2120; found 331.2122. 
N-(4-chlorobenzyl)-3-methyl-1-phenylbut-3-en-1-amine (47n) 
General procedure (d) was used, N-(4-chlorobenzyl)-1-
phenylmethaniminepale (1 gm, 4.3 mmol), yellow oil, 0.45 gm 34% 
yield. IR 3027, 3063, 2929, 1646, 1490, 1453, 1090, 700.
1
H NMR (δ; 
300 MHz, CDCl3); 1.66 (3H, s, CH3), 2.20-2.41 (2H, m, CHCHH), 3.54 (ABq, 2H, JAB13.7, 
JAB13.7, ArCHH), 3.69 (1H, dd, Jbc11.9, Jac5.9, CHCHH), 4.77 (1H, s, olefine CHH), 4.79 (1H, s, 
olefine CHH), 7.10-7.40 (9H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 22.1 (CH3), 47.6 
(CH2), 50.7 (CH2), 59.3 (CH), 113.5 (=CH2), 127.1 (ArCH), 127.3 (ArCH), 128.4 (ArCH), 129.5 
(ArCH), 132.5 (ArC), 139.1 (ArC), 142.7 (ArC), 144.1 (C). HRMS [M+H
+
] calculated for 
formula C18H21NCl
+
; 286.1363; found 286.1354. 
N-benzyl-3-methyl-1-(4-nitrophenyl) but-3-en-1-amine (47o) 
General procedure (d) was used, brown yellow oil, 0.34 gm 57% yield. 
IR 3020, 2912, 2840, 1640, 1445, 1120, 895, 697.
1
H NMR (δ; 300 MHz, 
CDCl3); 1.68 (3H, s, CH3), 2.22-2.35 (2H, m, CHCHH), 3.58 (ABq, 2H, 
JAB13.7.6, JAB13.7, ArCHH), 3.88 (1H, dd, Jbc11.9, Jac5.9, CHCHH), 4.77 
(1H, s, olfine CHH), 4.83 (1H, s, olefine CHH), 7.20-7.38 (5H, m, ArCH), 7.62 (2H, d, J8.1, 
ArCH), 8.20 (2H, d, J8.1, ArCH).
 13




(CH2), 58.9 (CH), 114.3 (=CH2), 123.8 (2ArCH), 127.1 (ArCH), 128.0 (2ArCH), 128.1 (2ArCH), 
128.5 (2ArCH), 139.9 (C), 141.7 (ArC), 147.2 (ArCNO2), 152.5 (ArC). HRMS [M+H
+
] 
calculated for formula C18H21N2O2
+
; 296.3700; found 296.3703. 
N-(4-methoxybenzyl)-3-methyl-1-(pyridin-3-yl)but-3-en-1-amine (47p) 
General procedure (d) was used, N-(4-methoxybenzyl)-1-(pyridin-
3-yl)methanimine (50 mg, 0.22 mmol), brown yellow oil, 60 mg 
75% yield. IR 3327, 3066, 2917, 1645, 1589, 1453, 1433, 1116, 
892, 748, 698.
1
H NMR (δ; 300 MHz, CDCl3); 1.65 (3H, s, CH3), 
2.21-2.41 (1H, m, CHCHH), 3.51 (ABq, 2H, JAB13.2,JAB13.2, ArCH2), 3.80 (3H, s, OCH3), 4.78 
(1H, app.t, J 24.9, CHCHH), 6.99 (4H, dd, J 85.1, 8.6, ArCH), 7.28 (1H, dd, J 7.9, 4.7, ArCH), 
7.76 (1H, dt, J 7.8, 1.9, ArCH), 8.51 (1H, dd, J 4.8, 1.6, ArCH), 8.58 (1H, s, ArCH).
13
C NMR (δ; 
100 MHz, CDCl3); 21.9 (CH3), 47.4 (CH2), 50.8 (CH2), 55.2 (CH), 56.8 (CH), 113.8 (2ArCH), 
114.0 (=CH2), 123.6 (ArCH), 129.2 (ArCH), 132.2 (C), 134.78 (PyrCH), 139.6 (PyrC), 147.0 
(C), 148.6 (PyrCH), 149.5 (PyrCH), 158.6 (COMe). HRMS [M+H
+
] calculated for formula 
C14H15N2O
+
; 227.1184; found 227.1175. 
1,4-Mimethyl-1-phenylbut-3-en-1-amine (47q) 
General procedure (d) was used, N-methyl-1-phenylmethanimine (50 mg, 0.41 
mmol), yellow oil, 0.57 mg 82% yield. IR 3322, 3060, 3026, 2932, 2821, 1946, 
1807, 1645.
1
H NMR (δ; 300 MHz, CDCl3); 1.64 (3H, s, CH3), 2.16 (3H, s, CH3), 
2.18-2.33 (2H, m, CHCHH), 3.52 (1H, dd, Jac9.1, Jbc5.2, CHCHH), 4.68 (H, s, olefine CHH), 
4.71 (1H, s, olefine CHH), 7.09-7.29 (5H, m, ArCH).
13




(CH3), 34.7 (CH3), 47.3 (CH2), 62.8 (CH), 113.4 (=CH2), 127.0 (ArCH), 127.2 (2ArCH), 128.4 
(2ArCH), 142.7 (ArC), 143.7 (C). HRMS calculated for formula C12H18N
+
; 176.1439; found 
176.1446. 
1,4-Mimethyl-1-(pyridin-3-yl)but-3-en-1-amine (47r) 
General procedure (d) was used, N-methyl-1-(pyridin-3-yl)methanimine (50 mg, 
0.41 mmol) brown yellow oil, 48 mg 67% yield. IR 3322, 3060, 3026, 2932, 
1946, 1807, 1645.
1
H NMR (δ; 300 MHz, CDCl3); 1.75 (3H, s, CH3), 2.26 (3H, s, 
CH3), 2.31 (2H, m, CHCHH), 3.69 (1H, dd, J9.1, J5.3, CHCHH), 4.71 (1H, s, olefine CHH), 4.81 
(1H, s, olefine CHH),7.29-7.36 (1H, m, PyrCH), 7.74- 7.79 (1H, m, PyrCH), 8.5-8.63 (2H, m, 2x 
PyrCH).
13
C NMR (δ; 100 MHz, CDCl3); 22.0 (CH3), 34.6 (CH3), 47.6 (CH2), 60.2 (CH), 114.1 
(=CH2), 123.9 (PyrCH), 135.5 (PyrCH), 139.8 (PyrC), 141.7 (PyrCH), 148.3 (PyrCH), 149.1 (C). 
HRMS calculated for formula C11H17N2
+
; 177.1392; found 177.1402. 
N-benzyl-2-methyl-1-phenylbut-3-en-1-amine (46a-cis and 46b-trans) 
General procedure (f) was used, N-benzyl-1-phenylmethanimine (50 mg, 
4.7 mmol), yellow oil, 21 mg 43% yield. IR 3063, 3026, 2973, 1638, 
1602, 1493, 1453, 916. 
1
H NMR (δ; 300 MHz, CDCl3); 0.81 (3H, d, J 
6.8, CH3 min), 1.04 (3H, d, J 6.9, CH3 maj), 2.43 (1H, q, J 7.1, 3.6, CHCH3 maj), 2.59 (1H, q, J 6.8, 
5.6, CHCH3 min), 3.33-3.58 (4H, m, 2x ArCH2 maj+min), 3.66-3.80 (2H, m, 2x CH=CH2 maj+min), 
4.99-5.29 (4H, m, 2x olefine CHH maj+min), 5.66-5.85 (2H, m, 2x NCHCH maj+min), 7.25-7.46 
(20H, m, ArCH).
13
C NMR (δ; 100MHz , CDCl3); 15.4 (CH3), 17.9 (CH3), 43.8 (CH), 45.7 (CH), 




(ArCH),126.9 (ArCH), 127.2 (ArCH), 128.0 (2ArCH), 128.1 (2ArCH), 128.2 (2ArCH), 128.2 
(2ArCH), 128.3 (2ArCH), 128.5 (2ArCH), 140.8 (2ArC), 141.2 (2ArCH),  141.9 (2ArC), 142.3 
(2ArCH), 142.5 (2C). HRMS calculated for formula C18H22N
+
; 252.0038; found 252.001631. 
(R)-N-benzylidene-2-methylpropane-2-sulfinamide (112) 
(R)-tert-butylsulfinamide (1g, 7.2 mmol) in dichloromethane, was mixed 
with (3 gm, 21.9 mmol) of benzaldehyde and (5 gm, 36.5 mmol) of 
magnesium sulphate and (0.1 gm, 0.1 mmol) of PPTs and stirred at room 
temperature for 24 hours. The product filtered and purified by column chromatography. Yellow 
oil, 120 mg 92% yield.
 1
H NMR (δ; 300 MHz, CDCl3); 1.25 (9H, s,CH3), 7.45-7.51 (3H, m, 
ArCH), 7.80 (1H, d, J 5.9, ArCH), 8.15 (1H, d, J 4.9, ArCH), 8.60 (CH=N).
13
C NMR (δ; 100 
MHz, CDCl3); 12.6 (3CH3), 27.1 (CH), 45.6 (CH2), 126.9 (2ArCH), 127.5 (2ArCH), 1128.1 
(ArCH), 133.3 (ArC), 151.9 (CH=N). HRMS [M+H]
+
 calculated for formula C11H15NOSNa
+
: 
232.0772; found: 232.0773. The spectral data are comparable with literature.
93 
(R)-1-phenyl-N-(1-phenylethyl)methanimine (119) 
General procedure (a1) was used, benzaldehyde (1 gm, 9.4 mmol), 
colourless oil, 1.81 gm 92% yield. IR 2851, 1889, 1623, 1480, 1091, 
1015.
1
H NMR (δ; 300 MHz, CDCl3); 1.61 (3H, s, CH3), 4.51 (1H, q, J 13.9, 10.1, CH), 7.17-7.41 
(8H, m, ArCH), 7.77 (2H, m, ArCH), 8.35 (CH=N).
13
C NMR (δ; 100 MHz, CDCl3); 24.9 (CH3), 
69.8 (CH), 126.2 (2ArCH), 126.7 (ArCH), 128.3 (2ArCH), 128.5 (2ArCH), 128.6 (2ArCH), 






Characterisation data for the synthesised enantiopure azetidine compounds: 
N-benzyl-1-((2S, 4R)-1-benzyl-4-phenylazetidin-2-yl)methanamine 
General procedure (h) was used, (R)-N-benzyl-1-phenylbut-3-en-1-
amine (100 mg, 0.33 mmol), flash chromatography (EA/hexane 
1:1), yellow brown oil, 85 mg 83% yield. IR 3027, 2929, 2850, 
2808, 1570, 1440, 1421, 1320, 1302, 1150.
1
H NMR (δ; 300 MHz, CDCl3); 2.29 (1H, q, J 9.7, 
PhCHCHH), 2.51 (1H, dd, J 12.5, 6.2, CHCHH), 2.61-2.88 (2H, m, NCH), 3.50-3.95 (3H, 
overlapping m, NCH2, CH2CHCH2), 4.15 (1H, app.t, J 7.2, CHCHH), 7.09-7.62 (10H, m, 
ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 18.3 (CH3), 19.2 (CH3), 32.0 (CH2), 48.0 (CH2), 51.0 
(CH), 58.4 (CH), 60.7 (CH2), 65.6 (CH), 126.8 (2ArCH), 127.6 (ArCH), 127.8 (ArCH), 128.7 
(2ArCH), 128.8 (2ArCH), 129.5 (2ArCH), 137.9 (ArC), 139.0 (ArC). High resolution MS 
[M+H]
+
calculated for formula C24H27N2
+
: 343.2174 found 343.2176. [α]D
20 
= +95.7 (c 5, CHCl3) 
lit. (+94.5), >99% ee.
23 
N-(((2S,4R)-1-benzyl-4-phenylazetidin-2-yl)methyl)propan-1-amine (126b) 
General procedure (h) was used, (R)-N-benzyl-1-phenylbut-3-en-1-
amine (200 mg, 8.5 mmol), flash chromatography (DCM/Methanol= 
9.5/0.5), yellow brown oil, 112 mg 46% yield. IR 3027, 2929, 2850, 
2808,1570, 1440, 1421, 1320, 1302, 1150.
1
H NMR (δ; 300 MHz, CDCl3); 1.18 (3H, d, J 6.5, 
CH3), 1.23 (3H, d, J 6.5, CH3), 2.29 (1H, dd, J 12.5, 8.2, CHCHH), 2.51 (1H, dd, J 12.5, 6.2, 
CHCHH), 2.61-2.88 (2H, m, NCH), 3.50-3.95 (3H, overlapping m, NCH2, CH2CHCH2), 4.15 
(1H, app.t, J 7.2, CHCHH), 7.09-7.62 (10H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 18.3 




(2ArCH), 127.6 (ArCH), 127.8 (ArCH), 128.7 (2ArCH), 128.8 (2ArCH), 129.5 (2ArCH), 137.9 
(ArC), 139.0 (ArC). High resolution MS [M+H]
+





= +89.4 (c 5, CHCl3) lit. (+96.4). 96% ee.
23 
3-(((2R,4S)-2-phenyl-4-(piperidin-1-ylmethyl)azetidin-1-yl)methyl)pyridine (126c) 
General procedure (h) was used, (R)-1-phenyl-N-(pyridin-3-
ylmethyl)but-3-en-1-amine (98 mg, 0.42 mmol), flash chromatography 
(DCM/Methanol= 9.5/0.5), yellow oil, 105 mg 82% yield. IR 3028, 
2934, 2852, 2803,1576, 1492, 1454, 1424, 1354, 1326, 1303, 1157, 1122, 1026, 998, 860, 752, 
714, 699.
1
H NMR (δ; 300 MHz, CDCl3); 0.91 (2H, dd, J 13.0, 5.8, CH2), 1.23-1.49 ( 2H, m, 
CH2), 1.60 (2H, dt, J 10.9, 5.4, 2x CH2), 1.80 (2H, dt, J 10.1, 8.5, CHCH2CH), 3.46 (1H, dt, J 
13.6, 6.9, CH), 3.72 (ABq, 2H, JAB 2.6,JAB 2.6,PyrCHH), 4.00 (1H, app.t, J 8.1, CHCHH), 7.10 
(2H, dd, J 7.4,4.8, ArCH), 7.15-7.39 (3H, m, ArCH), 7.59 (1H, dt, J7.8, 1.8, PyrCH), 8.39 (1H, 
dd, J 4.8, 1.4, PyrCH), 8.49 (1H, d, J 1.5, PyrCH).
13
C NMR (δ; 100 MHz, CDCl3), 23 (CH2), 25 
(CH2), 35 (CH2), 54 (CH2), 58 (CH2), 60 (CH), 64 (CH2), 66 (CH), 123 (CH), 127 (ArCH), 133 





: 322.2283 found 322.2284. [α]D
20 
= +84 (c 5.0, DCM). HPLC (AD column 





Figure 46: HPLC data for 2R,4S-126d 
N-benzyl-1-((2R,4S)-4-phenyl-1-(pyridin-3-ylmethyl)azetidin-2-yl)methanamine (126d) 
General procedure (h) was used, (R)-1-phenyl-N-(pyridin-3-
ylmethyl)but-3-en-1-amine (132 mg, 0.55 mmol), flash 
chromatography (DCM/Methanol= 9.5/0.5), yellow oil, 150 mg 
76% yield. IR 3027, 2824, 1673, 1260, 1157, 696. 
1
H NMR (δ; 300 MHz, CDCl3); 2.01 (1H, dd, 
J 18.8, 8.7, CHCHHCH), 2.39-2.49 (2H, m, CHCHHCH), 2.56 (1H, dd, J 12.1, 4.3, CHCHH), 
3.32 (1H, m, CHHCHCHH), 3.67 (ABq, 2H, JAB 13.2, JAB13.2, PyrCHH), 3.64 (2H, s, ArCH2), 
3.99 (1H, app.t, J 8.2, CHCHH), 7.08 (2H, ddd, J 7.7, 4.8, 0.6, ArCH),7.13-7.44 (10H, m, ArCH, 
PyrCH), 8.39 (1H, dd, J 4.8,1.6, PyrCH), 8.49 (1H, d, J 1.8, PyrCH).
13
C NMR (δ; 100 MHz, 
CDCl3), 31(CH2), 46 (CH2), 53 (CH2), 54 (CH2), 58 (CH2), 62 (CH), 65 (CH), 123 (CH), 126- 
128 (10ArCH), 134 (PyrC), 136 (2PyrCH), 140 (ArC), 143 (ArC), 148 (PyrCH), 150 (PyrCH). 
HRMS [M+H]
+ 
calculated for formula C23H26N3
+
344.2127; found 344.2122. [α]D
20 
= +82 (c 5.0, 






Figure 47: HPLC data for 2R, 4s-126d 
 
1-(((2R,4S)-1-benzyl-4-phenylazetidin-2-yl)methyl)pyrrolidine (126e) 
General procedure (h) was used, (S)-N-benzyl-1-phenylbut-3-en-1-amine 
(200 mg, 8.5 mmol), flash chromatography (DCM/Methanol= 9.5/0.5), 
yellow brown oil, 80 mg 57% yield. IR 3024, 2905, 2834, 2805,1560, 
1482, 1454, 1420, 1150.
1
H NMR (δ; 300 MHz, CDCl3); 1.52-1.70 (4H, overlapping m, 2x CH2), 
2.22 (4H, overlapping m, 2x CH2), 2.41-2.55 (2H, m, NCH2), 3.13-3.28 (2H, m, CHCH2CH), 
3.62 (ABq, 2H, JAB 14.1, JAB14.1, ArCH2), 3.89 (1H, app.t, J13.1, CHCHH), 7.07-7.38 (10H, m, 
ArCH).
13
C NMR (δ; 100 MHz, CDCl3), 23.3 (2CH2), 34.9 (CH2), 54.5 (2CH2), 58.5 (CH2), 60.4 
(CH), 61.3 (CH2), 66.1 (CH), 123.1 (ArCH), 126.7 (3ArCH), 127.1 (ArCH), 128.3 (3ArCH), 
137.1 (ArCH), 148.5 (ArC), 150.5 (ArC). High resolution MS [M+H]
+
calculated for formula 
C21H27N2
+
: 307.2127 found 307.2128. [α]D
20 
= +66 (c 5.0, DCM). HPLC (AD column was used), 





Figure 48: HPLC data for 2R, 4S-126e 
N-(((2R,4S)-1-neopentyl-4-phenylazetidin-2-yl)methyl)propan-1-amine (126f) 
General procedure (h) was used, (R)-N-neopentyl-1-phenylbut-3-en-
1-amine (120 mg, 0.55 mmol), flash chromatography (Hexane/EtOAc 
= 9/1 Rf = 0.3), yellow brown oil, 80 mg 50% yield. IR 3675, 2957, 
2925, 1668, 1455, 1394, 1258, 1066, 1027, 867, 795, 751, 698.
1
H NMR (δ; 300 MHz, CDCl3); 
0.64 (9H, s, CH3), 0.98 (3H, t, J 7.4, CH3), 1.60 (2H, dq, J 14.6, 7.4, CH2CH3), 1.95 (2H, dt, J 
10.4, 8.4, NCH2CH2), 2.39 (2H, s, NCH2C), 2.47 (1H, dt, J 10.5, 7.8, CHCHHCH), 2.61-2.68 
(1H, m, CHCHHCH), 2.78 (2H, ddd, J 17.6, 11.9, 4.8, NHCH2CH), 3.16-3.27 (1H, m, 
CHHCHCHH), 3.85 (1H,app.t, J 8.1, CHCHH),7.21-7.55 (5H, m, ArCH).
13
C NMR (δ; 100 
MHz, CDCl3); 11.8 (CH3), 23.2 (CH2), 28.4 (3CH3), 31.3 (CH2), 31.5 (C), 52.3 (CH), 54.2 (CH2), 
63.3 (CH2), 69.7 (CH2), 73.4 (CH), 127.0 (ArCH), 127.5 (2ArCH), 128.0 (2ArCH), 144.9 (ArC). 
HRMS [M+ H
+
] calculated for formula C18H30N2
+
: 275.2430; found: 275.2431. [α]D
20 
= +93 (c 











Characterisation data for the synthesised pyrrolidin-2-one compounds: 
N-benzyl-3-hydroxy-3-methyl-5-phenylpyrrolidin-2-one (cis-130a) 
General procedure (b) was used. N-Benzyl-3-methyl-1-phenylbut-3-en-1-
amine 44a (156 mg, 0.60 mmol), iodine (460 mg, 1.80 mmol), sodium 
bicarbonate (254 mg, 3.03 mmol), ethyl acetate/petroleum ether 40%, 
Rf=0.23, white crystal (mpt 155-156 ˚C), 63 mg 46% yield. IR 3286, 
3030, 2933, 1671 (s), 1576.
1
H NMR (δ; 300 MHz, CDCl3); 1.55 (3H, s, CH3), 1.92 (1H, dd, 
Jab13.0, Jac8.5, CHCHH), 2.59 (1H, dd, Jab13.0, Jbc6.8, CHCHH), 3.57 (ABq,1H, JAB14.6, 
ArCHH), 4.53 (1H, dd, Jac8.5, Jbc6.8, CHCHH), 5.09 (ABq,1H, JAB14.6, ArCHH), 7.04-7.43 
(10H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 24.5 (CH3), 44.0 (CH2), 44.5 (CH2), 57.8 (CH), 
74.0 (COH), 126.9 (ArCH), 127.6 (ArCH), 127.9 (ArCH), 128.4 (ArCH), 128.6 (ArCH), 129.0 
(ArCH), 135.8 (ArC), 139.0 (ArC), 177.1 (CO). HRMS [M+H]
+ 
calculated for the formula 
C18H19NO2
+
282.3519; found 282.3514. 
N-benzyl-3-hydroxy-3-methyl-5-phenylpyrrolidin-2-one (trans-130a) 
General procedure (b) was used. N-Benzyl-3-methyl-1-phenylbut-3-en-1-
amine 44a (156 mg, 0.60 mmol), iodine (460 mg, 1.80 mmol), sodium 
bicarbonate (254 mg, 3.03 mmol), ethyl acetate/ petroleum ether 40%, Rf= 
0.25, white crystal (mpt 161-162 ˚C), 78 mg, 54% yield. IR 3286, 3030, 2933, 1671, 1576.
1
H 
NMR (δ; 300 MHz, CDCl3); 1.44 (3H, s, CH3), 2.14 (1H, dd, Jab13.1, Jac8.4, CHCHH), 2.46 (1H, 
dd, Jab13.1, Jbc6.0, CHCHH), 3.47 (ABq, 1H, JAB14.4, ArCHH), 4.16 (1H, dd, Jac8.4, Jbc6.0, 
CHCHH), 5.06 (ABq, 1H, JAB14.4, ArCHH), 7.01-7.42 (10H, m, ArCH).
13




CDCl3); 25.2 (CH3), 43.9 (CH2), 44.5 (CH2), 58.1 (CH), 74.3 (COH), 126.9 (ArCH), 127.6 
(ArCH), 127.9 (ArCH), 128.2 (ArCH), 128.3 (ArCH), 128.6 (ArCH),129.0 (ArCH), 135.5 (ArC), 
139.7 (ArC), 176.9 (CO). HRMS [M+H]
+ 




N-(3-Pyridyl)-3-hydroxy-3-methyl-5-phenyl-pyrrolidin-2-one (cis-130b and trans-130b) 
(Mixture of diastereoisomers maj/min) General procedure (b) was used. 3-
Methyl-1-phenyl-N-(pyridin-3-ylmethyl)butan-1-amine 44b (255 mg, 1.01 
mmol), iodine (769 mg, 3.03 mmol), sodium bicarbonate (424 mg, 5.05 
mmol), ethyl acetate 100%. Rf=0.2, yellow oil (gum), 0.25 g 91% yield. 
IR 3323, 2927, 1668(s).
1
H NMR (δ; 300 MHz, CDCl3); 1.43 (3H, s, CH3 min), 1.56 (3H, s, CH3 
maj), 1.94 (1H, dd, Jab13.8, Jac7.1, CHCHHmaj), 2.19 (1H, dd, Jab13.1, Jac7.7, CHCHHmin), 2.49 
(1H, dd, Jab13.1,Jbc6.8, CHCHHmin), 2.59 (1H, dd,Jab13.8, Jbc7.4,CHCHHmaj), 3.64 (ABq, 1H, 
JAB17.1, PyrCHHmaj), 4.18 (1H, dd, Jac7.7, Jbc6.8, CHCHHmin), 4.50 (1H, dd, Jac7.1, Jbc7.4, 
CHCHHmaj), 4.97 (ABq, 1H, JAB15.4, PyrCHHmin) 7.06-7.46 (12H, m, ArCH), 7.49 (2H, dt, J 1.9, 
7.9, PyrCH), 8.17 (1H, d, J 2.0, PyrCH), 8.24(1H, d, J 2.0, PyrCH), 8.52 (2H, m, overlapping, 
PyrCH).
13
C NMR (δ; 100 MHz, CDCl3); 24.5 (CH3), 25.0 (CH3), 42.1 (CH2), 42.1 (CH2), 43.9 
(CH2), 44.0 (CH2), 58.2 (CH), 58.5 (CH), 73.9 (COH), 74.2 (COH), 123.6 (ArCH), 127.0 
(ArCH), 127.7 (ArCH), 128.5 (ArCH), 128.8 (ArCH), 129.2(ArCH), 131.5 (PyrC), 135.4 
(ArCH),136.1(ArCH), 136.2 (ArC), 138.5 (ArC), 139.2 (ArCH), 139.2 (ArCH), 149.1 (PyrCH), 
149.1 (PyrCH), 149.2 (PyrCH), 149.2 (PyrCH), 149.7(PyrCH), 149.7 (PyrCH), 149.9 (PyrCH), 
149.9 (PyrCH), 150.7 (CO), 152.9 (CO). HRMS [M+H]
+ 
calculated for the formula C17H19N2O2
+
 





General procedure (b) was used. N-Propyl-3-methyl-1-phenylbut-3-en-1-
amine 44c (800 mg, 3.9 mmol), iodine (300 mg, 11.8 mmol), sodium 
bicarbonate (1650 mg, 19.6 mmol), ethyl acetate/ hexane 50%, Rf= 0.25, 
yellow solid (mpt 95-96˚C), 200 mg, 22% yield. IR 3348, 2965, 1673 (s), 1457, 1366.
1
H NMR 
(δ; 300 MHz, CDCl3); 0.84 (3H, t, J 7.2, CH2CH3), 1.39-1.48 (2H, m, CH2CH3), 1.49 (3H, s, 
CH3), 1.88 (1H, dd, Jab13.7, Jac6.6, CHCHH), 2.55-2.70 (2H, m, NCH2), 3.63 (1H, dt, Jab13.7, 
Jbc6.6, CHCHH), 4.76 (1H, app.t, J7.1, CHCHH), 7.14-7.43 (5H, m, ArCH).
13
C NMR (δ; 100 
MHz, CDCl3); 11.1 (CH3), 19.9 (CH2), 25.1 (CH3), 42.4 (CH2), 44.2 (CH2), 58.8 (CH), 74.2 (C-
OH), 126.7 (ArCH), 128.1 (ArCH), 129.0 (ArCH), 140.2 (ArC), 176.8 (CO). HRMS [M+Na]
+ 
calculated for the formula C14H19NO2Na
+
 256.1318; found 256.1313. 
N-propyl-3-hydroxy-3-methyl-5-phenylpyrrolidin-2-one (trans-130c) 
General procedure (b) was used. N-Propyl-3-methyl-1-phenylbut-3-en-1-
amine 44c (800 mg, 3.9 mmol), iodine (300 mg, 11.8 mmol), sodium 
bicarbonate (1.65 gm, 19.6 mmol), ethyl acetate/hexane 50%. Rf= 0.27, 
yellow solid (mpt 84-85 ˚C), 120 mg, 13% yield. IR3348, 2965, 1673 (s), 1457, 1366.
1
H NMR 
(δ; 300 MHz, CDCl3); 0.84 (3H, t, J 7.4, CH2CH3), 1.38-1.48 (2H, m, CH2CH3), 1.49 (3H, s, 
CH3), 1.88 (1H, dd, Jab13.0, Jac7.0, CHCHH), 2.55-2.70 (2H, m, NCH2), 3.55-3.65 (1H, m, 
CHCHH), 4.46 (1H, app.t, J7.0, CHCHH), 7.24-7.45 (5H, m, ArCH).
13
C NMR (δ; 100 MHz, 




127.4 (ArCH), 128.5 (ArCH), 129.0 (ArCH), 139.4 (ArC), 176.8 (CO). HRMS [M+Na]
+ 
calculated for the formula C14H19NO2Na
+
 256.1318; found 256.1313. 
N-(2-methylbenzyl)-3-hydroxy-3-methyl-5-phenylpyrrolidin-2-one (cis-130d) 
General procedure (i) was used, N-(2-methylbenzyl)-3-methyl-1-
phenylbut-3-en-1-amine 44e (245 mg, 0.92 mmol), iodine (703 gm, 2.77 
mmol), sodium bicarbonate (388 gm, 4.60 mmol), ethyl acetate/petroleum 
ether 30%, Rf= 0.27, white solid (mpt 161-162 
°
C), 68 mg 25% yield. IR 3370, 2928, 1675(s), 1456.
1
H 
NMR (δ; 300 MHz, CDCl3);1.55 (3H, s, CH3), 1.91 (1H, dd, Jab13.8, Jac6.0, CHCHH), 2.09 (3H, s, 
ArCH3), 2.60 (1H, dd, Jab13.8, Jbc8.1, CHCHH), 3.69 (ABq, 1H, JAB14.8, ArCHH), 4.44 (1H, dd, Jac6.0, 
Jbc8.1, CHCHH),5.10 (ABq,1H, JAB15.0, ArCHH),6.80 (1H, d, J 7.4, ArCH), 6.94-7.41 (8H, m, 
ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 19.0 (CH3), 25.4 (CH3), 42.5 (CH2), 43.8 (CH2), 58.0 
(CH), 74.4 (COH), 125.8 (ArCH), 126.7 (ArCH), 127.7 (ArCH), 128.0 (ArCH), 129.0 (ArCH), 
129.1(ArCH), 130.4 (ArCH), 133.0 (ArC),136.9 (ArC), 140.0 (ArC), 176.2 (CO). HRMS 
[M+Na]
+
calculated for the formula C19H21NO2Na
+
318.1469; found 318.1470. 
N-(2-methylbenzyl)-3-hydroxy-3-methyl-5-phenylpyrrolidin-2-one (trans-130d) 
General procedure (i) was used. N-(2-methylbenzyl)-3-methyl-1-
phenylbut-3-en-1-amine 44e (245 mg, 0.92 mmol), iodine (703 gm, 2.77 
mmol), Sodium bicarbonate (388 gm, 4.60 mmol), ethyl acetate/petroleum 
ether 30%, Rf= 0.27, colourless crystals (mpt 132-133
°
C), 50 mg 18% yield. IR 3370, 2926, 
1675(s), 1456.
1
H NMR (δ; 300 MHz, CDCl3);1.49 (3H, s, CH3), 1.96 (1H, dd, Jab13.8, Jac6.1, 




ArCHH), 4.13 (1H, dd, Jac6.1, Jbc8.0, CHCHH), 4.44 (ABq, 1H, JAB14.8, ArCHH), 6.79 (1H, d, J 
7.4, ArCH), 6.94-7.41 (8H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3);18.9 (CH3), 25.0 (CH3), 
42.1 (CH2), 44.2 (CH2), 58.0 (CH), 74.2 (COH), 125.8 (ArCH), 127.6 (ArCH), 127.8 (ArCH), 
128.4 (ArCH), 128.9 (ArCH), 129.5 (ArCH), 130.5(ArCH), 133.2 (ArC), 136.8 (ArC), 139.4 
(ArC), 176.9 (CO). HRMS [M+Na]
+ 





General procedure (i) was used. N-benzyl-3-methyl-1-(furan-3-yl) but-3-
en-1-amine 44f (300 mg, 1.24 mmol), iodine (950 mg, 3.70 mmol), sodium 
bicarbonate (520 mg, 6.20 mmol), ethyl acetate/petroleum ether 30%, 
Rf=0.27, light yellow crystals (mpt 131-132
°
C), 60 mg 40% yield. IR 3356, 2932, 1663(s).
1
H 
NMR (δ; 300 MHz, CDCl3); 1.55 (3H, s, CH3), 1.95 (1H, dd, Jab13.2, Jac8.1, CHCHH), 2.50 (1H, 
dd,Jab13.2, Jbc6.9, CHCHH), 3.68 (ABq, 1H, JAB14.8, ArCHH), 4.55 (1H, Jac8.1, Jbc6.9, 
CHCHH), 5.03(ABq,1H, JAB14.8, ArCHH), 6.23 (1H, dd, J0.6, 1.5, FurCH), 7.08-7.48 (5H, 
overlapping m, ArCH, FurCH).
13
C NMR (δ; 100 MHz, CDCl3); 25.1 (CH3), 42.3 (CH2), 44.4 
(CH2), 49.6 (CH), 74.2 (COH), 108.3 (FurCH), 124.3 (FurC), 127.6 (ArCH), 128.2 (ArCH), 
128.7 (ArCH), 135.8 (ArC), 140.8 (FurCH), 144.3 (FurCH), 176.3 (CO). HRMS 
[M+Na]
+
calculated for the formula C16H17NO3Na
+






General procedure (i) was used, N-benzyl-3-methyl-1-(furan-3-yl) but-3-
en-1-amine 44f (300 mg, 1.24 mmol), iodine (950 mg, 3.70 mmol), sodium 
bicarbonate (520 mg, 6.20 mmol), ethyl acetate/petroleum ether 30%, 
Rf=0.25, white crystals (mpt 120-121 
°
C), 40 mg 35% yield. IR 3356, 
2932, 1663(s).
1
H NMR (δ; 300 MHz, CDCl3); 1.44 (3H, s, CH3), 2.17 (1H, dd, Jab13.2, Jac8.1, 
CHCHH), 2.38 (1H, dd, Jab12.9, Jbc6.9, CHCHH), 3.61 (ABq,1H, JAB14.6, ArCHH), 4.25 (1H, 
dd, Jac8.1, Jbc6.9, CHCHH), 5.02 (ABq, 1H, JAB14.6, ArCHH), 6.39 (1H, dd, J0.6, 1.5, FurCH), 
7.02-7.35 (5H, m, ArCH), 7.44 (2H, t, J 1.5, FurCH).
13
C NMR (δ; 100 MHz, CDCl3); 24.4 
(CH3), 42.4 (CH2), 44.3 (CH2), 48.9 (CH), 73.9 (COH), 108.8 (FurCH), 123.7 (FurC), 127.7 
(ArCH), 128.3 (ArCH), 128.7 (ArCH), 136.1 (ArC), 141.3 (FurCH), 144.3 (FurCH), 176.8 (CO). 
HRMS [M+Na]
+
calculated for the formula C16H17NO3Na
+
 294.1105; found 294.1106. 
N-benzyl-5-(tert-butyl)-3-hydroxy-3-methylpyrrolidin-2-one (cis-130f and trans-130f) 
(Mixture of diastereoisomers maj/min) General procedure (i) was used. N-
Benzyl-2,2,5-trimethylhex-5-en-3-amine 44g (100 mg, 0.68 mmol), iodine 
(520 mg, 2.06 mmol), sodium bicarbonate (288 mg, 3.43 mmol), ethyl 
acetate/petroleum ether 80%, Rf=0.65, pale yellow crystal, 120 mg, 67% 
yield. IR 3352, 2902, 1662(s).
1
HNMR (δ; 300 MHz, CDCl3); 0.89 (9H, s,CH3 min), 0.93 (9H, s, 
CH3 maj), 1.45 (3H, s, CH3 min), 1.56 (3H, s, CH3maj),1.77 (1H, dd, Jab14.1, Jac7.3, CHCHHmin), 
2.03 (1H, dd, Jab4.8, Jbc8.2, CHCHHmin), 2.45 (1H, dd, Jab13.1, Jac6.9, CHCHHmaj), 2.59 (1H, dd, 




CHCHHmaj), 5.06 (ABq, 2H, JAB14.4, ArCHHmaj), 5.30 (ABq, 2H, JAB15.7, ArCHH min), 6.87-
7.44 (10H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 22.1 (CH3), 22.6 (CH3), 26.9 (CH3), 27.1 
(CH3), 36.6 (CH), 37.1 (CH), 44.3 (CH2), 44.4 (CH2), 62.3 (CH), 63.0 (CH), 74.1 (COH), 74.3 
(COH), 127.0 (ArCH), 127.4 (ArCH), 127.7 (ArCH), 128.3 (ArCH), 128.5 (ArCH), 128.7 




 found 284.15. 
N-benzyl-5-(3,4-dimethoxyphenyl)-3-hydroxy-3-methylpyrrolidin-2-one (cis-130g and trans-130g) 
(Mixture of diastereoisomers maj/min) General procedure (i) was 
used. N-benzyl-1-(3,4-dimethoxyphenyl)-3-methylbut-3-en-1-amine 
44h (155 mg, 0.49 mmol), iodine (379 mg, 1.49 mmol), sodium 
bicarbonate (209 mg, 2.48 mmol), methanol/dichloromethane 5%, pale yellow precipitate, 110 
mg, 65% yield. IR 3380, 1680(s), 1682(s).
1
H NMR (δ; 300 MHz, CDCl3); 1.45 (3H, s, CH3min), 
1.58 (3H, s, CH3 maj.),1.92 (1H, dd, Jab13.8, Jac6.8, CHCHHmaj.), 2.18 (1H, dd,Jab13.0,Jbc8.2, 
CHCHHmaj.), 2.45 (1H, dd, Jab13.8, Jac6.8, CHCHHmin), 2.58 (1H, dd, Jab13.8, Jbc7.5, 
CHCHHmin), 3.53 (ABq, 1H, JAB14.8, PhCHHmin), 3.64 (ABq, 1H, JAB14.8, PhCHHmaj), 3.83 (6H, 
s, OCH3 min), 3.92 (6H, s, OCH3 maj), 4.14 (1H, dd, Jac6.8, Jbc7.5, CHCHHmin), 4.49 (1H, app.t, 
J6.8, CHCHH maj), 5.02 (1H, t, J 13.8, ArCHH maj+min), 6.54 (2H, d, J 1.6, ArCH), 6.65-6.76 (2H, 
m, ArCH),6.86 (2H, dd, Jab3.0,Jac8.2, ArCH), 6.98-7.03 (2H, m, ArCH), 7.05-7.11 (2H, m, 
ArCH), 7.28 (6H, d, J 3.7, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 24.4 (CH3), 25.2 (CH3), 29.7 
(CH2), 43.8 (CH2), 43.9 (CH2), 44.6 (CH), 44.7 (CH), 55.9 (2OCH3), 57.9 (CH), 58.2 (CH), 74.1 
(COH), 74.4 (COH), 109.6 (ArCH), 110.0 (ArCH), 110.8 (ArCH), 111.0 (ArCH), 111.3 (ArCH), 




(ArCH), 128.9 (ArCH), 129.0 (ArC), 148.9 (ArCOCH3), 149.1(ArC), 149.5 (ArCOCH3), 176.6 
(CO), 177.1 (CO). HRMS [M+H]
+ 





General procedure (i) was used. N-(4-Methoxylbenzyl)-3-methyl-1-
phenylbut-3-en-1-amine 44i (280 mg, 0.99 mmol), iodine (758 mg, 
2.98 mmol), sodium bicarbonate (417 mg, 4.97 mmol), ethyl 
acetate/petroleum ether 40%, RF=0.23, colourless crystal (mpt 141-
142 
°
C), 70 mg, 35% yield. IR 3377, 2929, 1680(s).
1
H NMR (δ; 300 MHz, CDCl3);1.55 (3H, s, 
CH3), 1.90 (1H, dd, Jab13.7, Jac6.6, CHCHH), 2.57 (1H, dd, Jab13.8,Jbc7.8, CHCHH), 3.51 (ABq, 
1H, JAB14.5, ArCHH), 3.77 (3H, s,OCH3), 4.51 (1H, app.t, J 7.2, CHCHH), 5.04 (ABq, 1H, 
JAB14.5, ArCHH), 6.78 (2H, d, J8.6, ArCH), 6.98 (2H, d, J 8.6,ArCH), 7.06-7.17 (2H, m, ArCH), 
7.29-7.43(3H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 25.2(CH3), 44.0(CH2), 55.2(CH), 
58.1(CH), 74.3(COH), 114.0 (ArCH), 127.0 (ArCH), 127.7(ArC), 128.2 (ArCH), 129.0 (ArCH), 
129.8 (ArCH), 140.0(ArC), 159.0(ArC), 176.8 (CO). HRMS [M+Na]
+
 calculated for the formula 
C19H21NO3Na
+
334.1421; found 334.1419. 
N-(4-methoxybenzyl)-3-hydroxy-3-methyl-5-phenylpyrrolidin-2-one (trans-130h) 
General procedure (i) was used. N-(4-Methoxylbenzyl)-3-methyl-1-
phenylbut-3-en-1-amine 44i (280 mg, 0.99 mmol), iodine (758 mg, 




petroleum ether 40%, Rf=0.25, colourless crystal (mpt 159-160 
°
C), 51 mg, 45% yield. IR 3377, 
2929, 1680(s).
1
H NMR (δ; 300 MHz, CDCl3);1.43 (3H, s, CH3), 2.13 (1H, dd, Jab13.0, Jac6.6, 
CHCHH), 2.45 (1H, dd, Jab13.0, Jbc6.8, CHCHH), 3.41 (ABq, 1H, JAB14.4, ArCHH), 3.78 (3H, s, 
OCH3), 4.14 (1H, dd, Jac6.6, Jbc6.8, CHCHH), 5.01 (ABq, 1H, JAB14.4, ArCHH), 6.79 (2H, d, J 
8.7, ArCH), 6.90 (2H, d, J 8.6, ArCH), 7.17-7.24 (2H, m, ArCH), 7.29-7.37(3H, m, ArCH).
13
C 
NMR (δ; 100 MHz, CDCl3); 24.4(CH3), 43.9(CH2), 44.2(CH2), 55.2(CH3), 74.1(COH), 
114.0(ArCH), 127.7 (ArCH), 128.0(ArC), 128.4 (ArCH), 129.0 (ArCH), 129.8 (ArCH), 
139.2(ArC), 159.1(ArC), 177.30 (CO). HRMS [M+Na]
+ 
calculated for the formula 
C19H21NO3Na
+
334.1421; found 334.1419. 
N-(adamantan-1-yl)-3-hydroxy-3-methyl-5-phenylpyrrolidin-2-one (cis-134i and trans-130i) 
General procedure (i) was used. N-(Admantan-1-yl) phenylbut-3-ene 44l (237 
mg, 0.80 mmol), iodine (610 mg, 2.40 mmol), sodium bicarbonate (337 mg, 
4.00 mmol), ethyl acetate (50 mL), ethyl acetate/hexane 50%, white 
precipitate, 150 mg, 57% yield. IR 2904, 2849, 1657(s).
1
H NMR (δ; 300 
MHz, CDCl3); 1.20-2.30 (24H, overlapping m, AdmantCH2), 2.44 (1H, dd, Jab13.4, Jac8.3, 
CHCHHmaj), 2.63 (1H, dd, Jab12.9, Jac10.0, CHCHHmin), 2.73 (1H, dd, Jab13.4, Jbc8.3, 
CHCHHmaj), 4.19 (1H, dd, Jab12.9, Jbc9.8, CHCHHmin), 4.47-4.55 (1H, m, CH), 4.63-4.71 (1H, 
m, CH), 4.74 (1H, dd, Jac8.3, Jbc8.3, CHCHHmaj), 4.77 (1H, d, Jac10.0, Jbc9.8, CHCHHmin), 5.04 
(3H, d, J 9.6, CH), 7.08-7.53 (10H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 19.9 (CH3), 26.5 
(CH3), 29.5 (CH), 29.7 (CH), 29.9 (CH), 36.2 (CH), 36.7 (CH), 41.8 (2CH2), 42.2 (2CH2), 49.5 
(CH2), 49.6 (CH2), 54.6 (CH2), 57.3 (CH), 59.3(CH), 77.8 (CH2), 87.0 (CH), 88.7 (CH), 125.4 




(ArCH), 127.8 (ArCH), 127.9 (ArCH), 128.0 (ArCH), 128.2 (ArCH), 128.7 (ArCH),144.9 (ArC), 
149.0 (ArC), 177.3 (CO), 177.8 (CO). HRMS [M+H]
+ 
calculated for the formula C21H28NO2
+
 
326.2122; found 326.2120. 
N-benzyl-3-hydroxy-3-methyl-5-(thiophen-2-yl) pyrrolidin-2-one (cis-130j) 
General procedure (i) was use.N-Benzyl-3-methyl-1-(thiophen-2-yl) but-3-
en-1-amine44j (156 mg, 0.6 mmol), iodine (460 mg, 1.80 mmol), sodium 
bicarbonate (254 mg, 3.03 mmol), ethyl acetate/ petroleum ether 40%, 
Rf=0.35, white crystal (mpt 142-143
°
C), 27 mg 36% yield. IR 3292, 2940, 
1671 (s).
1
H NMR (δ; 300 MHz, CDCl3); 1.45 (3H, s, CH3), 2.31 (1H, dd, Jab13.0, Jac8.6, 
CHCHH), 2.53 (1H, dd, Jab13.0, Jbc6.7, CHCHH), 3.59 (ABq, 1H, JAB14.7, ArCHH), 4.52 (1H, 
dd, Jac8.6, Jbc6.7, CHCHH), 5.05 (ABq, 1H, JAB14.7, ArCHH), 6.88-7.12 (3H, m, ThioCH), 7.22-
7.39 (5H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 24.2(CH3), 44.4 (CH2), 44.9 (CH2), 53.1 
(CH), 73.8 (COH), 126.4 (ArCH), 126.8 (ArCH), 127.5 (ArCH), 127.7 (ArCH), 128.4 (ThioCH), 
128.7 (ThioCH), 129.0 (ThioCH), 136.0 (ThioC), 142.7 (ArC), 176.9 (CO). HRMS 
[M+Na]
+
calculated for the formula C16H17NO2NaS
+
 310.0876; found 310.0878. 
N-benzyl-3-hydroxy-3-methyl-5-(thiophen-2-yl) pyrrolidin-2-one (trans-130j) 
General procedure (i) was used. N-Benzyl-3-methyl-1-(thiophen-2-yl) but-
3-en-1-amine 44j (156 mg, 0.60 mmol), iodine (460 mg, 1.80 mmol), 
sodium bicarbonate (254 mg, 3.03 mmol), ethyl acetate/ petroleum ether 
40%, Rf=0.25, white crystal (mpt 134-135 
°
C), 23 mg 30% yield. IR 3292, 2940, 1671 (s).
1
H 




dd, Jab13.1, Jbc7.7, CHCHH), 3.63 (ABq,1H, JAB14.7, ArCHH), 4.86 (1H, app.t, J7.1, CHCHH), 
5.20 (ABq,1H, JAB14.7, ArCHH), 6.80-7.36 (3H, m, ThioCH), 7.36-7.38 (5H, m, ArCH).
13
C 
NMR (δ; 100 MHz, CDCl3); 24.0 (CH3), 44.2 (CH2), 44.7 (CH2), 53.0 (CH), 73.9 (COH), 126.9 
(ArCH), 127.0 (ArCH), 127.3 (ArCH), 127.9 (2ArCH), 128.5 (ThioCH), 128.6 (ThioCH), 129.0 
(ThioCH), 136.4 (ThioC), 142.9 (ArC), 177.1 (CO). HRMS [M+Na]
+
calculated for the formula 
C16H17NO2NaS
+
 310.0876; found 310.0878. 
N-benzyl-5-(2-bromophenyl)-3-hydroxy-3-methylpyrrolidin-2-one (cis-130k) 
General procedure (i) was used. N-Benzyl-3-methyl-1-(2-
bromophenyl)but-3-en-1-amine 44k (200 mg, 0.60 mmol), iodine (460 
mg, 1.8 mmol), sodium bicarbonate (250 mg, 3.0 mmol), ethyl 
acetate/petroleum ether 40%, Rf= 0.18, white crystal (mpt 125-126
°
C), 74 
mg, 34% yield. IR 3327, 2926, 1679(s).
1
H NMR (δ; 300 MHz, CDCl3); 1.45 (3H, s,CH3), 1.89 
(1H, dd, Jab13.5, Jac3.7, CHCHH), 2.66 (1H, dd, Jab13.5, Jbc8.9, CHCHH), 3.67 (ABq, 1H, 
JAB14.5, ArCHH), 4.91 (1H, dd, Jac3.7, Jbc8.9, CHCHH), 5.16 (ABq, 1H, JAB14.5, ArCHH), 7.01-
7.42 (8H, m, ArCH), 7.59 (1H, dd, J 8.0, 1.0, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 24.8 
(CH3), 42.6 (CH2), 45.0 (CH2), 56.3 (COH), 123.4 (ArC), 127.8 (ArCH), 128.0 (ArCH), 128.3 
(ArCH), 128.6 (ArCH), 128.7 (ArCH), 129.4 (ArCH), 133.1 (ArCH), 135.3 (ArC), 147.0 (ArC), 
176.5 (CO). HRMS [M+Na]
+









General procedure (i) was used. N-Benzyl-3-methyl-1-(2-
bromophenyl)but-3-en-1-amine 44k (200 mg, 0.60 mmol), iodine (460 
mg, 1.8 mmol), sodium bicarbonate (250 mg, 3.0 mmol), ethyl 
acetate/petroleum ether 40%, Rf= 0.25, white crystal (mpt 112-113 
°
C), 48 mg 21% yield. IR 
3327, 2926, 1679(s).
1
H NMR (δ; 300 MHz, CDCl3); 1.43 (3H, s, CH3), 1.94 (1H, dd, Jab13.2, 
Jac7.3, CHCHH), 2.52 (1H, dd, Jab13.2, Jbc7.3, CHCHH),3.58 (ABq, 1H, JAB 14.4, ArCHH), 4.73 
(1H, app.t, J7.2, CHCHH), 5.09 (ABq, 1H, JAB14.4, ArCHH), 6.99 (2H, dd, J 6.5, 2.8, ArCH), 
7.15-7.45 (5H, m,ArCH), 7.55 (1H, d, J 7.3, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 24.8 (CH3), 
42.6 (CH2), 45.0 (CH2), 56.3 (COH), 123.4 (ArC), 127.8 (ArCH), 128.0 (ArCH), 128.3 (ArCH), 
128.6 (ArCH), 128.7 (ArCH), 129.4 (ArCH), 133.1 (ArCH), 135.3 (ArC), 147.0 (ArC), 176.5 
(CO). HRMS [M+Na]
+
calculated for the formula C18H18NO2BrNa
+
282.0410; found 282.0419. 
N-(4-chlorobenzyl)-3-hydroxy-3-methyl-5-phenylpyrrolidin-2-one (cis-130l and trans-130l) 
(Mixture of diastereoisomers maj/min) General procedure (i) was used. 
N-(4-Chlorobenzyl)-3-methyl-1-phenylbut-3-en-1-amine 44l (160 mg, 
0.56 mmol), iodine (426 mg, 1.68 mmol), sodium bicarbonate (235 mg, 
2.79 mmol), ethyl acetate/hexane 50%, white precipitate, 113mg, 64% 
yield. IR 3286, 1681(s).
1
H NMR (δ; 300 MHz, CDCl3); 1.43 (3H, s, CH3 min), 1.58 (3H, s, CH3 
maj), 1.94 (1H, dd, Jab13.8,Jac7.0, CHCHHmaj), 2.16 (1H, dd, Jab13.1, Jac8.5, CHCHHmin), 2.48 
(1H, dd, Jab13.1, Jbc8.3, CHCHHmin),2.61 (1H, dd, Jab13.8, Jbc7.5, CHCHHmaj), 3.47(ABq, 1H, 




CHCHHmin), 4.54 (1H, dd, Jac7.0, Jbc7.5, CHCHHmaj), 4.97 (ABq, 1H, JAB 9.6, ArCHHmin), 
5.02(ABq, 1H, JAB9.8, ArCHHmaj), 6.91 (2H, d, J 8.5, ArCH), 7.00 (2H, d, J 8.5, ArCH), 7.10 
(2H, d, J 8.1, ArCH), 7.12-7.38 (12H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 24.5 (CH3), 
25.1 (CH3), 43.9 (CH2), 44.1 (CH2), 58.0 (CH), 58.3 (CH), 74.0 (COH), 74.3 (COH), 127.0 
(ArCH), 127.7 (ArCH), 128.4 (ArCH), 128.6 (ArCH), 128.8 (ArCH), 129.1 (ArCH), 129.7 
(ArCH), 129.9 (ArCH), 133.5 (ArC), 133.6 (ArC), 134.2 (ArC), 134.4 (ArC), 138.7 (ArC), 139.4 
(ArC), 176.7 (CO), 176.8 (CO). HRMS [M+H]
+
calculated for the formula 
C18H19ClNO2
+
316.1110; found 316.1104. 
N-benzyl-3-hydroxy-3-methyl-5-(4-nitrophenyl) pyrrolidin-2-one (cis-130m) 
General procedure (i) was used. N-Benzyl-3-methyl-1-(4-
nitrophenyl)but-3-en-1-amine 44m (300 mg, 1.0 mmol), iodine (770 
mg, 3.0 mmol), sodium bicarbonate (425 mg, 5.0 mmol), ethyl 
acetate/petroleum ether 60%, Rf= 0.25, light brown precipitate (mpt 
238-239˚C), 88 mg 25% yield. IR 3386, 2928, 1681(s), 1527, 1349, 698.
1
H NMR (δ; 300 MHz, 
CDCl3);1.57 (3H, s, CH3), 1.88 (1H, dd, Jab13.8, Jac6.7, CHCHH), 2.65 (1H, dd, Jab13.8, Jbc7.8, 
CHCHH), 3.60 (ABq,1H, JAB14.7, ArCHH), 4.63 (1H, app.t, J 7.2, CHCHH), 5.16 (ABq, 1H, 
JAB14.7, ArCHH), 6.99-7.09 (2H, m, ArCH), 7.24- 7.37 (5H, m, ArCH), 8.26 (2H, d,J8.7, 
ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 25.2 (CH3), 43.7 (CH2), 45.0 (CH2), 57.6 (CH), 74.1 
(COH), 124.4 (2ArCH), 127.7 (2ArCH), 127.9 (2ArCH), 128.2 (2ArCH), 128.8 (ArCH), 134.9 
(ArC), 147.4 (ArC), 147.8 (ArCNO2), 176.7 (CO). HRMS [M+Na]
+
calculated for the formula 
C18H18N2O4Na
+




N-benzyl-3-hydroxy-3-methyl-5-(4-nitrophenyl) pyrrolidin-2-one (trans-130m) 
General procedure (i) was used. N-benzyl-3-methyl-1-(4-
nitrophenyl)but-3-en-1-amine 44m (300 mg, 1.0 mmol), iodine (770 
mg, 3.0 mmol), sodium bicarbonate (425mg, 5.0 mmol), ethyl 
acetate/ petroleum ether 60%, yellow oil, 100 mg, 30% yield. IR 
3386, 2928, 1681(s), 1527, 1349, 698.
1
H NMR (δ; 300 MHz, CDCl3); 1.47 (3H, s, CH3), 2.10 
(1H, dd, Jab13.2, Jac7.6, CHCHH), 2.50 (1H, dd, Jab13.3, Jbc7.3, CHCHH), 3.54 (ABq, 1H, 
JAB14.6, ArCHH), 4.28 (1H, app.t, J7.4, CHCHH), 5.16 (ABq,1H, JAB14.6, ArCHH), 7.17- 7.50 
(2H, m, ArCH), 7.35-7.15 (5H, m, ArCH), 8.24 (2H, d, J 6.9, ArCH).
13
C NMR (δ; 100 MHz, 
CDCl3); 25.2 (CH3), 43.6 (CH2), 44.9 (CH2), 57.6 (CH), 74.0 (COH), 124.3 (2ArCH), 127.7 
(2ArCH), 127.9 (2ArCH), 128.2 (2ArCH), 128.8 (ArCH), 134.9 (ArC), 147.4 (ArC), 147.8 
(ArC), 176.7 (CO). HRMS [M+Na]
+




N-benzyl-3-hydroxy-3-methyl-5-(naphthalen-1-yl)pyrrolidin-2-one (cis-130n and trans-130n) 
General procedure (i) was used. N-benzyl-3-methyl-1-(naphthalen-1-
yl)but-3-en-1-amine 44n (126 mg, 0.418 mmol), iodine (318 mg, 1.2 
mmol), sodium bicarbonate (175 mg, 2.09 mmol), ethyl acetate/hexane 
50%, white precipitate, 100 mg, 72% yield. IR 3355, 2985, 1676(s).
1
H NMR (δ; 300 MHz, 
CDCl3); 1.53 (3H, s, CH3maj.), 1.95 (3H, s, CH3min), 2.17 (1H, dd, Jab13.4,Jac7.2, CHCHH maj), 
2.50 (1H, dd, Jab13.1,Jac7.1, CHCHHmin), 2.64 (1H, dd, Jab13.4,Jbc7.4, CHCHHmaj), 2.82 (1H, dd, 
Jab13.1,Jbc9.9, CHCHHmin), 3.35 (1H, dd, J14.4, ArCHHmin), 3.70 (2H, d, J14.4,ArCHHmaj), 4.61 




J14.5,ArCHHmaj), 5.34 (2H, d, J14.5,ArCHHmin), 6.93 (4H, t, J 7.5, NaphCH), 7.06- 8.24 (20H, 
m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 24.9 (CH3), 25.0 (CH3), 41.4 (CH2), 44.0 (CH2), 44.9 
(CH2), 45.0 (CH2), 45.3 (CH2), 52.3 (CH), 60.5 (CH), 74.3 (COH), 121.7 (ArCH), 123.1 (ArCH), 
123.8 (ArCH), 124.9 (ArCH), 125.8 (ArCH), 126.4 (ArCH), 126.6 (ArCH), 127.0 (ArCH), 127.7 
(ArCH), 128.4 (ArCH), 128.5 (ArCH), 128.6 (ArCH), 128.7 (ArCH), 129.0 (ArCH), 129.5 
(ArCH), 130.1 (ArC), 131.0 (ArC), 133.9 (ArC), 135.6 (ArC), 135.9 (ArC), 177.4 (2CO). HRMS 
[M+H]
+ 
calculated for the formula C22H22NO2
+
 332.4150; found 332.4131. 
1,3-Dimethyl-3-hydroxy-5-phenylpyrrolidin-2-one (cis-130o) 
General procedure (i) was used. 1,3-dimethyl-1-phenylbut-3-en-1-amine 44q 
(500 mg, 2.80 mmol), iodine (2.15 mg, 8.5 mmol), sodium bicarbonate (118 
mg, 14.1 mmol), ethyl acetate/petroleum ether 70%, Rf= 2.28, white crystal 
(mpt 159-160 ˚C). 135mg, 24% yield. IR 3306, 2928, 1668, 1454, 1256.
1
H NMR (δ; 300 MHz, 
CDCl3); 1.48 (3H, s, CH3), 2.13 (1H, dd, Jab13.2, Jac8.1, CHCHH), 2.54 (1H, dd, Jab13.2, Jbc6.9, 
CHCHH), 2.65 (3H, s, NCH3), 4.34 (1H, dd, Jac8.1, Jbc6.9, CHCHH), 7.22-7.43 (5H, m, 
ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 25.3 (CH3), 28.7 (CH3), 44.3 (CH2), 61.4 (CH), 74.1 
(COH), 126.5 (ArCH), 128.1 (ArCH), 129.1 (ArCH), 140.3 (ArC), 177.0 (CO). HRMS 
[M+Na]
+
calculated for the formula C12H15NO2Na
+





1,3-Dimethyl-3-hydroxy- 5-phenylpyrrolidin-2-one (trans-130o) 
General procedure (i) was used. N, 3-dimethyl-1-phenylbut-3-en-1-amine 44q 
(500 mg, 2.80 mmol), iodine (2150 mg, 8.47 mmol), sodium bicarbonate 
(1180 mg, 14.10 mmol), ethyl acetate/petroleum ether 70%, Rf= 0.29, white 
crystal (mpt 168-169 ˚C), 118 mg 19% yield. IR 3306, 2928, 1668, 1454, 1256.
1
H NMR (δ; 300 
MHz, CDCl3); 1.51 (3H, s, CH3), 1.90 (1H, dd, Jab13.2, Jac7.0, CHCHH), 2.66 (1H, dd, Jab13.8, 
Jbc7.7, CHCHH), 2.72 (3H, s, NCH3), 4.65 (1H, dd, Jac7.0, Jbc7.7, CHCHH), 7.12-7.44 (5H, m, 
ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 24.8 (CH3), 28.4 (CH3), 44.4 (CH2), 61.0 (CH), 74.1 
(COH), 127.3(ArCH), 128.5 (ArCH), 129.0 (2ArCH), 139.6 (ArC), 177.3(CO). HRMS 
[M+Na]
+
calculated for the formula C12H15NO2Na
+
228.0996; found 228.1000. 
N-(4-methoxybenzyl)-3-hydroxy-3-methyl-5-(pyridin-3-yl)pyrrolidin-2-one (cis-130p) 
General procedure (i) was used. N-benzyl-3-methyl-1-phenylbut-3-
en-1-amine 44p (350 mg, 1.24 mmol), iodine (940 mg, 3.70 
mmol), sodium bicarbonate (520 mg, 6.19 mmol), the product was 
separated with crystallisation from dichloromethane/petroleum ether 50%, white crystal (mpt 
172-173 ˚C), 150 mg, 51% yield. IR 2934, 1689 (s), 1611, 1512, 1431, 1245.
1
H NMR (δ; 300 
MHz, CDCl3); 1.39 (3H, s, CH3), 2.08 (1H, dd, Jab13.8, Jac6.9, CHCHH), 2.41 (1H, dd, Jab13.8, 
Jbc7.6, CHCHH), 3.35 (ABq, 1H, JAB14.5, ArCHH), 3.71 (3H, s, OCH3), 4.13 (1H, app.t, J 7.5, 
CHCHH), 4.96 (ABq,1H, JAB14.5, ArCHH), 6.77 (4H, dt, J 1.9, 1.9,ArCH), 7.38 (2H, dt, J 1.9 
,1.9, PyrCH), 8.38(1H, d, J 1.9,PyrCH), 8.55 (1H, dd, J 4.7, 1.6, PyrCH).
13
C NMR (δ; 100 MHz, 




(ArCH), 123.9 (ArCH), 127.1 (ArC), 129.6 (ArCH), 134.6 (ArCH), 135.4 (ArC), 149.0 (ArCH), 
149.7 (ArCH), 159.1 (ArC), 176.8 (CO). HRMS [M+H]
+
calculated for the formula 
C18H21N2O3
+
313.1541; found 313.1552. 
N-(4-methoxybenzyl)-3-hydroxy-3-methyl-5-(pyridin-3-yl)pyrrolidin-2-one (trans-130p) 
General procedure (i) was used. N-(4-methoxybenzyl)-3-methyl-1-
3-pyridylbut-3-en-1-amine 44p (350 mg, 1.24mmol), iodine (940 
mg, 3.70 mmol), sodium bicarbonate (520 mg, 6.19 mmol), 
dichloromethane/petroleum ether 50%, yellow oil, 140 mg, 48% 
yield. IR 2934, 1689 (s), 1611, 1512, 1431, 1245. 
1
H NMR (δ; 300 MHz, CDCl3);1.55 (3H, s, 
CH3),1.88 (1H, dd, Jab13.7, Jac6.9, CHCHH), 2.58 (1H, dd, Jab13.7, Jbc7.0, CHCHH), 3.51 
(ABq,1H, JAB14.5, ArCHH), 3.78 (1H, s, OCH3), 4.53 (1H, app.t, J 7.3, CHCHH), 5.04 (ABq,1H, 
JAB14.5, ArCHH), 6.83 (4H, dt, J1.9,1.9, ArCH), 7.39 (1H, dt, J 1.9, 1.9, PyrCH), 8.38 (1H, d, J 
1.9, PyrCH), 8.61 (1H, dd, J1.6,4.7, PyrCH).
13
C NMR (δ; 100 MHz, CDCl3); 24.9 (CH3), 43.9 
(CH2), 44.1 (CH2), 55.2 (CH), 55.9 (CH), 74.0 (COH), 114.1 (ArCH), 123.9 (ArCH), 127.1 
(ArC), 129.6 (ArCH), 134.4 (ArCH), 135.4 (ArC), 149.0 (ArCH), 149.7 (ArCH), 159.1 (ArC), 
176.8 (CO). HRMS [M+H]
+
calculated for the formula C18H21N2O3
+
313.1541; found 313.1552. 
1,3-Dimethyl-3-hydroxyl-5-(pyridin-3-yl)pyrrolidin-2-one (cis-130q) 
General procedure (i) was used. 1,3-dimethyl-1-(pyridin-3-yl)but-3-en-1-
amine 44r (400 mg, 2.27 mmol), iodine (1730 mg, 1.80 mmol), sodium 
bicarbonate (950 mg, 11.30mmol), methanol/ dichloromethane 5%, Rf= 0.24, 
pale yellow crystal (mpt 168-169 ˚C), 150 mg, 36% yield. IR 3356, 2927, 1679(s).
1




300 MHz, CDCl3); 1.51 (3H, s, CH3), 1.89 (1H, dd, Jab13.8, Jac6.7, CHCHH), 2.62-2.77 (4H, 
overlapping, CHCHH, NCH3), 4.69 (1H, app t, J 7.2, CHCHH), 7.36 (1H, dd, J4.8,7.9, PyrCH), 
7.51 (1H, dt, J 7.9, 1.9, PyrCH), 8.52 (1H, s, PyrCH), 8.62 (1H, d, J 3.8, PyrCH).
13
C NMR (δ; 
100 MHz, CDCl3);25.2 (CH3), 28.7 (CH3), 43.9 (CH2), 59.1 (CH), 73.9 (COH), 124.0 (ArCH), 
133.8 (ArCH), 135.7 (ArC), 148.6 (ArCH), 149.8 (ArCH), 176.7 (CO). HRMS [M+H]
+
calculated 
for the formula C11H15N2O2
+
 207.1134 found 207.1136. 
N-benzyl-3-methoxy-3-methyl-5-phenylpyrrolidin-2-one (cis-137a) 
N-Benzyl-3-hydroxy-3-methyl-5-phenylpyrrolidin-2-one cis-130a and 
trans-130a (0.07 g, 0.25 mmol) in dry DMF (10 mL), was added sodium 
hydride (0.01g, 0.5mmol), the reaction mixture was stirred for 30 minutes, 
then iodomethane (0.7 mL, 0.5 mmol) was added and stirred for another 18 hours at room 
temperature (TLC was monitored), quenched by addition of (10 mL) water and extracted with 
ethyl acetate, the combined organic layer was washed with brine and dried with magnesium 
sulfate to give the alkylated product in quantitative yield, the single diastereoisomer was 
separated by column chromatography using silica gel and ethyl acetate/petroleum ether 30%, 
Rf=0.21, colourless solid (mpt 82-83 ˚C), 34 mg, 50% yield. IR 3360, 2928, 1683 (s).
1
H NMR 
(δ; 300 MHz, CDCl3); 1.51 (3H, s, CH3), 1.85 (1H, dd, Jab13.9, Jac7.6, CHCHH), 2.55 (1H, dd, 
Jab13.9, Jbc7.1, CHCHH), 3.36 (3H, s, CH3), 3.50 (ABq,1H, JAB 14.6, ArCHH), 4.46 (1H, app.t, J 
7.3, CHCHH), 5.13 (ABq, 1H, JAB14.6, ArCHH), 6.94- 7.47 (10H, m, ArCH). 
13
C NMR (δ; 100 
MHz, CDCl3); 21.5 (CH3), 40.2 (CH2), 44.5 (CH2), 51.7 (CH3), 57.2 (CH), 79.3 (COCH3), , 




(ArC), 139.7 (ArC), 174.7 (CO). HRMS [M+Na]
+
 calculated for the formula C19H21NO2Na
+
 
318.1470; found 318.1478. 
N-benzyl-3-methoxy-3-methyl-5-phenylpyrrolidin-2-one (trans-137b) 
N-Benzyl-3-hydroxy-3-methyl-5-phenylpyrrolidin-2-one cis-130a and 
trans-130a (0.07g, 0.25mmol) in dry DMF (10 mL), was added sodium 
hydride (0.01 g, 0.5 mmol), the reaction mixture was stirred for 30 
minutes, then iodomethane (0.7 mL, 0.5 mmol) was added and stirred for 
an other 18 hours at room temperature (TLC was monitored), quenched by addition of (10 mL) 
water and extracted with ethyl acetate, the combined organic layer was washed with brine and 
dried with magnesium sulfate to give the alkylated product, the single diastereoisomer was 
separated by column chromatography using silica gel and ethyl acetate/petroleum ether 30%, 
Rf=0.25, colourless solid (mpt 75-76˚C), 33 mg 49% yield. IR 3360, 2928, 1683.
1
H NMR (δ; 300 
MHz, CDCl3); 1.42 (3H, s, CH3), 2.17 (1H, dd, Jab 13.3, Jac7.9,CHCHH), 2.26 (1H, dd, Jab 13.3, 
Jbc7.3,CHCHH),, 3.43 (3H, s, OCH3), 3.47 (ABq, 1H, JAB14.5, ArCHH), 4.12 (1H, app.t, J 7.6, 
CHCHH), 5.12 (ABq, 1H, JAB14.5, ArCHH), 6.92-7.46 (10H, m, ArCH).
13
C NMR (δ; 100 MHz, 
CDCl3); 20.0 (CH3), 40.2 (CH2), 44.5 (CH2), 51.7 (CH3), 58.3 (CH), 78.5 (COCH3), 126.8 
(ArCH), 127.1 (ArCH), 127.7 (ArCH), 128.4 (ArCH), 128.4 (ArCH), 128.6 (ArCH), 136.0 
(ArC), 139.8 (ArC), 173.7 (CO). HRMS[M+Na]
+
 calculated for the formula C19H21NO2Na
+
 





N-(4-methoxybenzyl)-3-methyl-2-oxo-5-phenylpyrrolidin-3-yl acetate (cis-138a) 
N-(4-Methoxybenzyl)-3-hydroxy-3-methyl-5-phenylpyrrolidin-2-one 
134h (35 mg,0.11 mmol), triethylamine (22 mg, 0.22 mmol), DMAP 
(5.80 mg, 0.011 mmol) and acetic anhydride (22 mg, 0.22 mmol) 
were added in (10 mL) dry dichloromethane under nitrogen and 
stirred at room temperature for 24 hours with TLC monitoring. The reaction was quenched with 
(30mL) brine extracted with ethyl acetate (3x 25 mL) and the combined organic layer was 
washed with water and dried with MgSO4 and the product was obtained as colourless crystals 
after recrystallised from dichloromethane/petroleum ether 10%, colourless crystals (mpt 121-
122˚C), 36 mg, 92% yield. IR 3286, 3030, 2933, 1671(s), 1669(s).
1
H NMR (δ; 300 MHz, 
CDCl3); 1.56 (3H, s, CH3), 1.89(1H, dd, Jab14.4, Jac4.8, CHCHH), 2.03 (3H, s, COCH3), 2.73 
(1H, dd, Jab14.4, Jbc9.6, CHCHH), 3.44 (ABq,1H,JAB14.5, ArCHH),3.71 (3H, s, OCH3), 4.44 
(1H, dd, Jac4.8, Jbc9.6, CHCHH), 5.02 (ABq, 1H, JAB14.5, ArCHH), 6.85 (4H, dt, J2.9, 2.6, 
ArCH), 7.00-7.33 (5H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 20.2 (CH3), 24.7 (CH3), 40.0 
(CH2), 43.4 (CH2), 54.1 (CH), 56.7 (COCH3), 79.0 (COCOCH3), 112.6 (ArCH), 125.7 (ArCH), 
126.0 (ArCOCH3), 127.0 (ArCH), 128.0 (ArCH), 129.2 (ArCH), 139.5 (ArC), 158.0 (ArC), 
169.0 (CO), 171.9 (CO). HRMS [M+H]
+










cis-134a (135 mg, 0.43 mmol), triethylamine (80 mg, 0.86 mmol), 
DMAP (23 mg, 0.043 mmol) and acetic anhydride (88 mg, 0.86 
mmol) were added in (10 mL) dry dichloromethane under nitrogen 
and stirred at room temperature for 24 h with TLC monitoring. The reaction was quenched with 
(5 mL) brine extracted with ethyl acetate and the combined organic layer was washed with water 
and in vacuo evaporated solvent gave yellow solid (mpt 193-194˚C), 123 mg, 56% yield. IR 
3457, 2931, 1736 (s), 1701 (s).
1
H NMR (δ; 300 MHz, CDCl3); 1.56 (3H, s, CH3), 1.89 (1H, dd, 
Jab14.4, Jac4.8, CHCHH), 2.03 (3H, s, COCH3), 2.73 (1H, dd, Jab14.4, Jbc4.8, CHCHH), 3.44 
(ABq, 1H, JAB14.5, ArCHH), 3.71 (3H, s, COCH3), 4.44 (1H, dd, Jac4.8, Jbc4.8, CHCHH), 5.02 
(ABq, 1H, JAB14.5, ArCHH), 6.85 (4H, dd, Jab8.6, Jac69.4, ArCH), 7.00-7.33 (6H, m, ArCH).
13
C 
NMR (δ; 100 MHz, CDCl3); 20.2 (CH3), 24.7 (CH3), 40.0 (CH2), 43.4 (CH2), 54.1 (CH), 56.7 
(COCH3), 79.0 (COCOCH3), 112.6 (2ArCH), 125.7 (ArCH), 126.0 (ArCOCH3), 127.0 (ArCH), 
128.0 (ArCH), 129.2 (ArCH), 139.5 (ArC), 158.0 (ArC), 169.0 (CO), 171.9 (CO). HRMS 
[M+H]
+
calculated for the formula C20H23N2O4
+







cis-134l (30 mg, 0.096mmol) in dry THF (5 mL) was added drop 
wise to the refluxed solution of LiAlH4 (18 mg, 0.48mmol) in dry 
THF (5 mL) for three hours, the reaction was quenched with (20 mL) 
water and extracted with dichloromethane (3 x 20 mL) the combined organic layer was washed 
with brine and dried with magnesium sulfate and in vacuo evaporated solvent and column 
chromatography ethyl acetate/hexane 30% gave colourless oil 16 mg 56% yield. IR 3393, 2925, 
1510, 1245.
1
H NMR (δ; 300 MHz, CDCl3); 1.44 (3H, s, CH3), 1.82 (1H, Jab12.0, Jac9.0, 
CHCHH), 2.20 (1H, Jab12.0, Jbc6.0, CHCHH), 2.43 (1H, d, J10.0,CHH),3.11 (1H, d, J10.8, 




&CHCHH), 6.83 (2H, d, J 8.6, ArCH), 7.18 (2H, d, J 
8.5, ArCH), 7.23-7.53 (5H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 29.3 (CH3), 51.8 (CH2), 
55.2 (CH), 56.9 (2CH2), 67.4 (CH2), 113.5 (ArOCH3), 127.2 (ArCH), 127.4 (ArCH), 128.4 
(ArCH), 129.6 (ArCH), 131.4 (ArC), 158.4 (ArC). HRMS [M+H]
+ 
calculated for the formula 
C19H24NO2
+






3-Hydroxy-1,3-dimethyl-5-phenylpyrrolidin-2-one cis-134q (70 mg, 0.34 
mmol) in dry THF (5 mL) was added to refluxed solution of LiAlH4 (128 
mg, 3.4 mmol) in dry THF (5 mL) for three hours with TLC monitoring 
(methanol/DCM 10%), the reaction was quenched with (20 mL) water and extracted with 
dichloromethane (3 x 20 mL) the combined organic layers were washed with brine and dried with 
magnesium sulfate and in vacuo evaporated solvent and column chromatography (methanol/ 
dichloromethane/ petroleum ether 1:7:2) gave yellow oil 58 mg, 89% yield. IR 3361, 2966, 
2777.
1
H NMR (δ; 300 MHz, CDCl3); 1.39 (3H, s,CH3), 1.90 (1H, dd, Jab7.7, Jac1.6, CHCHH), 
1.92 (1H, dd, Jab7.7, Jbc1.6, CHCHH), 2.19 (3H, s, NCH3), 2.32-2.43 (2H, m, NCHH),3.07 (1H, 
dd, J1.5,9.7, NCHH), 3.22 (1H, dd, Jac 1.6, Jbc1.6, CHCHH), 7.29 (2H, dd, J 6.7, 3.8, PyrCH), 
7.74 (1H, dt, J 7.8, 1.8, PyrCH), 8.53 (1H, s, PyrCH).
13
C NMR (δ; 100 MHz, CDCl3); 24.9 
(CH3), 39.9 (CH3), 51.2 (CH2), 53.8 (COH), 68.2 (CH), 70.7 (CH2), 123.7 (PyrCH), 134.9 
(PyrCH), 138.0 (PyrC), 148.8 (PyrCH), 149.43 (PyrCH). HRMS [M+H]
+
calculated for the 
formula C11H17N2O
+
193.1344; found 193.1341. 
(R)-2-methyl-N-((S)-3-methyl-1-phenylbut-3-en-1-yl)propane-2-sulfinamide (138a) 
 General procedure (f) was used, yellow oil 50 mg, 80% yield. IR 2963, 
1709, 1453, 1024, 897.
1
H NMR (δ; 300 MHz, CDCl3); 1.18 (9H, s, 3x 
CH3), 1.77 (3H, s, CH3), 2.45 (2H, dd, J 8.1, 4.1,CHH), 3.70 (1H, s, NH), 
4.55 (1H, dd, J 8.9, J5.2, CHCHH), 4.85 (1H, s, olefine CHH), 4.96 (1H, s, olefine CHH), 7.23-
7.39 (5H, m, ArCH).
13




(CH), 55.6 (C), 115.0 (=CH2), 127.5 (2ArCH), 127.6 (ArCH), 128.5 (2ArCH), 142.1 (ArC),142.2 
(C). [α]D 
20




] calculated for formula C15H24NOS
+
; 
266.1579; found 266.1576. 
(R)-3-Methyl-1-phenylbut-3-en-1-amine (138b) 
General procedure (f) was used, colourless oil, 20 mg, 72% yield. IR 2932, 1646, 
1453, 1376, 893, 756, 700.
1
H NMR (δ; 300 MHz, CDCl3); 1.76 (3H, s, CH3), 
2.56 (2H, s, NH2), 3.58-3.64 (1H, m, CHCHH), 3.68-3.76 (1H, m, CHCHH), 
4.09 (1H, dd, J8.9, J5.2, CHCHH), 4.80 (1H, s, olefine CHH), 4.81 (1H, s, olefine CHH), 7.20-
7.39 (5H, m, ArCH).
13
C NMR (δ; 100MHz , CDCl3); 22.3 (CH3), 42.9 (CH2), 48.5 (CH), 113.3 
(=CH2), 126.3 (2ArCH), 127.0 (ArCH), 128.4 (2ArCH), 142.9 (ArC), 146.1 (C). [α]D 
20
=+34 (c 




] found 162.1. 
(S)-N-benzyl-3-methyl-1-phenylbut-3-en-1-amine (139) 
 General procedure (f) was used, (R)-1-phenylbut-3-en-1-amine (20 mg, 
0.13 mmol), colourless oil, 65 mg, 92% yield. IR 3324, 3063, 3026, 
2968, 2933, 2841, 1946, 1807, 1645, 1602, 1493, 1453, 1027, 697.
1
H 
NMR (δ; 300 MHz, CDCl3); 1.63 (3H, s, CH3), 1.77 (1H,s, NH), 2.26 
(1H, dd, Jab14.0, Jac4.8, CH2), 2.37 (1H, dd, Jab14.0, Jbc4.8, CH2), 3.57 (ABq, 2H, JAB13.4, 
JAB13.4, ArCHH), 3.80 (1H, dd, Jac4.8, Jbc4.8, NCH), 4.79 (1H, s, olefine CHH), 4.84 (1H, s, 
olefine CHH), 7.26-7.36 (10H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 22.1 (CH3), 47.7 
(CH2), 51.5 (CH2), 59.3 (CH), 113.5 (=CH2), 126.9 (ArCH), 127.1 (ArCH), 127.4 (2ArCH), 






5.0, DCM) =+54.5. HRMS [M+H]
+
 calculated for formula C18H22N
+
; 252.1752; found 252.1762. 





Characterisation data for the synthesised intermediates and fused tricyclic compounds: 
N-benzyl-1,3-diphenylbut-3-en-1-amine (140a) 
General procedure (e) was used, N-benzyl-1-phenylmethanimine (1 
gm, 5.1 mmol), pale yellow oil, 2.2 gm, 72% yield. IR 3060, 3023, 
3024, 2980, 2920, 1630, 1363. 
1
H NMR (δ; 300 MHz, CDCl3) ; 1.78 
(1H, s, NH), 2.76 (1H, ddd, J 14.2, 9.3, 0.6, CHCHH), 2.89 (1H, ddd, J 14.1, 4.7, 1.1,CHCHH), 
3.74 (ABq, 2H, JAB8.7, JAB8.7, ArCHH), 3.68 (1H, dd, J 9.4, J4.7, CHCHH), 5.07 (1H, s, olefine 
CHH), 5.29 (1H, s, olefine CHH), 7.07-7.39 (15H, m, ArCH).
13
C NMR (δ; 100MHz , CDCl3); 
45.3 (CH2), 51.5 (CH2), 60.1 (CH), 115.4 (C), 126.4 (ArCH), 126.7 (ArCH), 127.1 (ArCH), 
127.3 (ArCH), 127.6 (ArCH), 128.0 (ArCH), 128.3 (ArCH), 128.5 (ArCH), 142.2 (ArC), 146.2 
(ArC), 147.3 (ArC). HRMS [M+H
+
] calculated for formula C23H24N
+
; 314.1909; found 
314.19112. 
N-(4-methoxybenzyl)-1,3-diphenylbut-3-en-1-amine (140b) 
General procedure (e) was used, N-(4-methoxybenzyl)-1-
phenylmethanimine (1 gm, 4.4 mmol), yellow oil, 1.7 gm, 
82% yield. IR 3066, 3026, 3028, 2960, 2932, 2866, 2799, 
1646, 1602, 1454, 1375. 
1
H NMR (δ; 300 MHz, CDCl3); 1.80 (1H, s, NH), 2.69-2.93 (2H, m, 
CHCHH), 3.41 (ABq, 2H, JAB13.1, JAB13.1, ArCHH), 3.66 (1H, dd, J9.2, J 4.8, CHCHH), 3.76 
(3H, s, OCH3), 5.06 (1H, s, olefine CHH), 5.28 (1H, s, olefine CHH), 6.75 (2H, d, J 8.6, ArCH), 
7.02 (2H, dd, J 8.6, ArCH), 7.22-7.45 (10H, m, ArCH).
13
C NMR (δ; 100MHz , CDCl3); 45.2 




(ArCH), 127.1 (ArCH), 127.3 (ArCH), 127.6 (ArCH), 128.0 (ArCH), 128.4 (ArCH), 128.6 
(ArCH), 129.1 (ArCH), 132.6 (ArC), 140.5 (ArC), 144.1 (ArC), 145.7 (C), 158.4 (ArCOMe). 
HRMS [M+H
+
] calculated for formula C24H26NO
+
; 344.2014; found 344.2003. 
N-methyl-1,3-diphenylbut-3-en-1-amine (140c) 
General procedure (e) was used, N-methyl-1-phenylmethanimine (1 gm, 8.4 
mmol), yellow oil, 1.9 gm, 91% yield. IR 3045, 3024, , 2968, 2930, 2854, 
2707, 1640, 1618.
1
H NMR (δ; 300 MHz, CDCl3); 2.16 (3H, s, CH3), 2.83 
(2H, m, CHCHH), 3.50 (1H, dd, J 8.6, J 5.3, CHCHH), 5.06 (1H, s, olefine CHH), 5.30 (1H, s, 
olefine CHH), 7.19-7.44 (10H, m, ArCH).
13
C NMR (δ; 100MHz , CDCl3); 34.6 (CH3), 44.9 
(CH2), 63.0 (CH), 115.3 (CH2), 126.3 (ArCH), 127.0 (ArCH), 127.2 (ArCH), 127.6 (ArCH), 
128.3 (ArCH), 128.4 (ArCH), 140.5 (ArC), 128.5 (ArCH), 143.7 (ArC), 145.6 (C). HRMS 
[M+H
+
] calculated for formula C17H20N
+
; 238.1596; found 238.1593. 
3-bromoprop-1-en-2-yl)benzene (142) 
The literature procedure was used,
 73 
yellow oil, 2 gm, 62% yield. 
1
H NMR (δ; 
300 MHz, CDCl3); 4.38 (2H, s, CH2), 5.52 (2H, d, J 20.8, olefine CH2), 7.29-
7.41 (3H, m, ArCH), 7.47-7.53 (2H, m, ArCH).
 13
C NMR (δ; 100 MHz, CDCl3); 34.2 (CH2), 
117.2 (=CH2), 126.1 (2ArCH), 128.3 (ArCH), 128.5 (2ArCH), 137.6 (ArC), 144.3 (C). MS [m/z] 








General procedure (j) was used. N-Benzyl-1,3-diphenylbut-3-en-1-
amine 10a (500 mg, 1.5 mmol), iodine (1. 21 gm, 4.78 mmol), sodium 
bicarbonate (4.67 gm, 7.97 mmol), column chromatography ethyl 
acetate/ hexane 10%, Rf= 0.7, crystallisation with ethyl acetate/ petroleum ether 10%, colourless 
crystal (mpt 190-192 ˚C), 266 mg 48% yield. IR 3060, 2850, 1601, 1493, 1454, 1365, 1142.
1
H 
NMR (δ; 300 MHz, CDCl3); 1.85 (2H, dd, Jab13.8, Jac7.6, CHCHH), 2.67 (2H, dd, Jab13.8, 
Jbc8.4, CHCHH), 3.60 (ABq, 2H, JAB12.9, ArCHH),3.87 (ABq, 2H, JAB12.9, ArCHH), 3.99 (2H, 
app.t, J 8.0, CHCHH), 5.61 (2H, s, OCH), 7.06-7.48 (30H, overlapping m, ArCH).
13
C NMR (δ; 
100 MHz, CDCl3); 47.4 (CH2), 50.8 (CH2), 61.8 (C), 65.9 (CH), 98.0 (CH), 126.3 (ArCH), 126.9 
(ArCH), 127.0 (ArCH), 127.5 (ArCH), 128.2 (ArCH), 128.3 (ArCH), 128.9 (ArCH), 129.1 
(ArCH), 139.4 (ArC), 143.3 (ArC), 144.2 (ArC). HRMS [M+H]
+
calculated for formula 
C46H43N2O
+
639.3360; found 639.3375. 
N, N-bis(4-methoxybenzyl)-2,3a,3b,5-tetraphenyldecahydrofuro[2,3-b:5,4-b']dipyrrole (143b) 
General procedure (j) was used. N-(4-
Methoxybenzyl)-1,3-diphenylbut-3-en-1-amine 
10b (310 mg, 0.90 mmol), iodine (687 mg, 2.70 
mmol), sodium bicarbonate (379 mg, 4.50 mmol), column chromatography ethyl acetate/ hexane 
10%, Rf= 0.7, crystallisation with ethyl acetate/ petroleum ether 10%, colourless crystal (mpt 
215-216 ˚C), 120 mg, 20% yield. IR 2858, 1614, 1512.
1
H NMR (δ; 300 MHz, CDCl3); 1.84 (2H, 
dd,Jab13.8, Jac7.6, CHCHH), 2.67 (2H, dd,Jab13.8, Jbc8.4, CHCHH), 3.53 (ABq, 2H, 




CHCHH), 5.58 (2H, s, OCH), 6.93 (4H, d, J 8.6, ArCH), 7.06-7.28 (20H, overlapping m, ArCH), 
7.37 (4H, d, J 8.5, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 47.5 (CH2), 50.2 (CH2), 55.3 (CH3), 
61.7 (C), 65.8 (CH), 98.0 (CH), 113.6 (ArCH), 126.2 (ArCH), 126.9 (ArCH), 127.5 (ArCH), 
128.3 (ArCH), 128.9 (ArCH), 130.2 (ArCH), 131.4(ArC), 143.4 (ArC), 144.2 (ArC), 158.6 
(ArC). HRMS [M+H]
+
calculated for the formula C48H47N2O3
+
 699.3587; found 699.3591. 
N-1,6-dimethyl-2,3a,3b,5-tetraphenyldecahydrofuro[2,3-b:5,4-b']dipyrrole (143c) 
General procedure (j) was used. N-Methyl-1,3-diphenylbut-3-en-1-
amine 10c (265 mg, 1.12 mmol), iodine (850 mg, 3.34 mmol), sodium 
bicarbonate (468 mg, 5.58 mmol), ethyl acetate/ hexane 10%, Rf= 0.7, crystallisation with ethyl 
acetate/ petroleum ether 10%, colorless crystal (mpt 195-196 ˚C), 120 mg 22% yield. IR 3050, 
2800, 1602, 1491.
1
H NMR (δ; 300 MHz, CDCl3); 1.93 (2H, dd, Jab13.8, Jac7.6, CHCHH), 2.44 
(6H, s, NCH3), 2.82 (2H, dd, Jab13.8, Jbc8.5, CHCHH), 3.97 (2H, app.t, J 8.0, CHCHH), 5.82 
(2H, s, OCH), 7.04-7.36 (20H, m, ArCH).
13
C NMR (δ; 100 MHz, CDCl3); 34.6 (CH3), 47.7 
(CH2), 62.0 (PhC), 66.8 (CH), 103.1 (CH), 126.3 (ArCH), 127.0 (ArCH), 127.5 (ArCH), 127.6 










Characterisation data for the synthesised 2-pyrazoline compounds: 
5-iodo-1,3-diphenylhexahydropyridazine (157a) 
General procedure (k) was used. N-phenyl-2-(1-phenylbut-3-en-1-
yl)hydrazine (400 mg, 1.67 mmol), iodine (1270 mg, 5.00 mmol), 
sodium bicarbonate (705 mg, 8.40 mmol), dark green oil (gum). IR 2922, 
2852, 1686, 1597 (s), 1499, 1458(m), 1366 (m), 766.
1
H NMR (δ; 300 MHz, CDCl3) ; 3.06 (1H, 
app.t, J 10.2, CHHCH), 3.15 (1H, dd, Jab17.3, Jac4.2, CHHCH), 3.45 (1H, dd, J 11.8, 5.6, 
CHCHH), 3.51 (1H, dd, J 9.9, 2.7, CHCHH), 4.66 (1H, tdd, J 10.7, 4.2, 2.7, CHHCHCHH), 
6.80-6.97 (2H, m, ArCH), 7.66-7.81 (1H, m, ArCH),
13
C NMR (δ; 100MHz, CDCl3);23.2 (CH2), 
37.5 (CH2), 60.0 (CH), 113.2 (2ArCH), 126.7 (ArCH), 127.9 (2ArCH), 128.0 (2ArCH), 128.1 
(2ArCH), 128.2 (ArCH),133.0 (ArC=N), 140.2 (ArC), 141.9 (ArC).HRMS [M+H]
+
 calculated 
for the formula C16H16IN2
+
: 363.0364; found 363.00358. 
2-(1-(4-chlorophenyl)-5-(iodomethyl)-4,5-dihydro-1H-pyrazol-3-yl)pyridine (157f) 
General procedure (k) was used. 2-(1-(2-(4-
chlorophenyl)hydrazinyl)but-3-en-1-yl)pyridine (671 mg, 2.45 
mmol), iodine (1860 mg, 7.35 mmol), sodium bicarbonate (1029 mg, 
12.20 mmol), yellow brown oil. IR 2928, 1686, 1597(S), 1499, 1456(m), 1366(m).
1
H NMR (δ; 
300 MHz, CDCl3); 312 (1H, app.t, J 10.0, CHCHH), 3.39 (1H, dd, Jab18.3, Jbc 4.5 CHCHH), 
3.47 (1H, dd, J 10.1, 2.5, CHHCH), 3.62 (1H, dd, Jab18.3, Jac11.2, CHHCH), 4.63-4.75 (1H, m, 
CHHCHCHH), 7.05-7.14 (2H, m, ArCH), 7.15-7.32 (3H, m, ArCH), 7.66-7.72 (2H, m, PyrCH), 
8.05 (1H, dt, J 8.1, 1.0, PyrCH), 8.59 (1H, ddd, J 4.9, 1.7, 0.9, PyrCH).
13




CDCl3); 7.6 (CH2), 39.6 (CH2), 61.0 (CH), 114.5 (2ArCH), 120.7 (ArCH), 123.1 (ArCH), 124.9 
(ArCCl), 129.4 (2ArCH), 136.1 (PyrCH), 141.6 (ArC), 148.8 (ArC=N), 149.2 (PyrCH), 151.5 
(PyrC). HRMS [M+H]
+
 calculated for the formula C15H14IClN3
+
: 397.9921; found 397.9906. 
5-(iodomethyl)-3-phenyl-1-(p-tolyl)-4,5-dihydro-1H-pyrazole (157e) 
General procedure (k) was used. 1-(1-phenylbut-3-en-1-yl)-2-(p-
tolyl)hydrazine (550 mg, 2.20 mmol), iodine (1680 mg, 6.60 mmol), 
sodium bicarbonate (920 mg, 10.90 mmol), pale yellow oil. IR 2922, 
2852, 1686, 1597(s), 1499, 1458(m), 1366(m), 766.
1
H NMR (δ; 300 MHz, CDCl3); 2.29 (1H, s, 
CH3), 3.06 (1H, app.t, J 10.2, CHHCH), 3.14 (1H, dd, J 17.3, 4.5, CHHCH), 3.49 (1H, ddd, J 
20.1, 10.8, 6.8, CHCHH), 4.63 (1H, tdd, J 10.7, 4.4, 2.7, CHHCHCHH), 7.00-7.15 (2H, m, 
ArCH), 7.30-7.44 (5H, m, ArCH), 7.68-7.76 (2H, m, ArCH).
13
C NMR (δ; 100MHz, CDCl3); 8.9 
(CH2), 20.6 (CH3), 39.7 (CH2), 61.4 (CH), 113.5 (2ArCH), 125.8 (2ArCH), 128.8 (2ArCH), 
128.9 (2ArCH), 129 (ArCCH3), 130.0 (2ArCH), 132.6 (ArC), 141.4 (ArC), 146.6 (ArC=N). 
HRMS [M+H]
+
 calculated for the formula C17H18IN2
+
: 377.0515; found 377.0503. 
2,6-Diphenyl-N-propylhexahydropyridazin-4-amine (158a) 
General procedure (l) was used. N-phenyl-2-(1-phenylbut-3-en-1-
yl)hydrazine (400 mg, 1.67 mmol), iodine (1270 mg, 5.00 mmol), 
sodium bicarbonate (705 mg, 8.40 mmol). Column chromatography 
60% ethyl acetate Rf= 0.2, yield was calculated over two steps, yellow 
oil, 0.15 gm 80% yield. IR 3450, 3026, 2924, 2853, 1596(S), 1493, 1393(m), 1129(m).
1
H NMR 




6.0, NHCH2), 2.78 (1H, dd, Jab12.0, Jac7.3, CHHCH), 2.94 (1H, dd, Jab J 12.0, Jbc3.4, CHHCH), 
3.27 (1H, dd, J 16.9, 5.6, CHCHH), 3.41 (1H, dd, J 16.9, 11.2, CHCHH), 4.46 (1H, m, 
CHHCHCHH), 6.83 (1H, dt, J 7.4, 1.2, ArCH), 7.15-7.40 (7H, m, ArCH), 7.69-7.78 (2H, dd, J 
8.3, 1.4, ArCH).
13
C NMR (δ; 100MHz, CDCl3); 11.7 (CH3), 23.2 (CH2), 37.5 (CH2), 50.9 (CH2), 
52.0 (CH2), 60.1 (CH), 113.3 (2ArCH), 119.1 (ArCH), 125.8 (2ArCH), 128.5 (3ArCH), 129.2 
(2ArCH), 133.0 (ArC=N), 144.9 (ArCH), 148.4 (ArCH). HRMS [M+H]
+
 calculated for the 
formula C19H24N3
+
: 294.1967; found 294.1970. 
1,3-Diphenyl-5-(pyrrolidin-1-ylmethyl)-4,5-dihydro-1H-pyrazole (158b) 
General procedure (l) was used. N-phenyl-2-(1-phenylbut-3-en-1-
yl)hydrazine (200 mg, 0.84 mmol), iodine (640 mg, 2.50 mmol), sodium 
bicarbonate (350 mg, 4.20 mmol). Column chromatography 80% ethyl 
acetate/hexane Rf= 0.5, yield was calculated over two steps, yellow oil, 
0.16 gm 63% yield. IR 3350, 2921, 2860, 1592(S), 1487, 1392(m), 1128(m).
1
H NMR (δ; 300 
MHz, CDCl3); 1.75 (4H, dt, J 7.4, 6.8, 2x CH2), 2.35 (2H, dd, J 11.7, 8.7, CHHCH), 2.56-2.85 
(4H, m, 2x CH2), 3.55 (2H, dd, J 12.3, 7.7, CH2N),4.50 (1H, m, CHHCHCHH), 6.85 (1H, dd, J 
10.2, 4.2, ArCH), 7.05-7.45 (7H, m, ArCH), 7.70 (1H, t, J 8.4, ArCH), 7.87 (1H, dd, J 6.8, 1.7, 
ArCH).
13
C NMR (δ; 100MHz, CDCl3); 23.6 (2CH2), 37.9 (CH2), 54.7 (2CH2), 57.3 (CH2), 59.0 
(CH), 113.2 (2ArCH), 118.8 (ArCH), 125.0 (ArCH), 125.8 (2ArCH), 128.5 (2ArCH), 128.6 
(ArCH), 129.2 (ArCH), 133.1 (ArC), 144.5 (ArC), 148.1 (ArC=N). HRMS [M+H]
+
 calculated 
for the formula C20H24N3
+






General procedure (l) was used. N-phenyl-2-(1-phenylbut-3-en-1-
yl)hydrazine (294 mg, 1.24 mmol), iodine (900 mg, 3.70 mmol), sodium 
bicarbonate (500 mg, 6.15 mmol). Column chromatography 30% ethyl 
acetate/ hexane Rf= 0.25, yellow solid (mpt 98-99 
°
C), yield over two 
steps= 0.26 gm 80% yield. IR 3382, 2925, 1596(m), 1499, 1455(m), 
1123(m). 
1
H NMR (δ; 300 MHz, CDCl3); 2.36 (1H, dd, J12.7, 9.3, CHHN), 2.41-2.52 (2H, m, 
CH2), 2.55-2.67 (2H, m, CH2), 2.73 (1H, dd, J 12.7, 3.5, CHHN), 3.37 (2H, dd, J 7.8, 3.5, 
CHHCH), 3.66-3.79 (4H, m, 2x CH2), 3.45-4.55 (1H, m, CHHCHCHH), 6.81-6.86 (1H, m, 
ArCH), 7.10-7.47 (7H, m, ArCH), 7.76 (2H, dd, J 8.3, 1.4, ArCH).
13
C NMR (δ; 100MHz, 
CDCl3); 37.7 (CH2), 54.2 (2CH2), 57.6 (CH), 59.5 (CH2), 67.0 (2CH2), 113.2 (2ArCH), 119.0 
(ArCH), 125.8 (2ArCH), 128.6 (3ArCH), 129.2 (2ArCH), 133.1 (ArC=N), 144.5 (ArC), 148.1 
(ArC). HRMS [M+H]
+
 calculated for the formula C20H24N3O
+
: 322.1912; found 322.1919. 
1-(1,3-diphenyl-4,5-dihydro-1H-pyrazol-5-yl)-N-(pyridin-3-ylmethyl)methanamine (158d) 
General procedure (l) was used. N-phenyl-2-(1-phenylbut-3-en-1-
yl)hydrazine (588 mg, 2.47 mmol), iodine (1880 mg, 7.40 mmol), 
sodium bicarbonate (1036 mg, 12.30 mmol). Column 
chromatography 100% ethyl acetate Rf=0.25, yellow oil (Gum), yield over two steps= 0.28 gm 
75% yield. IR 3325, 2921, 1598(s), 1491, 1398(m), 1125(m). 
1
H NMR (δ; 300 MHz, CDCl3); 
2.79 (1H, dd, J 12.1, 3.2, CHHNH), 2.93 (1H, d, J 12.1, 5.9, CHHNH), 3.2-3.42 (2H, m, ArCH2), 




(2H, m, ArCH), 7.21-7.41 (7H, m, ArCH), 7.48-7.59 (1H, m, PyrCH), 7.65-7.77 (2H, m, ArCH), 
8.45 (1H, dd, J 4.8, 1.6, ArCH), 8.49 (1H, d, J 1.7, PyrCH).
13
C NMR (δ; 100MHz, CDCl3); 37.3 
(CH2), 50.2 (CH2), 51.2 (CH2), 59.9 (CH), 113.3 (2ArCH), 119.2 (ArCH), 123.4 (PyrCH), 125.8 
(2ArCH), 128.6 (2ArCH), 128.7 (2ArCH), 129.2 (2ArCH), 132.8 (ArC=N), 135.6 (ArC), 135.7 
(PyrCH), 144.9 (PyrC), 148.5 (PyrCH), 148.6 (ArC), 149.7 (PyrCH). HRMS [M+H]
+
 calculated 
for the formula C22H23N4
+
: 343.1920; found 343.1923. 
1-(3-(4-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-5-yl)-N-(pyridin-3-ylmethyl)methanamine (158e) 
General procedure (l) was used. 1-(1-(4-chlorophenyl)but-3-en-
1-yl)-2-phenylhydrazine (382 mg, 1.40 mmol), iodine (1066 
mg, 4.20 mmol), sodium bicarbonate (580 mg, 7.00 mmol). 
Column chromatography 100% ethyl acetate Rf=0.2, yellow oil, 0.182 gm 78% yield. IR 2923, 
1597(s), 1491(s), 1389, 1127(m), 828(m). 
1
H NMR (δ; 300 MHz, CDCl3); 2.80 (1H, dd, J 12.1, 
3.0, CHHNH), 2.96 (1H, dd, J 12.1, 5.8, CHHNH), 3.20-3.41 (2H, m, CHHCH), 3.68-3.94 (2H, 
m, PyrCH2), 4.42-4.52 (1H, m, CHHCHCHH), 6.82-6.88 (1H, m, ArCH), 7.13-7.21 (3H, m, 
ArCH), 7.23-7.36 (4H, m, ArCH), 7.55 (1H, dt, J 7.8, 1.8, PyrCH), 7.60-7.66 (2H, m, ArCH), 
8.46 (1H, dd, J 4.8, 1.6, PyrCH), 8.50 (1H, d, J 2.0, PyrCH).
13
C NMR (δ; 100MHz, CDCl3); 37.1 
(CH2), 50.0 (CH2), 51.1 (CH2), 60.0 (CH), 113.3 (2ArCH), 119.2 (ArCH), 123.4 (PyrCH), 128.7 
(2ArCH), 128.9 (2ArCH), 129.3 (2ArCH), 130.0 (ArC=N), 134.3 (ArC), 135.4 (ArC), 135.7 
(PyrCH), 144.5 (ArC), 147.4 (ArC), 148.5 (PyrCH), 149.6 (PyrCH). HRMS [M+H]
+
 calculated 
for the formula C22H22N4Cl
+






General procedure (l) was used.3-(1-(2-phenylhydrazinyl)but-3-en-1-
yl)pyridine (583 mg, 2.46 mmol), iodine (1850 mg, 7.30 mmol), sodium 
bicarbonate (1020 mg, 12.18 mmol). Column chromatography 5% 
methanol/dichloromethane Rf= 0.5, yellow oil, yield over two steps= 0.20 gm 61% yield. IR 
3285, 2925, 1597(s), 1499, 1389(m), 1125(m).
1
H NMR (δ; 300 MHz, CDCl3) ; 0.88 (3H, t, J 7.4, 
CH3), 1.39-1.53 (2H, m, CH2CH3), 2.59(2H, dd, J 8.5, 6.0, NHCH2), 2.84 (1H, dd, J 12.2, 7.0, 
CHHNH), 2.95 (1H, dd, J 12.1, 3.3, CHHNH), 3.33 (1H, dd, J 17.0, 5.9, CHHCH), 3.43 (1H, dd, 
J 16.9, 11.1, CHHCH), 4.47-4.62 (1H, m, CHHCHCHH), 6.87 (1H, dt, J 7.4, 1.2, ArCH), 6.84-
6.90 (5H, m, ArCH), 8.04-8.10 (1H, m, PyrCH), 8.53 (1H, dd, J 4.8,1.6, PyrCH), 8.87 (1H, J 2.2, 
0.7, PyrCH).
13
C NMR (δ; 100MHz, CDCl3); 11.6 (CH3), 22.9 (CH2), 37.0 (CH2), 50.5 (CH2), 
51.9 (CH2), 59.9 (CH), 113.4 (2ArCH), 119.6 (ArCH), 123.4 (ArCH), 128.9 (PyrC), 129.3 
(2ArCH), 132.6 (ArCH), 144.3 (ArC=N), 145.4 (ArC), 147.1 (PyCH), 149.3 (PyrCH).HRMS 
[M+H]
+
 calculated for the formula C18H23N4
+
: 295.1923; found 295.1912. 
N-benzyl-1-(1-phenyl-3-(pyridin-3-yl)-4,5-dihydro-1H-pyrazol-5-yl)methanamine (158g) 
General procedure (l) was used. 3-(1-(2-phenylhydrazinyl)but-3-en-
1-yl)pyridine (583 mg, 2.46 mmol), iodine (1850 mg, 7.30 mmol), 
sodium bicarbonate (1020 mg, 12.18 mmol), column chromatography 
100% ethyl acetate. Rf= 0.35, yellow oil, yield over two steps= 0.20 
gm 71% yield. IR 3340, 2953, 1591(s), 1489, 1391(m), 1123(m).
1
H NMR (δ; 300 MHz, CDCl3); 




CHHCH), 3.76 (2H, d, J 2.0, ArCH2), 4.39-4.55 (1H, m, CHHCHCHH), 6.85 (1H, t, J 7.2, 
ArCH), 7.11-7.33 (7H, m, ArCH), 8.04 (1H, dt, J 8.0, 1.9, PyrCH), 8.52 (1H, dd, J 4.8, 1.6, 
PyrCH), 8.85 (1H, d, J 1.7, PyrCH).
13
C NMR (δ; 100MHz, CDCl3); 36.8 (CH2), 49.9 (CH2), 53.8 
(CH2), 60.1 (CH), 113.4 (2ArCH), 119.6 (ArCH), 123.4 (ArCH), 127.1 (ArCH), 128.1 (2ArCH), 
128.4 (2ArCH), 128.6 (2ArCH), 129.0 (PyrC), 129.3 (2ArCH), 132.6 (PyrCH), 140.1 (ArC=N), 
144.3 (ArC), 145.5 (ArC), 147.1 (PyrCH), 149.3 (PyrCH). HRMS [M+H]
+
 calculated for the 
formula C22H23N4
+
: 343.1923; found 343.1926. 
N-benzyl-1-(1-phenyl-3-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)methanamine (158h) 
General procedure (l) was used. 2-(1-(2-phenylhydrazinyl)but-3-en-
1-yl)pyridine (305 mg, 1.25 mmol), iodine (970 mg, 3.80 mmol), 
sodium bicarbonate (535 mg, 6.35 mmol), column chromatography 
10% Methanol/ dichloromethane, Rf= 0.35, yellow brown oil, yield 
over two steps= 0.28 gm 65% yield. IR 3281, 2923, 1597(m), 1499, 1389(m), 1126(m).
1
H NMR 
(δ; 300 MHz, CDCl3); 2.89 (1H, t, J 6.3, CHHNH), 3.43-3.56 (2H, m, CHHCH), 3.78 (2H, s, 
ArCH2), 4.46-4.58 (1H, m, CHHCHCHH), 6.85 (1H, tt, J 13.7, 6.2, ArCH), 7.09-7.33 (7H, m, 
ArCH), 7.60-7.68 (1H, m, PyrCH), 8.05 (1H, dt, J 8.1, 0.9, PyrCH), 8.51-8.64 (1H, m, PyrCH).
 
13
C NMR (δ; 100MHz, CDCl3); 32.2 (CH2), 50.1 (CH2), 53.9 (CH2), 60.3 (CH), 113.5 (2ArCH), 
119.6 (ArCH), 120.6 (PyrCH), 122.6 (PyrCH), 127.0 (ArCH), 128.0 (2ArCH), 128.3 (2ArCH), 
129.2 (2ArCH), 135.9 (PyrCH), 140.2 (ArC=N), 144.2 (ArC), 149.1 (PyrCH), 149.5 (ArC), 
152.3 (PyrC). HRMS [M+H]
+
 calculated for the formula C22H23N4
+






General procedure (l) was used. 2-(1-(2-phenylhydrazinyl)but-3-en-1-
yl)pyridine (305 mg, 1.25 mmol), iodine (970 mg, 3.80 mmol), sodium 
bicarbonate (535 mg, 6.35 mmol), column chromatography 100% ethyl 
acetate Rf= 0.5, yellow oil, yield over two steps= 0.260 gm 70% yield. 
IR 3300, 2962, 1597, 1561(s), 1500, 1390(m), 1128(m).
1
H NMR (δ; 300 MHz, CDCl3); 1.03 
(6H, dd, J 6.2, 3.3, 2CH3), 2.66-2.84 (2H, m, CHHNH), 2.99 (1H, dd, J 15.9, 8.0, NHCH), 3.41 
(1H, dd, J 17.7, 5.7, CHHCH), 3.55 (1H, dd, J 17.7, 11.4, CHHCH), 4.48-4.59 (1H, m, 
CHHCHCHH), 6.80-6.92 (1H, m, ArCH), 7.12-7.35 (6H, m, ArCH), 7.66 (1H, dt, J 12.8, 6.2, 
PyrCH), 8.03-8.10 (1H, m, PyrCH), 8.49-8.61 (1H, m, PyrCH).
13
C NMR (δ; 100MHz, CDCl3); 
23.0 (CH3), 23.1 (CH3), 37.1 (CH2), 48.2 (CH2), 48.9 (CH), 60.5 (CH), 113.5 (2ArCH), 119.6 
(ArCH), 120.6 (PyrCH), 122.6 (2ArCH), 129.2 (2ArCH), 135.9 (PyrCH), 144.2 (ArC=N), 149.1 
(PyrCH), 149.2 (ArC), 152.3 (ArC). HRMS [M+H]
+
 calculated for the formula C18H23N4
+
: 
295.1923; found 295.1917. 
N-benzyl-1-(1-(4-chlorophenyl)-3-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)methanamine (158j) 
General procedure (l) was used. 2-(1-(2-(4-chlorophenyl) 
hydrazinyl)but-3-en-1-yl)pyridine (335 mg, 1.22 mmol), iodine (930 
mg, 3.67 mmol), sodium bicarbonate (500 mg, 6.10 mmol). Column 
chromatography 100% ethyl acetate Rf=0.45, yellow brown oil, yield over two steps= 0.230 gm 
86% yield. IR 3281, 2923, 1597(m), 1499, 1389(m), 1126(m).
1
H NMR (δ; 300 MHz, CDCl3); 
2.82 (2H, t, J 6.2, CHHNH), 3.49 (2H, dd, J 8.5, 5.6, CHHCH), 3.76 (2H, s, ArCH2), 4.40-4.50 




PyrCH), 8.02 (1H, dt, J 8.0, 0.9, PyrCH), 8.55 (1H, ddd, J 4.9, 1.7, 0.9, PyrCH).
13
C NMR (δ; 
100MHz, CDCl3); 37.2 (CH2), 49.8 (CH2), 53.8 (CH2), 60.3 (CH), 114.6 (2ArCH), 120.7 
(ArCH), 122.8 (PyrCH), 124.2 (ArCCl), 127.1 (ArCH), 128.0 (2ArCH), 128.4 (2ArCH), 129.1 
(2ArCH), 136.0 (PyrCH), 140.1 (ArC=N), 142.8 (ArC), 149.2 (PyrCH), 150.1 (ArC), 152.0 
(PyrC). HRMS [M+H]
+
 calculated for the formula C22H22ClN4
+
: 377.1533; found 377.1530. 
N-benzyl-1-(3-phenyl-1-(p-tolyl)-4,5-dihydro-1H-pyrazol-5-yl)methanamine (158k) 
General procedure (l) was used. 1-(1-phenylbut-3-en-1-yl)-2-(p-tolyl) 
hydrazine (275 mg, 1.10 mmol), iodine (840 mg, 3.30 mmol), sodium 
bicarbonate (460 mg, 5.45 mmol). Column chromatography 20% 
ethyl acetate/hexane Rf= 0.35, yellow brown oil, yield over two steps= 0.30 gm 76% yield. IR 
3450, 3026, 2924, 2853, 1596(S), 1493, 1393(m), 1129(m). 
1
H NMR (δ; 300 MHz, CDCl3); 2.28 
(3H, s, CH3), 2.85 (2H, d, J 4.9, CHHNH), 3.21-3.40 (2H, m, CHHCH), 3.76 (2H, s, ArCH2), 
4.33-4.44 (1H, m, CHHCHCHH), 7.14-7.49 (10H, m, ArCH), 7.65-7.81 (4H, m, ArCH).
13
C 
NMR (δ; 100MHz, CDCl3); 20.7 (CH3), 37.4 (CH2), 50.2 (CH2), 53.9 (CH2), 60.5 (CH), 113.7 
(2ArCH), 125.8 (2ArCH), 127.1 (2ArCH), 128.5 (2ArCH), 128.6 (3ArCH), 129.8 (2ArCH), 
133.1 (ArCCH3), 133.1 (ArC), 140.3 (ArC), 142.9 (ArC), 148.2 (ArC=N). HRMS [M+H]
+
 
calculated for the formula C24H26N3
+






General procedure (l) was used. 2-chloro-5-(1-(2-phenylhydrazinyl) 
but-3-en-1-yl)pyridine (500 mg, 1.8 mmol), iodine (139 mg, 5.47 
mmol), sodium bicarbonate (767 mg, 9.13 mmol). Column 
chromatography 80% ethyl acetate/hexane Rf= 0.45, yellow brown 
oil, yield over two steps= 0.33 gm 75% yield. IR 3452, 3021, 2924, 
2852, 1599(S), 1490, 1392(m), 1125(m).
1
H NMR (δ; 300 MHz, CDCl3); 2.82 (1H, dd, J 12.3, 
3.1, CHHCH), 2.92 (1H, dd, J 12.3, 6.2, CHHCH), 3.29 (2H, dd, J 8.6, 6.7, CHHNH), 3.76 (2H, 
d, J 2.0, ArCH2), 4.49 (1H, dtd, J 9.7, 6.4, 3.1, CHHCHCHH), 6.83-6.90 (1H, m, ArCH), 7.13 
(2H, dd, J 8.7, 1.0, ArCH), 7.19-7.32 (7H, m, ArCH), 8.03 (2H, dd, J 8.4, 2.4, 2xPyrCH), 8.54 
(1H, d, J 0.5, PyrCH).
13
C NMR (δ; 100MHz, CDCl3); 36.7 (CH2), 49.7 (CH2), 53.8 (CH2), 60.2 
(CH), 113.5 (2ArCH), 119.8 (ArCH), 124.2 (PyrCH), 127.1 (ArCH), 128.1 (2ArCH), 128.5 
(2ArCH), 129.0 (2ArCH), 135.3 (PyrCH), 140.1 (ArC), 144.0 (ArC), 144.3 (ArC=N), 146.6 
(PyrCH), 150.6 (PyrCCl). HRMS [M+H]
+






5-yl)methanamine (50 mg, 0.146 mmol) was dissolved in toluene 
(20 mL), then DDQ (9.9 mg, 0.438 mmol) was added, the 
reaction mixture was refluxed for 6 hours, when the reaction completed judged by TLC then 
cooled to room temperature and filtered to remove the excess of DDQ. The crude product was 




yield= 0.025 gm 50% yield. IR 3280, 2923, 1660(m), 1592(m), 1490, 1125(m).
1
H NMR (δ; 300 
MHz, CDCl3); 2.89 (4H, m, CHHNCHH), 5.28 (1H, s, olefin CH), 7.25-7.32 (5H, m, PhCH), ), 
7.35-7.40 (5H, m, PhCH), 7.68 (2H, m, PyrCH), 8.05 (1H, dt, J 8.1, 0.9, PyrCH), 8.64 (1H, d, 
J0.5, PyrCH).
 13
C NMR (δ; 100MHz, CDCl3); 31.2 (CH2), 45.1 (CH2), 110.0 (CH), 113.5 
(ArCH), 113.4 (ArCH), 119.6 (ArCH), 120.6 (PyrCH), 122.6 (PyrCH), 127.0 (ArCH), 128.0 
(2ArCH), 128.3 (2ArCH), 129.2 (2ArCH), 134.0 (PyrCH), 140.5 (ArC=N), 144.0 (ArC), 147.0 
(C=C), 149.2 (PyrCH), 149.8 (ArC), 151.2 (PyrC). HRMS [M+H]
+
 calculated for the formula 
C22H21N4
+






X-Ray crystallographic data 
 
 
Figure 50: X-ray crystal structure of cis-130a with ellipsoids drawn at the 50 % probability level. 
 
Figure 51: X-ray crystal structure of trans-130a with ellipsoids drawn at the 50 % probability level. The phenyl group C 






Figure 52: X-ray crystal structure of trans-130d with ellipsoids drawn at the 50 % probability level. 
 
 
Figure 53: X-ray crystal structure of cis-130e with ellipsoids drawn at the 50 % probability level. The structure contains 







Figure 54: X-ray crystal structure of cis-130h with ellipsoids drawn at the 50 % probability level. The structure contains 







Figure 55: X-ray crystal structure of cis-130m with ellipsoids drawn at the 50 % probability level. The structure contains 








Figure 56: X-ray crystal structure of cis-130pwith ellipsoids drawn at the 50 % probability level. The structure contains 






Figure 57: X-ray crystal structure of cis-130q with ellipsoids drawn at the 50 % probability level. The structure contains 























Crystal structure determination of cis-130a: 
C18H19NO2 (M =281.34): monoclinic, space group P21/c (no. 14), a = 7.63367(18) Å, b = 
29.2305(5) Å, c = 6.84862(15) Å, β = 102.295(2)°, V = 1493.12(6) Å
3
, Z = 4, T = 99.94(19) K, 
μ(CuKα) = 0.646 mm
-1
, Dcalc = 1.252 g/mm
3
, 10140 reflections measured (11.866 ≤ 2 ≤ 
148.962), 2899 unique (Rint = 0.0248, Rsigma = 0.0231) which were used in all calculations. The 
final R1 was 0.0367 (I>2σ (I)) and wR2 (F2) was 0.0934 (all data).
96, 97 
Crystal structure determination of trans-130a: 
C18H19NO2 (M =281.34): monoclinic, space group C2/c (no. 15), a = 20.2930(2) Å, b = 
6.84225(8) Å, c = 22.5979(2) Å, β = 90.8593(9)°, V = 3137.36(5) Å
3
, Z = 8, T = 99.94(17) K, 
μ(CuKα) = 0.615 mm
-1
, Dcalc = 1.191 g/mm
3
, 28439 reflections measured (7.826 ≤ 2 ≤ 
149.016), 3181 unique (Rint = 0.0244, Rsigma = 0.0109) which were used in all calculations. The 
final R1 was 0.0343 (I>2σ (I)) and wR2 (F2) was 0.1396 (all data).
97, 97 
Crystal structure determination of trans-130d: 
C19H21NO2 (M =295.37): orthorhombic, space group Pbca (no. 61), a = 12.4972(2) Å, b = 
14.1613(2) Å, c = 17.5538(3) Å, V = 3106.62(9) Å
3
, Z = 8, T = 100.01(10) K, μ(CuKα) = 0.645 
mm
-1
, Dcalc = 1.263 g/cm
3
, 15485 reflections measured (10.078° ≤ 2 ≤ 148.89°), 3132 unique 
(Rint = 0.0249, Rsigma = 0.0184) which were used in all calculations. The final R1 was 0.0379 
(I>2σ (I)) and wR2 (F2) was 0.0966 (all data).





Crystal structure determination of cis-130e:  
C16H17NO3 (M =271.30): orthorhombic, space group P212121 (no. 19), a = 6.86998(8) Å, b = 
15.21957(20) Å, c = 27.0563(4) Å, V = 2828.95(6) Å
3
, Z = 8, T = 100.00(10) K, μ(CuKα) = 
0.717 mm
-1
, Dcalc = 1.274 g/mm
3
, 15654 reflections measured (6.534 ≤ 2 ≤ 148.936), 5473 
unique (Rint = 0.0239, Rsigma = 0.0248) which were used in all calculations. The final R1 was 
0.0289 (I>2σ (I)) and wR2 (F2) was 0.0703 (all data).
96, 97 
Crystal structure determination of cis-130h: 
C19H21NO3 (M =311.37): triclinic, space group P-1 (no. 2), a = 6.98428(14) Å, b = 15.3845(4) Å, 
c = 16.6168(4) Å, α = 110.497(2)°, β = 97.0023(18)°, γ = 102.2736(19)°, V = 1596.16(7) Å
3
, Z = 
4, T = 100.00(10) K, μ(CuKα) = 0.703 mm
-1
, Dcalc = 1.296 g/mm
3
, 30499 reflections measured 
(5.814 ≤ 2 ≤ 149.132), 6446 unique (Rint = 0.0314, Rsigma = 0.0265) which were used in all 
calculations. The final R1 was 0.0420 (I>2σ (I)) and wR2 (F2) was 0.1611 (all data).
 96, 97 
Crystal structure determination of cis-130m: 
C18H18N2O4 (M = 326.34): triclinic, space group P-1 (no. 2), a = 7.87442(17) Å, b = 
13.1736(2) Å, c = 15.8461(3) Å, α = 88.7943(13)°, β = 76.7697(16)°, γ = 88.4490(15)°, V = 
1599.38(5) Å
3
, Z = 4, T = 100.01(10) K, μ(CuKα) = 0.798 mm
-1
, Dcalc = 1.355 g/cm
3
, 55778 
reflections measured (5.73° ≤ 2 ≤ 148.794°), 6470 unique (Rint = 0.0294, Rsigma = 0.0141) which 








Crystal structure determination of cis-130p-:  
C18H20N2O3 (M =312.36): triclinic, space group P-1 (no. 2), a = 6.8071(3) Å, b = 15.0202(7) Å, 
c = 15.8559(8) Å, α = 90.798(4)°, β = 101.156(4)°, γ = 100.035(4)°, V = 1564.30(13) Å
3
, Z = 4, 
T = 99.98(10) K, μ(CuKα) = 0.739 mm
-1
, Dcalc = 1.326 g/cm
3
, 11128 reflections measured  
(5.688° ≤ 2 ≤ 149.102°), 6195 unique (Rint = 0.0285, Rsigma = 0.0384) which were used in all 
calculations. The final R1 was 0.0391 (I>2σ (I)) and wR2 (F2) was 0.1067 (all data).
 96, 97
 
Crystal structure determination of cis-130q:  
C11H14N2O2 (M =206.24): triclinic, space group P-1 (no. 2), a = 7.5414(3) Å, b = 11.8446(5) Å, 
c = 12.2635(5) Å, α = 80.154(4)°, β = 88.093(4)°, γ = 88.519(3)°, V = 1078.48(8) Å
3
, Z = 4, T = 
100.00(10) K, μ(CuKα) = 0.724 mm
-1
, Dcalc = 1.270 g/mm
3
, 7212 reflections measured  
(7.32 ≤ 2 ≤ 148.982), 4221 unique (Rint = 0.0222, Rsigma = 0.0333) which were used in all 
calculations. The final R1 was 0.0399 (I>2σ (I)) and wR2 (F2) was 0.1031 (all data).
96, 97
 
Crystal structure determination of 143a: 
C46H42N2O (M =638.81): monoclinic, space group C2/c (no. 15), a = 12.55604(14) Å, b = 
15.09459(13) Å, c = 18.96430(17) Å, β = 105.8657(10)°, V = 3457.35(6) Å
3
, Z = 4, T = 
99.9(2) K, μ(CuKα) = 0.557 mm
-1
, Dcalc = 1.227 g/cm
3
, 32364 reflections measured (9.378° ≤ 
2 ≤ 148.662°), 3515 unique (Rint = 0.0309, Rsigma = 0.0135) which were used in all calculations. 







Crystal structure determination of 143b: 
C48H46N2O3 (M =698.87): triclinic, space group P-1 (no. 2), a = 10.1705(3) Å, b = 10.2903(3) Å, 
c = 19.4528(5) Å, α = 99.778(2)°, β = 99.679(2)°, γ = 106.888(2)°, V = 1868.03(9) Å
3
, Z = 2, T = 
99.99(11) K, μ(CuKα) = 0.600 mm
-1
, Dcalc = 1.242 g/cm
3
, 31249 reflections measured  
(14.244° ≤ 2 ≤ 140.124°), 7054 unique (Rint = 0.0352, Rsigma = 0.0246) which were used in all 
calculations. The final R1 was 0.0863 (I>2σ (I)) and wR2 (F2) was 0.2339 (all data).
 96, 97
 
Crystal structure determination of 143c: 
C34H34N2O (M =486.63): monoclinic, space group P21/c (no. 14), a = 11.9986(2) Å, b = 
10.60180(16) Å, c = 20.9045(4) Å, β = 104.8514(19)°, V = 2570.37(8) Å
3
, Z = 4, T = 
100.00(10) K, μ(CuKα) = 0.580 mm
-1
, Dcalc = 1.258 g/cm
3
, 17451 reflections measured (7.622° 
≤ 2 ≤ 148.838°), 5186 unique (Rint = 0.0340, Rsigma = 0.0268) which were used in all 
calculations. The final R1 was 0.0404 (I> 2σ (I)) and wR2 (F2) was 0.1100 (all data).
 96, 97
 
The datasets were measured on an Agilent SuperNova diffractometer using an Atlas detector. The 
data collections were driven and processed and numerical absorption corrections based on 
Gaussian integration over multifaceted crystal models were applied using CrysAlisPro 
(CrysAlisPro, Agilent Technologies Version 1.171.36.28, 2013). The structures were solved 
using ShelXS
 [2]





hydrogen atoms were refined with anisotropic displacement parameters. For cis-130a, trans-
130a, trans-130d, cis-130e, cis-130h, cis-130m, cis-130p and cis-130q the hydrogen atoms 
belonging to the hydroxyl group(s) (O (2) and O (102)) were located in the electron density and 




positions and refined by use of a riding model with isotropic displacement parameters based on 
the equivalent isotropic displacement parameter (Ueq) of the parent atom.  
In cis-130e, cis-130h, cis-130m, cis-130p and cis-130q there are two crystalographically-
independent molecules in the asymmetric unit. In trans-130a the phenyl group C (13)-C (18)/C 
(13’)-C (18’) is disordered over two positions with a refined occupancy ratio of 54(1):46(1). 
Figures were produced using OLEX2.
95
The CIFs for trans-130a, cis-130a, trans-130d, cis-130e, 
cis-130h, cis-130p, cis-130q, 143a, 143b, 143c and cis-130m have been deposited with the 
CCDC and have been given the deposition numbers 1028121-1028130 and 1038737 respectively. 
In 158a the space group is centrosymmetric such that in four of the molecules in the unit cell C 
(4) is S and in the other four molecules in the unit cell C (4) is R. The relative stereochemistry is 
the same in all the molecules in the unit cell. The hydrogen atoms belonging to N (3) were 
located in the electron density and freely refined (with a DFIX restraint applied to N (3)-H (3d)). 
All remaining hydrogen atoms were added at calculated positions and refined by use of a riding 
model with isotropic displacement parameters based on the equivalent isotropic displacement 








Adult zebrafish from the wild-type AB* strain were maintained and used according to animal 
experimentation licensing requirements of the Scientific Procedures Act 1986 (UK) under 
standard conditions with a 14 hour light and 10 hour dark cycle in a Tecniplast flow-through 
system.
82 
Zebrafish breeding and embryo collection 
Adult zebrafish were divided into separate crossing cages consisting of one male and one female 
zebrafish the night before embryo collection. Zebrafish embryos were then collected the next 
morning within four hours following fertilization. The unfertilized eggs and dead or abnormal 
embryos were removed and the normally developed embryos were placed in E3 embryo medium 
and stored in an incubator at 28°C until required for use.
82 
Toxicity testing 
Zebrafish embryos were exposed to nine derivatives of gamma lactam family. Zebrafish embryos 
were tested in 96 well plates with one embryo in each well. One row was allocated for each 
concentration, in total six concentrations were tested per drug. One row per plate was also 
assigned to the solvent control and one row to the E3 control. Treatment was initiated at six hours 







Compound stock solutions were prepared using DMSO and subsequent dilutions were prepared 
using E3 medium with no dilutions exceeding 1% DMSO.  
In the first part of the toxicity, testing embryos were exposed to each compound at 6 different 
concentrations (0.01, 0.1, 1, 10, 100 and 1000 µM). For compound 3 however, the range was 
adjusted to 0.001, 0.01, 0.1, 1, 10 and 100 µM due to solubility problems at 1000 µM.   
In this first phase the mortality rate was documented every 24 hours. Additionally small 
selections of general phenotypes were also scored using the following scoring criteria: ++++ = 
very severe, +++ = severe, ++ = moderate, + = mild, +/- = slight/no effect and - = no effect.  
For the second phase a narrower concentration range was used to score a wide variety of 
morphological defects with 33 features scored in total. The features were scored using a defined 
scoring criteria with 5 = normal, 4 = slight effect/almost normal, 3 = mild, 2 = moderate, 1 = 
severe, 0.5 = very severe and 0 = not applicable.  
Oil Red O staining 
Samples were fixed overnight in 4% PFA, before being infiltrated with a graded series of 
propylene glycol (25%, 50%, 75% and 100%) and being stained with 0.5% Oil Red O 
commercially available solution in 100% propylene glycol overnight at room temperature. The 
following day washes in decreasing concentrations of propylene glycol (100%, 75%, 50% and 








Alizarin red S staining 
Samples were fixed overnight in 4% PFA and then stained for 2-3 hours with Alizarin Red S 
commercially available staining solution. To stop the reaction, samples were washed twice with 




Samples were fixed overnight in 4% PFA. The next day the samples were washed once with PBS 
and then stained with O-dianisidine commercially available staining solution for 15 minutes in 




Acridine orange staining 
Live embryos were exposed to 5 µg/ml of commercially available acridine orange solution for 30 




Sudan black staining 
For the tail fin wounding assay, zebrafish larvae at 3 dpf in groups of 10 were exposed to each 
compound at 10 µM for 1 hour. After the 1 hour exposure period the larvae were anaesthetized 
and the caudal fin tips were cut. The larvae were then allowed to recover in E3 embryo medium 
for 3 hours before being fixed in 4% PFA overnight. The next day the larvae were washed twice 
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Figure 63: HMBC 2D-NMR for compound 158a 
 
 
